10th European Congress on Tropical Medicine and International Health

Antwerp, Belgium
16-20 October 2017

Final Programme

www.ECTMIH2017.be
# Table of Contents

- **Committees** ................................................................. 4
- **Welcome Address** ...................................................... 5
- **Legend** ........................................................................ 6
- **Colour Codes & Tracks** ............................................... 7
- **Venue Floorplans** ....................................................... 8
- **Programme**
  - **Monday**
    - Opening Session .......................................................... 11
  - **Tuesday**
    - Programme at a Glance ............................................... 12
    - Programme ................................................................ 14
  - **Wednesday**
    - Programme at a Glance ............................................... 40
    - Programme ................................................................ 42
  - **Thursday**
    - Programme at a Glance ............................................... 64
    - Programme ................................................................ 66
  - **Friday**
    - Programme at a Glance ............................................... 92
    - Programme ................................................................ 94
- **Posters**
  - Poster List Tuesday ...................................................... 103
  - Poster List Wednesday .................................................. 119
  - Poster List Thursday ..................................................... 136
- **Satellite Symposia & Meetings** .................................... 155
- **Exhibitors & Sponsors** .................................................. 158
- **General Information**
  - Registration ................................................................ 163
  - Social Activities ............................................................ 166
  - General Information ...................................................... 167

ECTMIH 2017

16-20 October 2017 • Antwerp, Belgium

Scan to download
Congress Chair
Bruno Gryseels, Director, Institute of Tropical Medicine, Antwerp, Belgium

Chair Scientific Boards
Anne Buvé, Head, Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium

Scientific Committee (Track Coordinators)
Kevin Aliën, Head, Unit of Virology, Department of Biomedical Sciences, Institute of Tropical Medicine, Belgium
Emmanuel Bottraud, Head, Unit of Tropical Diseases Department of Clinical Sciences Institute of Tropical Medicine, Antwerp, Belgium
Xavier de Béthune, Medical Director, Médecins du Monde, Belgium
Marleen Boelaert, Head, Unit of Epidemiology and Control of Tropical Diseases, Institute of Tropical Medicine, Belgium
Faustin Chenge, Ecole de Santé Publique, Université de Lubumbashi, RDC
Marc Coosemans, Head, Unit of Entomology, Institute of Tropical Medicine, Antwerp, Belgium
Bart Criel, Head, Unit of Equity and Health, Institute of Tropical Medicine, Antwerp, Belgium
Olivier Denis, Clinical Microbiologist, Chirec and Professor at Université Libre de Bruxelles, Belgium
Philippe Donnen, Ecole de Santé Publique, Université Libre de Bruxelles, Belgium
Jean-Claude Dujardin, Head, Department of Biomedical Sciences, Institute of Tropical Medicine, Belgium
Sarah Gabriël, Professor, Faculty of Veterinary Sciences, University of Ghent, Belgium
Edward Gotuzzo, Director, von Humboldt Institute of Tropical Medicine, Lima, Peru
John Gyapong, Vice Chancellor, University of Health and Allied Sciences, Ghana
Karel Gyselinck, Chair, Be-Cause Health; Belgian Technical Cooperation, Belgium
Christian Lengeler, Department Head, Swiss Tropical and Public Health Institute, Basel, Switzerland
Hechmi Louzir, Director, Pasteur Institute, Tunis
Lut Lynen, Head, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
Jose Muñoz, Head, Tropical Medicine and International Health, Hospital Clinic, Barcelona, Spain
Jorge Perez Avilla, Director, Pedro Kouri Institute of Tropical Medicine, Havana, Cuba
Inger Scheel, President, Norwegian Forum for Global Health Research, Norway (FESTMIH)
Pierre Van Damme, Head, Department of Vaccinology, University of Antwerp, Belgium
Wim Van Damme, Head, Unit of Health Policy, Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium
José Muñoz, Head, Tropical Medicine and International Health, Hospital Clinic, Barcelona, Spain

ITM Organising Committee
Jean-Christophe Donck (Chair)
Naima Al Bdiouni
Nathalie Brouwers
Vicky Croonen
Cleo Maerivoet
Roeland Scholtalbers
Nico Van Aerde
Ann Van Gyseghem
Eline Van Meervenne
Niki Vanwesenbeeck

ECTMIH2017: World-Class Science for World-Wide Development

From 16 to 20 October 2017, some 1500 scientists and experts from all over the world will come together in Antwerp for the 10th European Congress on Tropical Medicine and International Health. They will share the state of the art and new research results in tropical medicine and public health in developing countries, these exciting scientific fields which contribute so much to the advancement of human development and the understanding of evolutionary medicine.

More than 100 sessions will deal not only with long-standing topics as malaria, tuberculosis, parasitic diseases, tropical bacteria, haemorrhagic and vector-borne viruses, but also with their ramifications in world-wide challenges as antimicrobial resistance, universal health care, epidemic responsiveness, migration and climate change. In a unique interdisciplinary context, data will be presented from research laboratories and the clinical bedside as well as from the community and policy levels. As in no other field, the excellence of the science will be matched by its societal impact at local, national and international level.

Besides the listed sessions, there is ample opportunity for informal exchanges and discussion in the beautiful halls of the Elisabeth Centre and in the adjacent, freely accessible Zoo of Antwerp. The meeting will give a prominent floor to scientists from the South and to young international researchers.

Antwerp’s nickname among its citizens is “the metropole”, in spite of its modest size. Over the past ten centuries, it has been a port of access to the heart of Europe for merchants, travellers and migrants from all over the world. Its history and spirit are reflected in its marvellous city centre, splendid museums, elegant shopping streets and hundreds of excellent restaurants and cafés.

We wish you excellent and relevant science, and a wonderful stay in Antwerp.

For the organisers,
Prof Bruno Gryseels
Congress Chair

Official Organiser
MediCongress Services NV
Noorwegenstraat 49
9940 Evergem, Belgium
www.medicongress.com
info@medicongress.com

www.ectmih2017.be
Colour Codes & Tracks

**Track 1. Breakthroughs and innovations in tropical biomedical sciences**
- Molecular biology and epidemiology
- Vector biology
- Diagnostic and therapeutic innovations
- Immunology
- Vaccinology

**Track 2. Ecology of tropical disease agents**
- One health
- Transmission dynamics
- Vector ecology
- Human ecology

**Track 3. State of the art in clinical tropical medicine**
- Novel diagnostics, drugs, vaccines
- Travel and migrant health
- Quality assurance of products and procedures
- Biosafety and biosecurity
- Clinical trials, ethics and regulation
- Nursing and patient care

**Track 4. Control, elimination and eradication sciences**
- State of the art in the control of tropical diseases, TB and HIV
- Theory and practice of elimination and eradication
- Social sciences, the human factor and community involvement
- Sustainability and integration of control strategies
- Economic and political considerations

**Track 5. Health systems and public health**
- Financial, human and material resources for health
- Quality management and regulation, including drugs and diagnostics
- Management and integration of disease-specific programmes including NCD’s
- Access, equity, sustainability and resilience
- Digitalisation and e-health
- National health policies and governance

**Track 6. International health collaboration**
- The role of international cooperation in health development
- Instruments of international health cooperation
- The position of tropical institutes and global health centres
- Funding, governance and ownership
- Ownership, principles and ethics in international health
- Evidence-based humanitarian and emergency aid

**Track 7. Global health**
- Global health inequity and Universal Health Coverage
- Demographics and migration
- International trade and the global economy
- Environmental, urban and industrial health
- Global health policies and governance

**Track 8. Integrated and other subjects**
- Social sciences in health related research
- Reproductive and maternal health
- Child health and nutrition
- Subjects not captured by any of the other tracks
- Subjects integrating or covering several of the above themes

Legend

The programme is organised in 8 tracks. These 8 tracks are listed on page 7. You will find the track numbers (1 to 8) in the session codes.

There are 4 types of sessions, coded as S, OS, IPS and LBS:

- **S** sessions are composed of oral presentations selected via the Call for Abstracts
  - 1S1 = Session 1 in track 1
  - 1S2 = Session 2 in track 1

- **OS** sessions are sessions selected via the Call for Organised Sessions
  - 1OS1 = Organised Session 1 in track 1
  - 1OS2 = Organised Session 2 in track 1

- **IPS** sessions are Interactive Poster Sessions in which the best Posters will be briefly presented
  - 1IPS1 = Interactive Poster Session 1 in track 1
  - 2IPS1 = Interactive Poster Session 1 in track 2

- **LBS** sessions are Late Breaker Sessions and are composed of oral and poster presentations selected via the Call for Late Breaker Abstracts
  - LBS1 = Late Breaker Session 1
  - LBP = Late Breaker Poster

Furthermore each track has been given a different colour (see page 7). When you look at the day-by-day programme at a glance you can easily find the track and sessions you are interested in.
Monday

15.00 Registration

17.00 Opening Session

With music by Belgium's most important wind ensemble, I Solisti Belgian wind ensemble Antwerp

Master of Ceremony: Bharathi Ghanasyam
Freelance Journalist India & 2015 Journalist-in-Residence at the Institute of Tropical Medicine (ITM), Antwerp

Welcome Addresses

Official Opening of the Congress
Bruno Gryseels (Congress Chair, ITM Director)
Cathy Berx (Governor of the Province of Antwerp)

A word from the Federation of European Societies of Tropical Medicine and International Health
Karel Gyselinck (President of FESTMIH)

Introduction to the programme
Anne Buvé (Chair of the Scientific Committee, ITM)

A new generation in global health: Views from Africa, Asia, Latin America and Europe

Aku Kwamie (Research Consultant, Health Policy and Systems Research, Ghana)
Vijayashree Yellappa (Institute of Public Health, India)
Dalila Martinez (Instituto de Medicina Tropical Alexander von Humboldt, Peru)
Conor Meehan (Institute of Tropical Medicine Antwerp, Belgium/Ireland)

Keynote Lectures

Leadership and ownership in tropical health research
Rose Leke (Emeritus Professor of Immunology and Parasitology and Director of the Biotechnology Centre at the University of Yaoundé, Cameroon)

The past, present and future of tropical diseases in Europe
Denis Coulombier (Head of Unit for Surveillance and Response Support, European Centre for Disease Prevention and Control, Stockholm, Sweden)

19.00 Welcome Reception
**Programme at a glance - Tuesday 17/10**

<table>
<thead>
<tr>
<th>08.30 - 10.00</th>
<th>10.00</th>
<th>10.30 - 12.00</th>
<th>12.30</th>
<th>13.30 - 15.00</th>
<th>15.00</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Programme</strong></td>
<td><strong>Plenary Talks</strong></td>
<td><strong>Lunch Break &amp; Poster Tour</strong></td>
<td><strong>Coffee Break</strong></td>
<td><strong>Lunch Break &amp; Poster Tour</strong></td>
<td><strong>Coffee Break</strong></td>
</tr>
<tr>
<td><strong>Elisabeth Hall</strong></td>
<td><strong>Pelican</strong></td>
<td><strong>Gorilla 3</strong></td>
<td><strong>Coffee Break</strong></td>
<td><strong>Gorilla 4</strong></td>
<td><strong>Coffee Break</strong></td>
</tr>
<tr>
<td><strong>Darwin</strong></td>
<td><strong>Nightingale</strong></td>
<td><strong>Gorilla 1</strong></td>
<td><strong>Coffee Break</strong></td>
<td><strong>Gorilla 5</strong></td>
<td><strong>Coffee Break</strong></td>
</tr>
<tr>
<td><strong>Stanley</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Toucan</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Programme at a glance - Tuesday 17/10**

<table>
<thead>
<tr>
<th>08.30 - 10.00</th>
<th>10.00</th>
<th>10.30 - 12.00</th>
<th>12.30</th>
<th>13.30 - 15.00</th>
<th>15.00</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Programme</strong></td>
<td><strong>Plenary Talks</strong></td>
<td><strong>Lunch Break &amp; Poster Tour</strong></td>
<td><strong>Coffee Break</strong></td>
<td><strong>Lunch Break &amp; Poster Tour</strong></td>
<td><strong>Coffee Break</strong></td>
</tr>
<tr>
<td><strong>Elisabeth Hall</strong></td>
<td><strong>Pelican</strong></td>
<td><strong>Gorilla 3</strong></td>
<td><strong>Coffee Break</strong></td>
<td><strong>Gorilla 4</strong></td>
<td><strong>Coffee Break</strong></td>
</tr>
<tr>
<td><strong>Darwin</strong></td>
<td><strong>Nightingale</strong></td>
<td><strong>Gorilla 1</strong></td>
<td><strong>Coffee Break</strong></td>
<td><strong>Gorilla 5</strong></td>
<td><strong>Coffee Break</strong></td>
</tr>
<tr>
<td><strong>Stanley</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Toucan</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
08.30

**Plenary Talks**  
Chairs: Shyam Sundar (India) and Elisabeth Paul (Belgium)

**New tools for vector control**  
Steven W. Lindsay, Durham University, UK

**Debate: Doing development differently: The future role of international cooperation**  
Christine Kirunga Tashobya, Makerere School of Public Health, Uganda  
Jan Paehler, EuropeAid, DG DEVCO, European Commission  
Remco van de Pas, Institute of Tropical Medicine, Belgium

10.00  
Coffee Break

10.30  
**3S1 - Arboviruses**  
Chairs: Annelies Wilder-Smith (Sweden) and Denis Malvy (France)

**3S1.1 Comparison of laboratory and clinical Dengue virus strains reveals major differences in endothelial cell pathology**  
Vervaeke P., Noppen S., Meyen E., Arlain K.K., Liekens S. (Belgium)

**3S1.2 Clinical features of Chikungunya infection and chronic polyarthralgia after the 2014-2015 outbreak on Aruba**  

**3S1.3 Detection of Zika virus NS1 antigen in semen by a prototype rapid test**  
Cnops L., Nakayama E.E., Caron E., Eggermont K., Van Esbroeck M., Bottieau E., Jacobs J., Shiota T., Huits R. (Belgium & Japan)

**3S1.4 Epidemiological and clinical data of children exposed to Zika virus registered in Spanish database. How often is microcephaly?**  

**3S1.5 Surveillance of Zika virus in pregnant women returning from affected areas: Results from a cohort study in Southern Europe**  

**3S1.6 Incidence of travel-associated Zika virus infection in 2016: Preliminary results of a prospective cohort study in Belgian travellers to the Americas**  

12.00  
Lunch Break and Poster Tour (12.30 - 13.30)

13.30  
**3S2 - Ebola and other Viruses**  
Chairs: Alexandre Delamou (Belgium) and Johan van Griensven (Belgium)

**3S2.1 Which personal protective equipment to provide? – Challenges during the ebola outbreak and lessons learned**  
Lee M.H., Meersbach A., Straub J., Neidhardt I., Gresser N., Gies S., Verbeek L. (Germany)

**3S2.2 Inclusion of pregnant women in ebola clinical trials**  
Caluwaerts S., Ebola Investigational Platform, Ronsse A., Lagrou D., Antierens A. (Belgium)

**3S2.3 Human T-lymphotropic virus 1 and 2 infections among patients with neurological disorders in the Democratic Republic of the Congo**  
Vervoort K., Mukendi D., Barba B., Arlain K., Janssens C.P., Chong L., Boelaert M., Chappuis F., Muyembe T.J.J., Bottieau E. (Belgium, Democratic Republic of Congo, Canada & Switzerland)

**3S2.4 Presence of defective HTLV-1 provirus in Peruvian asymptomatic carriers**  
Mora R., Rosado J., Falconi-Agapito F., Ciepulo D., Goulombo D., Alvarez C., Talledo M. (Peru)

**3S2.5 The clinical characterization of human monkeypox infections in the Democratic Republic of Congo**  

**3S2.6 AIDS-related systemic mycoses endemic to Western Cape, South Africa and clinical mimics: A cross-sectional study of adults with advanced HIV and recent-onset, widespread skin lesions**  
Schwartz I.S., Kerney C.R., Claassen S., Spengane Z., Lehloenya R., Prozesky H.W., Colebunders R., Diamin S. (Belgium, Canada & South Africa)

15.00  
Coffee Break

15.30  
**3OS1 - Zika: Epidemiology and Clinical Manifestations**

**Organisers:**  
Jointly organised by three Zika related research consortia funded under Horizon 2020 by the European Commission

**Chairs:**  
Annelies Wilder-Smith (Sweden) and Carlo Giaquinto (Italy)

**3OS1.1 ZikaPLAN introduction - Epidemiology and geographic spread**  
Wildersmith A. (Sweden)

**3OS1.2 ZIKAlliance introduction - Zika seroepidemiological studies**  
de Lamberlire X. (France)

**3OS1.3 Zika virus epidemiology and geographic spread in Jamaica**  
Christie C.D.C. (Jamaica)

**3OS1.4 Risk estimates for birth defects**  
Jaenisch T. (Germany)

**3OS1.5 Children and Zika: How to approach this challenge after birth?**  
Soriano-Arandes A. (Spain)

**3OS1.6 Neurological complications of Zika in adults**  
Solomon T. (UK)
**1OS1 - Zika: Basic Science and Social Implications**

**Organisers:**
Jointly organised by three Zika related research consortia funded under Horizon 2020 by the European Commission

Chairs:
Xavier de Lamballerie (France) and Johan Neyts (Belgium)

**1OS1.1 Zika virus and vector competence**
Failloux A.B. (France)

**1OS1.2 Zika virus replication in testicles in mice and impact of viral replication inhibitors**
Neyts J. (Belgium)

**1OS1.3 Neuropathogenesis in peripheral versus central nervous system**
Willison H. (UK)

**1OS1.4 Zika virus replication at the placental interface: The role of non-neutralizing immunity**
Bonfante F. (Italy)

**1OS1.5 The role of risk proximity in the beliefs and behaviors related to emerging infectious diseases: The cases of Chikungunya and Zika in French Guiana**
Raude J. (France)

---

**3S3 – Malaria (clinical)**

Chairs: Tinto Halidou (Burkina Faso) and Arjen Dondorp (Thailand)

**3S3.1 Vivax malaria morbidity after radical treatment: A 2-year cohort study in Central Vietnam**

**3S3.2 P. Vivax recurrences after radical treatment in the Peruvian Amazon: A 2-year cohort study**

**3S3.3 Low dose primaquine efficacy and safety: A review and individual patient data meta-analysis**
Humphreys G.S. on behalf of the WWARN Single Low Dose Primaquine Study Group (UK)

**3S3.4 The consequences of censoring new infections when deriving antimalarial efficacy against uncomplicated P. Falciparum malaria**
Dahal P. on behalf of the WWARN Methods Study Group (UK)

**3S3.5 Drug discovery towards the eradication of malaria: Harnessing the power of a global network of partners**
Abla Geiser N., Willis P.A. (Switzerland)

---

**12.00 Lunch Break and Poster Tour (12.30 - 13.30)**

---

**3OS2 – New Clinical Developments of Antimalarials**

**Organisers:**
Dr. Dr. Carsten Köhler, President of the German Society for Tropical Medicine and International Health (DTG) and Director of Center of Excellence for Tropical Medicine in the state of Baden-Württemberg; Professor Dr. Peter G. Kremsner, Malaria branch speaker of the German Center for Infection Research (DZIF) Tübingen and Director of Institute of Tropical Medicine, University of Tübingen; Tübingen, Germany

**Chairs:**
Peter G. Kremsner (Germany) and Carsten Köhler (Germany)

**3OS2.1 Controversies around artemisinins**
Krishna S. (UK)

**3OS2.2 State-of-the-art of the clinical development of KAF156, a novel antimalarial**
Grobusch M.P. (The Netherlands)

**3OS2.3 OZ-Piperazine as single dose antimalarial: A multinational phase IIb study**
Ramharter M. (Austria)

**3OS2.4 DSM265, a promising novel antimalarial compound for chemoprophylaxis**
Sulyok M. (Germany)

**3OS2.5 Fosmidomycin-piperazine as non-artemisinin-based combination therapy for acute uncomplicated Plasmodium falciparum malaria**
Mombo-Ngoma G. (Gabon)

---

**15.00 Coffee Break**
8S1 - Malaria in Pregnancy

Chairs: Jean-Pierre Van Geertruyden (Belgium) and Sabine Gies (Germany)

8S1.1 Malaria in pregnancy preventive treatments may provide additional protection against febrile illnesses during the first year of life


8S1.2 Safety of antimarial drug use during early pregnancy in Bobo Dioulasso: Examining low birth weight and congenital malformations as potential adverse outcomes

Roambita T., Kpoda H., Valla I., Mens P.F., Gomes M., Tinto H., Krapkowa-samadouloogou F. (Burkina Faso, Belgium, The Netherlands & Switzerland)

8S1.3 Optimal duration of follow-up for assessing efficacy of drugs for uncomplicated falciparum malaria in pregnancy in Asia: A systematic review and individual patient data meta-analysis


8S1.4 Malaria screening during pregnancy with RDTs performed by community health workers in Nanoro, Burkina Faso


8S1.5 Malaria is more prevalent than iron deficiency among pregnant women at the first antenatal visit in rural South-Kivu


8S2 - Malaria in Children

Chairs: Halidou Tinto (Burkina Faso) and Anna Rosanas-Urgell (Belgium)

8S2.1 Delivery strategies of malaria chemoprevention for post-discharge management of children with severe anaemia in Malawi

Gondwe T., Robbestedt B., Mukaka M., Banda S., Lange S., Blomberg B., Phiri K.S. (Malawi, Norway & USA)

8S2.2 Impact of a malaria rapid diagnostic test detecting Plasmodium falciparum-specific histidine-rich protein-2 (RDT-PHRHP2) on the management of febrile children under-5-years of age in a high seasonal malaria transmission area


8S2.3 Safety of artesunate-amodiaquine combined with methylene blue or primaquine for the treatment of uncomplicated falciparum malaria in young African children: A randomised controlled non-inferiority trial

Mendes Jorge M., Meisner P., Ouerri L., Coulibaly B., Nebie E., Compaore G., Kieser M., Klose C., Kreiss K.J., Mockenhaupt F., Sie A., Muller O. (Germany & Burkina Faso)

8S2.4 A qualitative study of the acceptability of weekly iron supplementation prior to the first pregnancy in Burkina Faso

Compahre A., Gies S., Brabin B.J., Tinto H., Brabin L. (Burkina Faso, Belgium, Germany, UK & The Netherlands)

8S2.5 Malaria risk in young children after periconceptional supplementation of mothers in rural Burkina Faso

Gies S., Diallo S., Tinto H., Brabin L., Roberts S., D’Alessandro U., Brabin B.J. (Belgium, Germany, Burkina Faso, UK, The Gambia & The Netherlands)

8S2.6 Impact of micronutrient powders combined with malaria chemoprevention on anaemia, malaria and cognitive development: A cluster-randomized study in Malian children


10.30 4S1 - Elimination of Human African Trypanosomiasis

Chairs: Joseph Ndungu and Veerle Lejon (France)

4S1.1 Innovative methods of case finding to achieve elimination of human African trypanosomiasis in the Democratic Republic of Congo


4S1.2 Development of a framework for integrated passive surveillance to drive elimination of human African trypanosomiasis in Kongo Central province, DRC

Lumbala C., Kayembe S., Bessell P.R., Picado A., Biéler S., Ndung’u J.M. (DRC, UK & Switzerland)

4S1.3 The conflict in South Sudan: A threat to the elimination of gambiense human African trypanosomiasis in Uganda?

Wannboag C., Picado A., Watsi C., Matovu E., Tor S., Biéler S., Katz Z., Bessell P.R., Ndung’u J.M. (Uganda, Switzerland & UK)

4S1.4 A strategy combining passive screening and reactive screening to control human African trypanosomiasis during the Ebola crisis in Guinea

Camara O., Camara M., Bucheton B., Camara M., Biéler S., Ndung’u J.M. (Republic of Guinea, France & Switzerland)

4S1.5 Adding Taeske control to medical activities contributes to decreasing transmission of sleeping sickness in the mandoul focus (Chad)


Lunch Break and Poster Tour (12.30 - 13.30)

4OS1 - Phase II/III Results for Fexinidazole, the First Oral Treatment for Human African Trypanosomiasis (NAT)

Organiser: Nathalie Strub-Wourgaft, Drugs for Neglected Diseases initiative, Geneva, Switzerland

Chair: José Ramon Franco (Switzerland)

4OS1.1 Developing treatments for sleeping sickness: DNDi’s R&D strategy

Strub-Wourgaft N. (Switzerland)

4OS1.2 Results from the pivotal trial of fexinidazole: Non-inferiority shown to the gold standardNECT

Tarral A. (Switzerland)

4OS1.3 The efficacy of fexinidazole in children and stage 1 patients

Bardonneau C. (Switzerland)

4OS1.4 Working together across continents to organize and run clinical trials in remote areas

Mutombo Kallonji W. (DRC) and Valverde Mordt O. (Switzerland)

4OS1.5 The potential impact of fexinidazole on the global strategy to eliminate sleeping sickness

Lumbala C. (DRC) and Perez Simarro P. (Switzerland)

Coffee Break

Tuesday Darwin
15.30

4S2 – Outbreak Surveillance and Response
Chair: Veerle Vanlamberghene (Belgium)

4S2.1 Developing and operationalizing national-level early warning and response systems (EWARS) for dengue and other Aedes-borne arboviral diseases
Olliaro P., Kroeger A., Tozan Y., Rocklöv J. (Switzerland, Germany, USA & Sweden)

4S2.2 Why the outbreak of Ebola virus disease in West Africa could have been detected one month - not three - after patient zero and lessons learned for surveillance systems strengthening
Badenschier F. (Germany & UK)

4S2.3 Catching the risk of measles outbreaks in a clustered society
Willem L., Verelst F., Kuylen E., Abboud L.A., Bicke J., Hens N., Broeckhove J., Beutels P. (Belgium & Australia)

4S2.4 A One Health team to improve Monkeypox virus outbreak response: An example from the Democratic Republic of the Congo

4S2.5 The association of cholera outbreak with conflict-related factors in Yemen
Dureab F., Shabib K., Jahn A. (Germany)

17.00

4S3 – Spatial Analysis Approaches and Modelling in Support of Disease Control
Chairs: Epco Hasker (Belgium) and Elies Van Belle (Belgium)

4S3.1 Considering the spatial heterogeneity of dengue transmission for designing an Aedes control strategy
Vanlamberghene V., Toledo M.E., Ocampo C., Manrique-Saide P., Honorio N., Vazquez-Prokopec G., Mirabal M., Alexander N., Fruhuoo P.L.L., Van der Stuyft P. (Belgium, Cuba, Colombia, Mexico, Brazil & USA)

4S3.2 Digitalization and planning of active HAT screening in the Democratic Republic of Congo to reach elimination

4S3.3 Modelling to support the planning of malaria elimination in southern Palawan, the Philippines
Britt O.J.T., Angluben R., Torno M., Navarro M.A.H., Deray R., Schapira A. (Switzerland & Philippines)

4S3.4 Mapping of leprosy cases as a tool for rationalizing contact screening

4S3.5 A spatial decision support system approach to implementing malaria surveillance as a core intervention activity in high priority Vietnam
Caravati S.E., Vo T.H., Ngo Duc T., Tran D.T., Ngo T.D., Kelly G., Martin N.J. (Vietnam, Australia, Finland & Singapore)

10.30

5S1 - Digitalisation and e-Health
Chair: Peter Delobelle (South Africa)

5S1.1 An open source API for real time drug prescription monitoring at the point of care in low resource settings
Verbeke F., Van Laere S., Nyssen M. (Belgium)

5S1.2 Defining a supervision strategy using artificial intelligence (AI) - The case of data supervision for the results based financing intervention in Benin
Lurtgen G., Antony M., Legrand A., de Borman N. (USA & Belgium)

5S1.3 Primitive metrics for predicting clinical documentation performance in Burundian public hospitals
Verbeke F., Karara G., Van Bastelaere S. (Belgium)

5S1.4 Connecting the unsupported in sub-Saharan Africa: Non-discriminating access for digital inclusion with an emphasis on health (Digil)
Holst C., Knobloch J., Schmidt V., Mwapepeje E., Ngowi H., Ngowi B., Prazeres da Costa C., Brügge B., Winkler A.S., Noli J. (Norway, Germany & Tanzania)

5S1.5 Digitizing routine health facility assessment in low-resource settings
Legrand A., Nembetwa N. (Belgium)

12.00

5S2 - Patients, Communities and Health Services
Chair: Paul Bossyns (Belgium)

5S2.1 Is health protected: Life histories of vulnerable groups in fragile and conflict-affected situations
Fustukian S., Vidal N., O’Malley F., Armar R., Buzuzi S., Ros B., Sali S., McPake B. (UK, Sierra Leone, Zambia, Cambodia, Uganda & Australia)

5S2.2 10 years of research on India’s ASHA program: A literature review framing health systems interfaces supporting a national community health worker program
Scott K., George A., Ummer O., Ved R. (India & South Africa)

5S2.3 Reasons for not attending a health care centre for soil-transmitted helminth infections in a rural village in Indonesia
Meyariti F., Verdonck K., Polman K., Mahendrahardha Y. (Indonesia & Belgium)

5S2.4 Mid-term evaluation results of improvement in medical interventions and midwifery care in five medical regions in Senegal

5S2.5 Integration of maternal postpartum services in maternal and child health services in Kaya health district (Burkina Faso): An intervention time trend analysis
Yugbaré Belemsaga D., Goujon A., Mbet A., Toure H., Bicke J., Beutels P. (Belgium, Benin & Burkina Faso)

13.30

Lunch Break and Poster Tour (12.30 - 13.30)

5S3 - Primary Care and Primary Health Care
Chair: Paul Bossyns (Belgium)

5S3.1 Improving maternal and child health services in a rural community in Uganda
Fustukian S., Vidal N., O’Malley F., Armar R., Buzuzi S., Ros B., Sali S., McPake B. (UK, Sierra Leone, Zambia, Cambodia, Uganda & Australia)

5S3.2 10 years of research on India’s ASHA program: A literature review framing health systems interfaces supporting a national community health worker program
Scott K., George A., Ummer O., Ved R. (India & South Africa)

5S3.3 Reasons for not attending a health care centre for soil-transmitted helminth infections in a rural village in Indonesia
Meyariti F., Verdonck K., Polman K., Mahendrahardha Y. (Indonesia & Belgium)

5S3.4 Mid-term evaluation results of improvement in medical interventions and midwifery care in five medical regions in Senegal

5S3.5 Integration of maternal postpartum services in maternal and child health services in Kaya health district (Burkina Faso): An intervention time trend analysis
Yugbaré Belemsaga D., Goujon A., Mbet A., Toure H., Bicke J., Beutels P. (Belgium, Benin & Burkina Faso)

15.00

Coffee Break
5OS1 - Patient Centered Care (PCC)

Organisers:
Bart Criel, ITM, Public Health Department and chair of the Be-cause Health People-Centered Care working group
Evelyne Waweru, ITM, PhD student, Public Health Department

Chair:
Bart Criel (Belgium)

5OS1.1 Setting the scene for Patient-Centered Care and health systems in low and middle income countries
De Man J. (Belgium)

5OS1.2 A state of mind: Reflections on Patient Centered Care approaches and experiences in the North and South
Hoerée T. (Belgium)

5OS1.3 Patient-centeredness from education to practice: Towards a personal style of context-sensitive patient centeredness
Meers A. (Belgium)

5OS1.4 Understanding Patient-Centered Care approaches at primary health care level in sub-Saharan Africa: The case of Uganda
Waweru E. (Belgium)

5OS1.5 Necessities, not luxuries: Lessons for Patient Centered Care learnt from mental healthcare in resource-constrained settings
Sarkar N. (Belgium)

5S3 - Health Policies

Chairs: Susannah Mayhew (UK) and Sara Van Belle (Belgium)

5S3.1 Supporting community health worker programs at scale: Lessons from policy reforms shaping the evolution of India’s ASHA program

5S3.2 Assessing and preparing health systems for integration of services in low- and middle-income countries – A systematic review
Topp S.M., Abimbola S., Joshi R., Negin J. (Australia)

5S3.3 Models of engagement between the state and faith sector in Sub-Saharan Africa: A systematic review
Whyle E.B., Oliver J. (South Africa)

5S3.4 State to the test of trust: Implementation of a public fee exemption policy in non-state facilities in Benin
Dossou J.P., Marchal B. (Benin & Belgium)

5S3.5 The politics of the basic benefit package reforms in Tajikistan: Health governance constraints in neo-patrimonial settings
Jacobs E. (The Netherlands & Switzerland)

5OS2 - Experiences in Capacity Building in Public Health Institutes in Low-Income Countries, putting Local Public Health Institutes in the Lead of Research for Policy Development

Organiser:
European Commission, International Cooperation and Development-EuropeAid – Supporting Public Health Institutes Programme (SPHIP)

Chairs:
Kevin McCarthy (EC) and Jaap Koot (The Netherlands)

5OS2.1 Using evidence for mobilising support for NCD transition strategic plan in Myanmar
Ram Jat T. (Myanmar)

5OS2.2 Evidence for mobilising access to care for the poor in Bangladesh
Rahman Shaheen A. (Bangladesh)

5OS2.3 Evidence for strengthening Universal Health Coverage in Uganda
Kiwanuka S. (Uganda)

5OS2.4 Closing remarks and overview of knowledge translation activities in the SPHIP programme
Koot J. (The Netherlands)

6OS1 - Building Capacity for Policy Influence and Health Systems Management: Experiences from two European Union funded Programmes in the Democratic Republic of Congo and in Uganda

Organisers:
The RIPSEC (Uganda) and the SPEED (Democratic Republic of Congo) Partnerships

Chair:
Suzanne Kiwanuka (Uganda)

6OS1.1 Brief general introduction RIPSEC and SPEED program
Ssengooba F. (Uganda) & Criel B. (Belgium)

6OS1.2 The strategy of learning and research health districts in a health systems strengthening perspective in the Democratic Republic of Congo: Clarification of the concept and review of similar experiences in Sub Saharan Africa
Michaux G. (Belgium)

6OS1.3 Theory of Change (ToC) as an inclusive methodology for planning, monitoring and evaluating health district transformation in the Democratic Republic of Congo
Ntambwe A. (RDC)

6OS1.4 Research priority setting health systems development to advance universal health coverage in Uganda: The stakeholder engagements and perspectives
Ssennyonjo A. (Uganda)

6OS1.5 Policy implementation barometer in Uganda: What are barriers to policy implementation? Development of a measuring instrument in Uganda
Hongoro C. (South Africa)
15.30 6OS2 - Health Cooperation beyond Aid

Organisers:
Remco van de Pas, Board member
Medicus Mundi International Network – Health for All (MMI), Basel, Switzerland
Tim Roosen, Coordinator
Be-Cause Health, Belgian Platform for International Health, Antwerpen, Belgium

Chair:
Thomas Schwarz (Switzerland)

6OS2.1 Health Cooperation: Its relevance, legitimacy and effectiveness as a contribution to achieving universal access to health
van de Pas R. (Belgium)

6OS2.2 Health cooperation beyond aid: How we do it!
Lecture by the winner of a story contest

6OS2.3 Health systems strengthening in fragile settings – The role of international health cooperation
van Belle E. (Belgium)

6OS2.4 Unpacking the ‘private’ sector and the new business model in international health cooperation: Blurred boundaries and mandates
Kapilashrami A. (UK)

6OS2.5 Ending 50 years of bilateral cooperation in Latin America – Strategies for the future?
Van Bastelaere S. (Belgium)

17.00 4S4 – Biosocial Approaches in Disease Control
Chairs: Christiana Noestlinger (Belgium) and Dennis Perez (Cuba)

4S4.1 Micro-epidemiology of malaria exposure in Central Vietnam: A mixed-methods case study

4S4.2 Stigma among healthcare workers as a barrier to the use of TB services at occupational health units in South Africa
Sommerland N., Wouters E., Masquillier C., Rau A., Engelbrecht M., Van Belle S., Van Wyk B. (South Africa & Belgium)

4S4.3 Why would antiretroviral treatment adherence clubs work in the Western Cape Province, South Africa?
Mukumbang F.C., Van Belle S., Marchal B., Van Wyk B. (South Africa & Belgium)

4S4.4 Community participation in mosquito breeding site control: A multidisciplinary mixed methods study in Curaçao

10.30 1S1 - Diagnostics 1 - Serology and Hemo-Culture
Chairs: Stijn Deborggraeve (Belgium) and Pascal Mertens (Belgium)

1S1.1 Re-defining blood culture for resource-limited settings: Developing draft target product profiles for simplified diagnostics
Dailey P., Osborn J., Martino R., Isaacs C., Dittrich S. (Switzerland & USA)

1S1.2 Prospective evaluation of a rapid diagnostic test for gambiense human African trypanosomiasis developed using recombinant antigens in the Democratic Republic of the Congo
Lumbala C., Biéler S., Kayembe S., Makabuza J., Mbugwia L., Ndyeni R., Nkungi J. (Democratic Republic of Congo & Switzerland)

1S1.3 Finding Mimo: Developing an alternative rapid test for the serodiagnosis of visceral leishmaniasis in Eastern African populations
Kühne V., Dri E., El-Sall S., Büscher P. (Belgium, Ethiopia & Sudan)

1S1.4 Visceral leishmaniasis: a combined wet-lab and in silico approach to the discovery of biomarkers of disease progression and post-chemotherapy relapse
Bremer Hinckel B.C., Marlasa T., Aris S., Inamura H., Dujardin J.C., Falconer A.K., Bhattacharyya T., Anderson B., Mertens P., Miles M.A. (Belgium, UK, Colombia & Sweden)

12.00 Lunch Break and Poster Tour (12.30 - 13.30)

13.30 1S2 - Diagnostics 2 - DNA-Based Assays
Chairs: Isra Cruz (Switzerland) and Kevin Ariën (Belgium)

1S2.1 Combination of random isothermal amplification and nanopore sequencing for rapid identification of the causative agent of an outbreak
Hansen S., Faye O., Faye M., Sanabani S.S., Pessola R., Faye O., Böhken-Fascher S., Sall A.A., Weidmann M., Czerny C.P., Abd El Wahed A. (Belgium, Senegal, Brazil & UK)

1S2.2 Loop-mediated isothermal amplification for asymptomatic malaria diagnosis in the Peruvian Amazon: Technical performance and pilot implementation in challenging field settings

1S2.3 Dry reagent-based loop-mediated isothermal amplification for confirmation of buruli ulcer using a portable fluorimeter
Beissner M., de Souza D.K., Marlan I., Saar M., Zwirglmaier K., Wiedmann F., Bretzel G., Ndung’u J.M., Cruz I., Abloraye D. (Germany, Ghana, Togo & Switzerland)


15.00 Coffee Break
15.30  3OS3 - Raising Standards and Quality of Parasite Diagnostics in Non-Endemic Clinical Settings using Molecular and Lateral Flow Technologies

Organisers:
Dr. Jaya Shrivastava and Prof. Peter L Chiodini
Institution: UKNEQAS Parasitology
Organisations: University College London Hospitals and Public Health England

Chairs:
Jaya Shrivastava (UK) and Ingrid Felger (Switzerland)

3OS3.1 Molecular diagnosis of Leishmania species in European travel clinics
Felger I. (Switzerland)

3OS3.2 The first malaria molecular EQA scheme launched by UK NEQAS(P) [United Kingdom National External Quality Assessment Service Parasitology]
Shrivastava J. (UK)

3OS3.3 PCR as a first line diagnostic tool for diagnosis of intestinal parasitic infections in a clinical laboratory
Verweij J.J. (The Netherlands)

3OS3.4 RDTs in malaria diagnosis: Pushing new boundaries with lateral flow assays
Weigl H.B. (USA)

3OS3.5 Effective detection of asymptomatic malaria infections across geographically diverse areas using loop-mediated isothermal amplification
Ding X.C. (Switzerland)

17.00  3OS4 - New Developments in the Diagnosis of Imported Parasitic Infections in Europe

Organisers:
Lisette van Lieshout (MSc, PhD), Dept. of Parasitology, Leiden University Medical Center (LUMC), RC Leiden, The Netherlands
Marjan van Esbroeck (MD), Institute of Tropical Medicine (ITM), Antwerp, Belgium

Chairs:
Lisette van Lieshout (The Netherlands) and Marjan van Esbroeck (Belgium)

3OS4.1 Nucleic acid amplification techniques, the future of malaria diagnosis?
Polley S.D. (UK)

3OS4.2 New developments in the diagnosis of schistosomiasis in European travellers and migrants: Will PCR and the detection of CCA and CAA replace microscopy?
Van Lieshout L. (The Netherlands)

3OS4.3 Is there a need to screen asymptomatic migrants for parasitic infections?
Lier T. (Sweden & Norway)

3OS4.4 Will PCR replace microscopy in the diagnosis of imported intestinal parasites?
Bisoffi Z. (Italy)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
</table>
| 15.30 | 2S3 – Trematodes | **Chairs:** Tine Huyse (Belgium) and Katja Polman (Belgium)  
**2S3.1** *Opisthorchis viverrini* and a novel sister species in ducks share the same intermediate snail and fish hosts in Central Vietnam  
Dao T., Nguyen T., Derrauw V., Gabriel S., Dormy P. (Vietnam & Belgium)  
**2S3.2** Human and animal trematode infections in a mobile pastoralist setting at Lake Chad: Added value of a one health approach beyond zoonotic diseases research  
**2S3.3** Dynamics of *S. haematobium* and *S. mansoni* infection and morbidity: An eight-year follow-up study in a rural community in the north of Senegal  
Meurs L., Mbou M., Vereecken K., Van den Broeck F., Mpabanzí L., Boon N., Huyse T., Polman K. (Belgium & Senegal)  
**2S3.4** Incorporating the ecology of intermediate hosts of schistosomiasis into spatially explicit models of disease transmission in seasonal climates  
Perez-Saiz J., Mande T., Ceperley N., Bertuzzo E., Bertuzzo E., Mari L., Gatto M., Rinaldo A. (Switzerland & Italy)  
**2S3.5** Transmission and hybridisation dynamics of *Schistosoma haematobium* in the Senegal River Basin: No barrier breakdown between human and cattle schistosomiasis?  
Boon N., Mbou M., Paredis L., Maes T., Moris P., Mboup S., Volckaert F., Boissier J., Polman K., Huyse T. (Belgium, Senegal & France) |
| 17.00 | 2S4 – Onchocerciasis & Modelling | **Chairs:** Niel Hens (Belgium) and Andreas Krüger (Germany)  
**2S4.1** An update of blackfly (Diptera: Simuliidae) vectors and *Onchocerca volvulus* transmission in Mahenge, south eastern Tanzania  
Kalinga A., Krüger A., Pfarr K., De Witte J., Post R.J., Mwingira U., Colebunders B., Dujardin J.C., O'Neill S., Hendy A. (Belgium, Germany, UK & Tanzania)  
**2S4.2** Onchocerciasis associated epilepsy in the Ituri and Tshopo province in the Democratic Republic of the Congo: A case-control study  
**2S4.3** Onchocerciasis associated epilepsy in the Ituri and Tshopo province in the Democratic Republic of the Congo: A case-control study  
**2S4.4** Mathematical modelling of transmission dynamics of *Opisthorchis viverrini*  
Bürli C., Harbrecht H., Oddernatt P., Sayasone S., Chitnis N. (Switzerland & Lao PDR)  
**2S4.5** Estimating age-time dependent malaria force of infection accounting for unobserved heterogeneity  
Hens N., Mugenyi L., Abrams S. (Belgium & Uganda)  
**2S4.6** Mathematical modelling of dog rabies transmission in N’Djaména, Chad  
Laager M., Mbilo C., Léchenne M., Zinnstag J., Chitnis N. (Switzerland) |
| 10.30 | 8S3 - Sexual and Reproductive Health Rights | **Chairs:** Susannah Mayhew (UK) and Esther Jurgens (The Netherlands)  
**8S3.1** Critical reflections on SRHR policies and law  
Bomsann M., Gyselinck K., Van Bastelaere S., Bossyns P. (Belgium)  
**8S3.2** Evaluating DANIDA's global SRHR policy: Tracing accountability pathways at the global policy level  
Mayhew S., Van Belle S. (Belgium)  
**8S3.3** Body & rights – E-learning on sexual and reproductive health and rights for stakeholders of development cooperation  
**8S3.4** Academic network for sexual and reproductive health and rights policy (ANSER)  
Ivanova O., Degomme O., Michielsen K., Van Braeckel D. (Belgium)  
**8S3.5** Addressing unsafe abortion in Benin: Why is the current policy inappropriate?  
Dossou J.P., Kanhonou L., Bello K., Goufodi S. (Benin & Belgium) |
| 12.00 | Lunch Break and Poster Tour (12.30 - 13.30) | |
| 13.30 | 8S4 - Sexual and Reproductive Health | **Chairs:** Steven Callens (Belgium) and Bea Vuyksteke (Belgium)  
**8S4.1** Sexual practices among men who have sex with men in Kinshasa, DRC  
**8S4.2** Socioeconomic counters of intimate partner violence and impact on reproductive health services in India  
Gogoi M., Kumar A. (India)  
**8S4.3** Post circumcision beliefs influencing sexual behaviour among men in Wakiso district, Uganda  
Kibira S.P.S., Atiyambe L.M., Sanday I.F., Makumbi F.E., Daniel M. (Norway & Uganda)  
**8S4.4** “Never trust an open door” - Controversies of sexual pleasure, pain and female genital mutilation among African migrants in Belgium, the Netherlands and the UK  
Zewolde S., Florquin S., Bos M., Dubourg D., Richard F., O'Neill S. (UK, Belgium & The Netherlands) |
| 15.00 | Coffee Break | |
**8OS1 - Abortion and Post Abortion Care: Politics, Religion, Public Health, Health Care and Legal Systems**

**Organisers:** Maria Lisa Odland, Norwegian University of Science and Technology, Trondheim, Norway

**Chairs:** Berit Austveg (Norway) and Elisabeth Darj (Norway)

**8OS1.1** Use of manual vacuum aspiration in the treatment of incomplete abortions: A cross sectional study from three public hospitals in Malawi

Odland M.L. (Norway)

**8OS1.2** International actors’ legitimacy seeking practices in Malawi’s abortion law reform

Kloster M. (Norway)

**8OS1.3** Working on the edge: Ambiguity, responsibility and ethical dilemmas faced by abortion providers in Ethiopia

McLean E. (Norway)

**8OS1.4** Beyond restrictive public health policies: The role of misoprostol in the perception and access to illegally induced abortion in Burkino Faso

Drabo S. (Norway)

**10.30**

**3OS5 - Nodding Syndrome: Interdisciplinary Findings and Ways forward in Prevention and Treatment**

**Organisers:** Sarah O’Neill, Medical Anthropology Unit, Institute of Tropical Medicine, Belgium

Robert Colebunders, Global Health Institute, University of Antwerp, Belgium

Koen Peeters, Medical Anthropology Unit, Institute of Tropical Medicine, Belgium

**Chairs:**

Patrick Suykerbuyk (Belgium) and Koen Peeters (Belgium)

**3OS5.1** Nodding syndrome clinical manifestations and treatment

Idro R. (Uganda)

**3OS5.2** Nodding Syndrome: Etiology remains unknown

Winkler A. (Norway)

**3OS5.3** How politics and research fatigue challenge NS control in Uganda

Irani J. (Belgium)

**3OS5.4** High prevalence of epilepsy and onchocerciasis after 20 years of ivermectin use in four villages of the Mahenge area in Tanzania

Mmbando B. (Tanzania)

**3OS5.5** Community-based perceptions of ivermectin in the Sanaga basin of Cameroon

Ronsé M. (Belgium)

**8S5 – HIV**

**Chairs:** Brian Van Wyck (South Africa) and Thérèse Delvaux (Belgium)

**8S5.1** Same day ART initiation versus clinic-based pre-ART assessment and counselling for individuals newly tested HIV-positive during community-based HIV testing in rural Lesotho – A randomized controlled trial (CASCADE trial): Preliminary results

Labhardt N.D., Ringera I., Lejone T.I., Klimkait T., Muhairwe J., Cerutti B., Glass T.R. (Switzerland & Lesotho)

**8S5.2** Prevention of mother-to-child transmission of HIV: Postpartum adherence to option B+ until 18 months in Western Uganda

Theuring S., Decker S., Remps E., Schnack A., Braun V., Rubaihayo J., Busingye P., Tumweigye N.M., Harms G. (Germany & Uganda)

**8S5.3** Screening of human Papillomavirus, cervical cytological abnormalities and associated risk factors in HIV-positive and HIV-negative women in Rwanda

Manzi O.M. (Rwanda)

**8S5.4** HIV prevalence declines in Southern Africa: Have we misread the landscape?

Loevinsohn M.E. (The Netherlands)

**8S5.5** High prevalence of epilepsy and onchocerciasis after 20 years of ivermectin use in four villages of the Mahenge area in Tanzania

Mmbando B. (Tanzania)

**8S5.6** Nodding Syndrome is preventable

Colebunders R. (Belgium)

**12.00**

Lunch Break and Poster Tour (12.30 - 13.30)

**13.30**

**9S1 - Emerging Voices: Making Promises, breaking Commitments: What is the Role of Health Policy and Systems Researchers in transforming Political Commitments into better Health Systems?**

**Chair:** Seye Abimbola (Editor in Chief, BMJ Global Health, UK)

**Speakers/Debaters:**

Khalid F. (Health Financing Consultant, Prime Minister’s National Health Insurance Program, Pakistan, EV 2016)

Choonara S. (Southern African AIDS Trust, Johannesburg, South Africa, EV 2014)

Scott K. (Independent Consultant, Bangalore, India & Johns Hopkins University, USA, EV 2014)

Prashanth N.S. (Assistant Director Research, Institute of Public Health Bangalore, India, EV 2010)

Bermejo R. (Health Policy and Systems Researcher, PhD student - Institute of Tropical Medicine, Antwerp, EV 2010)

**15.00**

Coffee Break
17.00

9S3 - Training on Neglected Tropical Diseases: Are you Brave or Crazy?

Organiser: EuroLeish.net, Marie Skłodowska-Curie – Innovative Training Network, Coordinated by ISGlobal, Barcelona, Spain

Chairs: Nuria Casamitjana (Spain) and Albert Picado (Spain/Switzerland)

9S3.1 Access to Leishmaniasis care – Bridging research and humanitarian needs: A EuroLeish experience
Sunyoto T. (Indonesia)

9S3.2 Reality versus idealism: Was Rutherford right?
Bremer Hinckel B. (Belgium)

9S3.3 The challenges and motivations for doing a PhD in a neglected tropical disease
Hefnawy A. (Belgium)

9S3.4 Capacity strengthening strategies for clinical research in NTDs: A fellowship experience
Castro Noriega M.M. (Colombia)

9S3.5 Vector-borne disease research is rewarding but risky
Macleod Austin V. (UK)

9S3.6 Entomological investigations to identify novel interventions against Chagas Disease in the Bolivian Gran Chaco
Gonçalves R. (UK)

10.30

5IPS1 - Interactive Poster Session 1 - Track 5: Health Systems and Resilience

Chair: Ariadna Nebot (Belgium)

5P5 Exploring resilience in a complex crisis: Iraq’s health system response to a triple security, financial and ecological shock
Mangouri Z., Zanga G.A. (Iraq)

5P6 The side effects of the 2014/15 ebola epidemic: A review
Strasser R., Schuster V., Lee M.H., Sasse J., Schwarz N.G. (Germany)

5P38 Do under-resourced health systems have the ability to offer financial risk protection for primary healthcare? A baseline study of outpatient expenditure to inform health financing and universal coverage reform in the Democratic Republic of Congo (DRC)
Laokri S., Soelaeman R., Hotchkiss D. (Belgium & USA)

5P40 Performed-based financing in Mali: Can it be called emergence?
Coulibaly A., Touré L., Riddle V. (Mali & Canada)

5P55 Performance for universal health coverage – Efficiency analysis of sub-national health systems in Pakistan
Khalid F., Petro Brunel M.T., Sattar A., Hotchkiss D.R. (Pakistan, Switzerland & USA)

5P63 Community engagement, personal responsibility and self help in Cuba's health system reform

5P64 Improving prison health governance: The Zambian Prisons Health System Strengthening (ZAPHSS) project
Topp S.M., Moonga C.M., Chileshe C., Magwende G., Henostroza G. (Australia, Zambia & USA)

12.00

Lunch Break and Poster Tour (12.30 - 13.30)

13.30

5IPS2 - Interactive Poster Session 2 - Track 5: Health Problems & Solutions

Chair: Jean-Paul Dossou (Belgium)

5P6 A systematic literature review of effective strategies for delivery of child health interventions using the private sector in low and middle income settings
Awor P. (Uganda)

5P10 Improving health system capacity to address healthcare disparities: A systematic review of the role of academic health centres in contributing to equitable health systems

5P20 The Kenyan malaria market after AMFm
Musuva A.M., Njigi J., Mwambi D. (Kenya)

5P45 Impact of short term clinical training on tropical and infectious disease to medical doctors working at remote part of Nepal
Rijal S., Karki P., Bhatta N., Sharma S.K., Uranw S., Koirala P., Chhetri R., Boelaert M., Marasini B., Kattel V. (India, Nepal & Belgium)
5P65 Enhancing chronic condition care for urban poor: Role of the local health systems
Bhojani U., Devadasan N., Kolsteren P., De Henauw S., Criell B. (India & Belgium)

5P68 Effect of primary health care worker training on identification of child- and adolescent mental health conditions: A randomised controlled trial in Uganda
Akol A., Babiyi J.N., Makumbi F., Engebretsen I.M.S. (Norway & Uganda)

5P72 A task-shifting mental health program: Integration of primary health care and social care on depression

15.00 Coffee Break

15.30 6/7IPS1 - Interactive Poster Session - Track 6/7: Selected Topics on Tropical Medicine and International Health
Chair: Peter Eerens (Belgium)

6P1 Gender equality in healthcare access during international health crises
Osorio V., Oliver B. (UK)

6P3 Evolving governance options to enhance equitable data sharing

6P5 NCD monitoring: A challenge and a chance for global public health cooperation
Fehr A., Ziese T. (Germany)

6P8 Continued agents of change? Follow-up of graduates from MPH program
Zwanikken P.A.C., Gerstel L. (The Netherlands)

6P9 HERACLES collaborative and translational project on cystic echinococcosis funded by the European Commission
Casulli A. on behalf of the HERACLES consortium (Italy)

7P3 Urban health interventions and vector-borne and other infectious diseases of poverty: An international collaboration to analyse knowledge gaps

7P6 Responsive to who/what? A review of conceptualisations of ‘responsiveness’ in health systems literature
Whyle E.B., Olivier, J. (South Africa)

3OS6 - Integrating Mental Health into Local Health Systems (LHS):
Low and Middle Income Country (LMIC) Experiences

Organisers:
Nandini D.P. Sarkar and Bart Criel, Equity and Health Unit, Department of Public Health Institute of Tropical Medicine, Antwerp, Belgium

Chair:
Bart Criel (Belgium)

3OS6.1 Interface between demand, need and supply of mental health care in local health systems in low- and middle-income countries: A worrisome picture
Criel B. (Belgium)

3OS6.2 Mental health in primary health care in India: The Gumballi experience
Prashanth N.S. (India)

3OS6.3 Role of front-line professionals in providing care for the mentally ill in Guinea
Sow A. (Guinee-Conakry)

3OS6.4 Workings of a Ugandan district hospital's mental health clinic – Patient-caregiver and health worker perspectives
Sarkar N.D.P. (Belgium & The Netherlands)

3OS6.5 Integrating mental health care into health system: Rwanda experience
Ait Mohand A. (Rwanda) and Kayiteshonga Y. (Rwanda)

General discussion, concluding remarks and ways forward
Criel B. (Belgium)
10.30  
**4IPS1 - Interactive Poster Session 1 - Track 4: Biosocial Approaches to Disease Control**  
Chair: Koen Peeters (Belgium)

4P1  
Economic and disease and burden of dengue from the perspective of the patients and their families  
Baly A., Abadi A., Cabrera P., Van der Stuyft P. (Cuba & Belgium)

4P50  
Community participation as part of formative research to design innovative malaria elimination strategies in The Gambia  
Masunaga Y., Jafieh F., D’Alessandro U., Okebe J., Muela Ribera J., Peeters Grietens K. (Belgium, Gambia & Switzerland)

4P62  
Factors limiting the effectiveness of standardized malaria control strategies in forested highlands of Vietnam: A qualitative study  

4P75  
Epilepsy perceptions and experiences of different stakeholders prior to the implementation of an epilepsy treatment programme in an onchocerciasis endemic region in Ituri, Democratic Republic of the Congo (DRC)  
Dolo H., Ucima Wonya'Rossi D., Mandro N.M., Ngave F., Fraeyman J., Suykerbuyk P., Colebunders R. (Belgium, DRC, Mali & Belgium)

12.00  
Lunch Break and Poster Tour (12.30 - 13.30)

13.30  
**4IPS2 - Interactive Poster Session 2 - Track 4: Surveillance & Response**  
Chair: Delphin Phanzu Mavinga (Congo)

4P28  
Performance of community tracing system of people affected by Tuberculosis duringbola in Conakry, Guinea  
Ortuo-Gutiérrez N., Chérf G.-F., Loua F., Souleymane H.H., Bouangou A., Dama L.-M. (Guinea)

4P52  
Targeted-reactive case detection at sleeping sites to interrupt malaria transmission in Vietnam I - Risk behaviors associated with malaria cases sleeping in a farm or forest  
Canavati S.E., Thuan V.H., Khanh L.T., Oht C., Ngo T.D., Tran D.T., Martin N.J. (Vietnam, Australia, Finland & Singapore)

4P74  
Visceral leishmaniasis cases in the non-endemic districts: Challenges to ongoing elimination programme in Nepal  

4P119  
Evaluation and analysis of Acute Flaccid Paralysis (AFP), surveillance system data in the N’Djamena regional health delegation, Chad, 2012-2014  
Nadougo D.H., Diasia F., Mbaolho T., Mathieu E. (Cameroon & Chad)

15.00  
Coffee Break

15.30  
**3IPS1 - Interactive Poster Session 1 - Track 3: Traveler and Migrant Health**  
Chair: Jan Clerinx (Belgium)

3P34  
Treatment issues with acute Schistosomiasis in a cluster cohort of 34 travelers infected in South Africa - An observational study  
Clerinx J., Maniewski U., Cnops L., Soentjens P., Van Esbroeck M., Bottieau E. (Belgium)

3P42  
Arterial stiffness in chronic indeterminate Chagas disease: A case-control study  

3P73  
Pre-travel guidelines needed for travelers with an Immunocompromised status or chronic disease  
Van Aalst M., Verhoeven R., Omar F., Stijns C., van Vugt M., de Bree G.J., Goorhuis A., Grobusch M.P. (The Netherlands)

3P74  
Lobomycosis in an Italian traveler acquired during 5 days-honeymoon in the Amazon region of Venezuela  
Beltrame A., Danesi P., Fanina C., Orza P., Perandini F., Capelli G., Rodari P., Staffolani S., Bisoffi Z. (Italy)

3P75  
Cardiovascular disease risk prediction in sub-Saharan African migrant and home populations – Comparative analysis of risk algorithms in the Rodam study  

3P77  
The challenge of persistent parasitic and viral infections among prisoners from sub-Saharan Africa and Latin America: A cross-sectional study in Geneva, Switzerland  
Getal L., Chappuis F., Wolff H., Albajar-Vinas P., Vitoria M., Tran N.T., Da Silva Santos L. (Switzerland)

3P78  
“He doesn’t seem to understand it as an illness”: Mental health interventions for migrant victims of torture and other forms of ill treatment  
Womersley G., Klotzer L., Van den Bergh R., Vennesles E., Kotsioni I., Kokkinotis M., Zamatto F. (Switzerland & Greece)

3P79  
Epidemiological, microbiological and clinical data of traveller pregnant women returning from vector-borne endemic areas for Zika virus  
3IPS2 - Interactive Poster Session 2 - Track 3: Clinical Medicine in the Tropics
Chair: Emmanuel Bottieau (Belgium)

3P9 Implication of using the GeneXpert for the detection of STIs in pregnant women in Kisantu Health Zone, DRC

3P10 Safety of RVSV ebola vaccine, after 6 months follow-up, in adults: A phase 1 trial conducted in Lambaréné, Gabon

3P17 Accuracy of a rapid test for the diagnosis of cutaneous leishmaniasis in patients with suggestive skin lesions in Morocco
Bennis I., Verdonck K., Riyad M., el Khatfaoui N., Fehlai H., Sahibi H., Van der Auwera G., Dujardin J.C., Boelaert M. (Morocco & Belgium)

3P25 Chronic multi-morbidity among bangladeshi adult population
Khan N., Rahman M., Afsana K. (Bangladesh)

3P31 Onchocerciasis associated epilepsy and blackflies in the Democratic Republic of the Congo (DRC)

3P33 Frequency of Taenia solium antigen positivity in patients admitted for neurological disorders in the Rural Hospital of Mosango, Province of Kwilu, the Democratic Republic of Congo
Bottieau E., Mukendi D., Barbe B., Yansouni C.P., Dorny P., Gabriël S., Winkler A.S., Lutumba F., Chappuis F., Boelaert M. (Belgium, the Democratic Republic of Congo, Canada, Norway & Switzerland)

3P67 Investigation of markers of artemisinin resistance at selected intervals during the 72- hour period after artemisinin based combination therapy dosing in Kisumu western Kenya
**Monday**

08.30

**Plenary Talks**

*Chairs:* François Chappuis (Switzerland) and Zeno Bisoffi (Italy)

**Fevers and cold feet**
Paul Newton, University of Oxford, UK and LOMWRU, Laos

**Access to new and expensive essential medicines, as part of universal health coverage**
Hans V. Hogerzeil, University Medical Centre, Groningen, The Netherlands

10.00

**Coffee Break**

10.30

**SOS3 - Poor Quality Medicines: A Hidden Threat to Health Systems and International Health**

*Organisers:* Raffaella Ravinetto, Medicines Working Group of Be-cause Health, Brussels, Belgium and Anne Whitehouse, Medicines Working Group of the Infectious Diseases Data Observatory, Oxford, UK

*Chairs:* Hans Hogerzeil (The Netherlands) and Raffaella Ravinetto (Belgium)

5OS3.1 **Quality of artemisinin combination therapies in Sub-Saharan Africa and Cambodia, assessed using laboratory analytical techniques**
Kaur H. (UK)

5OS3.2 **Medicine quality screening devices – Many devils in the details**
Newton P. (UK & Laos)

5OS3.3 **Poor quality-medicines: The regulatory challenges in Sub-Saharan Africa**
Siyoi F. (Kenya)

5OS3.4 **Poor quality-medicines: A perspective from the WHO pre-qualification program**
Mubangizi D. (Switzerland)

12.00

**Lunch Break and Poster Tour (12.30 - 13.30)**

13.30

**5S4 - Drugs, Diagnostics & Supplies**

*Chairs:* Deus Mubangizi (Switzerland) and Raffaella Ravinetto (Belgium)

5S4.1 **The quality of artemether-lumefantrine combination and characteristics of pharmacies in the periurban areas of Kinshasa**
Mavungu Landu D.J., Liégeois S., Manzambi Kuwekita J., Mbainze J., Mavungu Naiona J., Hubert P., Michel B., Reginster J.Y., Frédéric M., Mariní Djoung’Eing’ A.R. (Belgium & DRC)

5S4.2 **The impact of local private distributors on quality of medicines available in non-African low- and middle-income countries**
Van Assche K., Nebot Giralt A., Caudron J.M., Ravinetto R. (Belgium & France)

5S4.3 **How the quality strategy can tackle the challenges of procuring medicines in weak regulatory environments: The experience of a sub-Saharan African Procurement Centre**
Singh Lotay P., De Santi O., Ravinetto R. (Kenya & Belgium)

5S4.4 **A health system perspective to improving pharmaceutical supply: Lessons from Zimbabwe**
Carasso K.B., Naylor M., Ngwara T., Caffrey M., Witter S. (Belgium, UK & South Africa)

15.00

**Coffee Break**

15.30

**7OS1: How does Global Trade impact Health? Panel Debate**

*Organisers:* Peter Eerens, Living Health Systems, Brussels, Belgium; working group ‘Social Determinants of Health’ of Be-Cause Health, Brussels, Belgium and Liesbet Vangeel, Policy Dept., FOS, Brussels, Belgium; working group ‘Social Determinants of Health’ of Be-Cause Health, Brussels, Belgium

*Chair:* Peter Eerens (Belgium)

*Panellists:*

7OS1.1 Steendam J. (Belgium)

7OS1.2 Loridan J. (Belgium)

7OS1.3 Koivusalo M. (Finland)

17.00

**World Premiere of The Heart of the Matter, a Film focusing on Peter Piot’s Research**

Followed by an interview with Peter Piot led by Andrew Jack, Editor of Curated Content at the Financial Times and member of the Global Health Film Initiative Advisory Board
Monday

10.30  3OS7 - How to stop Global Antibiotic Resistance? How to translate the WHO Global Action Plan for the Field Reality of Low-Resources Settings?

Organiser:
Bacterial Infections in the Tropics (BIT) research cluster, ITM Antwerp
In collaboration with University of Antwerp and Radboud UMC, Nijmegen, The Netherlands

Chairs:
Erika Vlieghe (Belgium) and Halidou Tinto (Burkina Faso)

3OS7.1 Best practices of implementing clinical bacteriology in low resource settings
Affolabi D. (Benin)

3OS7.2 Infection prevention and control in high- burden low-resource settings: Where to start, and what to do?
Hopman J. (The Netherlands)

3OS7.3 Optimizing worldwide use of antibiotics: What works?
Wertheim H. (The Netherlands)

3OS7.4 Veterinary antibiotic stewardship: The One Health perspective
Carrique Mas J. (Vietnam)

12.00 Lunch Break and Poster Tour (12.30 - 13.30)

13.30  3S4 - Antibacterial Resistance

Chairs: Cedric Yansouni (Canada) and Heimand Wertheim (The Netherlands)

3S4.1 Asymptomatic bacteriuria in pregnant women as a proxy for antibiotic resistance surveillance in the community: Preliminary results from a study in Nanoro, rural Burkina Faso
Issa G., Palpouguini L., Post A., Barbara B., Tinto H., Jacobs J. (Burkina Faso & Belgium)

3S4.2 Meta-analysis of proportion estimates of extended-spectrum-beta-lactamase-producing Enterobacteriaceae in East Africa hospitals

3S4.3 Antibiotics under pressure: Azithromycin as malaria treatment, fluoroquinolones in TB treatment and co-trimoxazole for HIV-patients: How to balance increased use with the risk of emerging resistance in reserve antibiotics?
Vlieghe E. (Belgium)

15.00 Coffee Break

Wednesday Nightingale

Tuesday

15.30  3OS8 - Non-malarial Febrile Illness in the Tropics: The Ultimate Clinical Challenge?

Organiser:
Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium

Chairs:
Cedric Yansouni (Canada) and Emmanuel Bottieau (Belgium)

3OS8.1 Can we decrease the antibiotic misuse for febrile illnesses in the tropical primary care setting?
Keitel K. (Switzerland)

3OS8.2 Surveillance of febrile illness in the tropics: Beyond the point-of-care to sentinel laboratories
Yansouni C. (Canada)

3OS8.3 Prolonged fever in the tropics: A challenging clinical entity deserving more attention?
Chappuis F. (Switzerland)
10.30  
**4S5 – Malaria: From Control to Elimination?**  
**Chairs:** Halidou Tinto (Burkina Faso) and Jo Robays (Belgium)

**4S5.1** Pregnant women as sentinels: A pragmatic approach to malaria surveillance  
Brunner N.C., Chacky F., Mandike R., Mohamed A., Lengeler C., Molteni F., Hetzel M.W.  
(Switzerland, United Republic of Tanzania)

**4S5.2** Harnessing the wisdom of crowds to inform health spending: The case of malaria eradication  
Brew J.R., Pradhan M.P., Sicuri E. (Spain, The Netherlands & UK)

**4S5.3** School-based malaria prevalence survey: Important longitudinal surveillance tool to assess epidemiological impact of malaria control interventions in the Democratic Republic of the Congo  
Swana K.E., Suprianto, Makan Mawaw P., Yav T., Clarence Kaut Mukeng, Hetzel M.W. (DRC & Indonesia)

**4S5.4** Epidemiological profile of malaria transmission in the Brazilian Amazon, 2010-2015  
Canelas T., Castillo-Salgado C., Ribeiro H. (Brazil & USA)

12.00  
**4OS2 - Targeted Malaria Elimination in the Greater Mekong Subregion using Mass Drug Administrations**  
**Organiser:** Lorenz von Seidlein, Mahidol-Oxford Tropical Medicine Research Unit (MORU)  
Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand  
**Chair:** Lorenz von Seidlein (Thailand)

**4OS2.1** Introduction: Rationale and methods of targeted malaria elimination  
White N. (Thailand)

**4OS2.2** The impact of mass drug administrations on plasmodium parasitaemia in four villages in Vietnam: Findings from a randomised, controlled trial  
Thuy-Nhien N. (Vietnam), Hien T. (Vietnam)

**4OS2.3** A cluster randomised trial of mass administration of dihydroartemisinin-piperaquine in a multidrug-resistant area of Cambodia  
Tripura R. (Thailand), Tom Peto (Thailand)

**4OS2.4** A mass administration of dihydroartemisinin-piperaquine in Savannakhet, Lao PDR: A cluster randomised controlled trial  
Phommasone K. (Vietnam), Mayfong M. (Vietnam)

15.00  
**Coffee Break**

15.30  
**2S5 - Malaria Vectors and Transmission**  
**Chairs:** Marc Coosemans (Belgium) and Alain Nahum (Benin)

**2S5.1** Entomological indices of *Plasmodium falciparum* transmission in Sahelian area before panafroicn Great Green Wall initiative implementation, Burkina Faso, West Africa  

**2S5.2** Pharmacokinetic and pharmacodynamic modeling for the prediction of the mosquitocidal effect duration of high-dose ivermectin (The IVERMAL PK/PD Model)  

**2S5.3** The effectiveness of a topical repellents and long-lasting insecticidal nets on mosquito populations in a malaria pre-elimination setting of Cambodia  
Mao S., Durnez L., Coosemans M. (Cambodia & Belgium)

**2S5.4** Evidence of cuticular resistance to pyrethroids in Anopheles gambiae  

**2S5.5** Science and nature: Susceptibility of wild caught adult *Anopheles gambiae* s.s. to insecticides may not decrease with age  

**2S5.6** Bringing quality assurance for indoor residual spraying (IRS) into the 21st century: Improving IRS policy implementation  
Gleaves K., Coleman M., Mbokazi F., Kok G., Coetzee M., Saaiman M., Paine M., Foster G. (UK & South Africa)
5S5 - Risk Factors and NCD

Chair: Upendra Bhojani (India) and Josefien van Olmen (Belgium)

Keynote: The intersection between NCD and chronic infectious diseases - A sub-Saharan Africa perspective
Levitt N. (South Africa)

5S5.1 Tracing Africa’s progress towards implementing the Non-Communicable Diseases Global action plan 2013-2020: A synthesis of WHO country profile reports
Nyaaba G.N., Stronks K., de-Graft Aikins A., Kengne A.P., Agyemang C. (The Netherlands, Ghana & South Africa)

5S5.2 Assessment of diabetes care in the municipalities of Cardenas and Santiago (Cuba)
Londoño Agudelo E., Rodríguez Salvá A., Seuc Jo A., Díaz Piñera A., Maldonado Cantillo G., Balciñdes Acosta S., Van der Stuyft P. (Belgium & Cuba)

Mpondo B.C., Bintabara D. (Tanzania)

5S5.4 How are resource-limited countries addressing global versus national implementation challenges in diabetes prevention and control? The Kenya experience
Shiroya V.N., Deckert A., Mayeden S., Neuhann F. (Germany)

12.00 Lunch Break and Poster Tour (12.30 - 13.30)

13.30 5OS4 - Tackling the Non-Communicable Disease Epidemics in Low- and Middle Income Countries

Organisers: Josefien Van Olmen and Jeroen De Man, ITM, Public Health Department and the Be-cause Health NCD group

Chairs: Peter Delobelle (South Africa) and Josefien Van Olmen (Belgium)

5OS4.1 Magnitude and prognosis of strokes at Bobo-Dioulasso
Donnen P. (Belgium)

5OS4.2 Enhancing chronic condition care for urban poor: Role of the local health systems
Bhojani U. (India)

5OS4.3 Identifying strategies to support self-management for type 2 diabetes: A multi-country comparative case study
De Man J. (Belgium)

5OS4.4 Out-of-pocket expenditures for hypertension care in a low-income urban community of Medellin-Colombia
Londoño Agudelo E. (Belgium)

5OS4.5 Towards patient-centered engagement in chronic care: a patient-provider perspective in rural Malawi
Angwenyi V. (Kenya)

15.00 7OS2 - Refugee Mental Health in the Global South and North: Current Research and Best Practices

Organisers: Nandini D.P. Sarkar, Equity and Health Unit, Department of Public Health Institute of Tropical Medicine, Antwerp, Belgium
Christiana Noestlinger, HIV and Sexual Health Unit, Department of Public Health Institute of Tropical Medicine, Antwerp, Belgium

Chairs: Christiana Noestlinger (Belgium) and Nandini Sarkar (Belgium)

7OS2.1 Mental wellbeing of refugee children: Prevalence and associated factors
Derluyn I. (Belgium)

7OS2.2 The Ugandan approach to Africa’s largest refugee crisis – How does mental health fit in? An interactive conversation
Ventevogel P. (Switzerland)

7OS2.3 PACCT® (Psychiatry Assisting the Cultural diverse Community in creating healing Ties): An intervention methodology strengthening the social networks of refugee families in order to make mental health more accessible and effective for refugee children and adolescents
Serneels G. (Belgium)

7OS2.4 Providing mental healthcare to migrants: Different needs, different settings – Example of Italy
Severny N. (Belgium)

General Q&A with audience interaction and debate
Sarkar N.D.P. (Belgium)
5S6 - Human Resources for Health
Chair: Faustin Chenge (DR Congo) and Stefaan Van Bastelaere (Belgium)

5S6.1 Nurse mentoring as a means to improve quality of obstetric care in Bihar, India
Srivastava S., Warren N., Mayra K., Rao K.D. (USA & India)

5S6.2 Factors associated with mental wellbeing of health workers in Malawi – Findings from a health worker survey using the WHO-5 Wellbeing Index
Lohmann J., Shukenbayev O., Wilhelm D., Brenner S., Karnbala C., Mula A.S., de Allegri M. (Germany & Malawi)

5S6.3 Non-state providers responding to system changes: Exploring the adaptive capacities of faith-based health providers in the Ecuadorian health system
Ullauri A.N., Olivier J. (South Africa)

12.00 Lunch Break and Poster Tour (12.30 - 13.30)

13.30 5OS5 - Human Resources for Health in Low Income Countries and Complex Settings: An Opportunity to address Global Challenges?
Organisers:
Stefaan Van Bastelaere, Belgian Development Agency Brussels, Belgium
Anne Fromont, School of Public Health, Université Libre de Bruxelles, Brussels, Belgium
Remco Van De Pas, Institute of Tropical Medicine, Antwerp, Belgium
Mit Philips, Médecins Sans Frontières Operational Centre Brussels, Analysis Department, Brussels, Belgium
Nimer Ortuño-Gutiérrez, Damien Foundation, Brussels, Belgium
Chair:
Stefaan Van Bastelaere (Belgium)

5OS5.1 Human resources for health in Guinea: A baseline study and policy analysis
van de Pas R. (Belgium) and Kolie D. (Guinée)

5OS5.2 Lifting of fiscal space restrictions to boost the Health Workforce in the public sector in Sierra Leone and Malawi: What options does WHO’s HRH-action plan provide?
Philips M. (Belgium)

5OS5.3 Implementation of occupational health program and upholding Tuberculosis services during Ebola epidemic in Conakry, Guinea
Ortuño-Gutiérrez N. (Belgium)

5OS5.4 How to support health worker capacity in fragile context: Case of a coaching strategy in Burundi
Fromont A. (Belgium)

15.00 Coffee Break
10.30 1S3 - Molecular Biology and Epidemiology - Before Whole Genome Sequencing
Chairs: Henk Schallig (The Netherlands) and Anna Rosanas-Urgell (Belgium)

1S3.1 Molecular epidemiology of plasmodium vivax in Solomon Islands

1S3.2 Increase of mutations associated with SP resistance in Plasmodium falciparum isolates collected during pregnancy in Nanoro, Burkina Faso

1S3.4 Revealing the genetic diversity of mycobacterium tuberculosis strains causing tuberculous lymphadenitis in Southwest Ethiopia
Tadesse M., Abebe G., de Rijk P., Meekan C., de Jong B.C., Rigouts L. (Ethiopia & Belgium)

1S3.5 Detecting schistosoma mansoni transmission using environmental DNA in water samples

12.00 Lunch Break and Poster Tour (12.30 - 13.30)

13.30 1S4 - Molecular Biology and Epidemiology - 2nd Generation Tools: Whole Genome Sequencing and Hereafter
Chairs: Pedro Alcolea (Spain) and Jean-Claude Dujardin (Belgium)

1S4.1 Micro-epidemiological approach to understanding transmission dynamics of Mycobacterium ulcerans in the Ouémé river valley in southern Benin
Esseryani M., Vandelannoote K., Meehan C., Afiolotl D., Aguilar J., Marion E., Sopah G., Porteaux F., de Jong B.C., Stinear T. (Belgium, Benin, Australia & France)

1S4.2 Clonal waves of meningococcal colonization and disease in the African meningitis belt: Emergence of a hypervirulent W:ST-2881(CC175) clone by capsule switching
Pluschke G. (Switzerland)

1S4.3 Zika virus genetic diversity and selective pressure: Importance for diagnostics, vaccines and therapeutics

1S4.4 Direct sequencing of Leishmania genome in clinical samples
Domagalska M.A., Imamura H., Sanders M., Rijal S., Berriman M., Cotton J., Dujardin J.C. (Belgium, UK & Nepal)

15.00 Coffee Break
10.30 4OS3 - Using the One Health Concept for Preparedness of Emerging Diseases

Organisers: The Post-Ebola Resilience Project Consortium Partners
Ankie van den Broek, Jurrien Toonen and Ingrid Zuleta, KIT- Royal Tropical Institute, Amsterdam, The Netherlands
Maarten Voors, Wageningen University, Wageningen, The Netherlands
Kofi Bonney, Noguchi Memorial Institute for Medical Research, Accra, Ghana

Chairs: Ger Steenbergen (Ghana) and Ankie van den Broek (The Netherlands)

4OS3.1 Grassroots One Health: Community disease surveillance in Sierra Leone
Voors M. (The Netherlands)

4OS3.2 Capacity building and strengthening laboratory services for humans and animals
Bonney K. (Ghana)

4OS3.3 Strengthening social accountability through RBF (Results Based Financing)
Habineza C. (Rwanda)

4OS3.4 Increasing the resilience and preparedness of EBV and other emerging diseases in Sierra Leone and Guinea through collaboration achieved between both the human health and animal health working in various systems and sectors
Van den Broek A. (The Netherlands)

After the presentations, there will be an interactive session (debate) with the participants.

12.00 Lunch Break and Poster Tour (12.30 - 13.30)

13.30 2S6 – Zoonoses

Chairs: Josef Vercruysse (Belgium) and Pierre Dorny (Belgium)

2S6.1 Viral pathogens at the human-wildlife interface in DRC: Wild mammals as natural hosts of zoonotic viruses
Ngay L.I., Midingi G., Mbala K.P., Kumakamba M.C., Nkawa F., Monagin C., Jolly D., Mulembakani M.P., Makuwa M., Muyembe Tamfum J.J. (DRC, USA & Canada)

2S6.2 Transmission of ESBL-producing Escherichia coli between humans and poultry - A one-health study from Ghana
Elbach D., Irizalalologu C., Hogan B., Krumkamp R., Falgenhauer L., Danquah C., Poppert S., Sarpong N., Owusu-Dabo E., May J. (Germany & Ghana)

2S6.3 Vector-borne zoonoses surveillance in Piedmont region, northwestern Italy (2011-2016)
Pautasso A., Verna F., Radael M.C., Bellavia V., Mosca A., Pintore M.D., Tomassone L., Mandola M.L., Julli B., Casalone C. (Italy)

2S6.4 Spatial patterns and abundance of rodents in Lassa fever endemic rural villages in Guinea
Marien J., Magassouba N., Leirs H., Fichet-Calvet E. (Belgium, Guinea & Germany)

15.00 Coffee Break

15.30 3OS9 - Hepatitis C Care in Resource-Constrained Settings - Do We have a Scalable Public Health Approach anno 2017?

Organisers: Lutgarde Lynen, Department of Clinical Sciences, HIV & infectious diseases unit Institute of Tropical Medicine Antwerp, Belgium
Thomas Van Wolleghem, Sven Francque, University Hospital of Antwerp, Gastroenterology and Hepatology, Edegem, Belgium

Chairs: Lutgarde Lynen (Belgium) and Thomas Van Wolleghem (Belgium)

Introduction to the public health approach to HCV care
Lynen L. (Belgium)

3OS9.1 Access to HCV medicines and diagnostics worldwide – Successes & remaining challenges
Burry J. (Switzerland)

3OS9.2 The innovative R&D model of the Drug for Neglected Disease Initiative (DNDi) to increase access to HCV care in low- and middle income countries
Diap G. (Switzerland)

3OS9.3 Unlocking the Hepatitis C market for diagnostics
Marinucci F. (Switzerland)

3OS9.4 Hepatitis C testing & treatment roll-out in Rwanda – Policy development & Program implementation
Nsanzimana S. (Rwanda)

3OS9.5 Prevalence of Hepatitis C/HIV co-infection in Phnom Penh, Cambodia
Kien A. (Cambodia)

3OS9.6 Treatment with generic Direct Acting Antivirals - Results from a pilot HCV/HIV coinfection project in Cambodia
De Weggheleire A. (Belgium)
10.30 8S6 - Child Mortality
Chairs: Olaf Müller (Germany) and Claudia Beiersmann (Germany)

8S6.1 Seasonal variation in child mortality in rural Guinea-Bissau
Nielsen B.U., Byberg S., Aaby P., Rodrigues A., Benn C.S., Fisker A.B. (Guinea-Bissau & Denmark)

8S6.2 Child mortality in Guinea-Bissau – The effects of out-of-sequence vaccination
Thysen S.M., Rodrigues A., Aaby P., Fisker A.B. (Guinea-Bissau & Denmark)

8S6.3 Country-specific pathways from socioeconomic determinants to under-five mortality in Sub-Saharan Africa
Van Malderen C., Amouzou A., Masquelier B., Van Oyen H., Speybroeck N. (Belgium & USA)

8S6.4 Saving children's lives with colours

12.00 Lunch Break and Poster Tour (12.30 - 13.30)

13.30 8S7 - Child Health Problems
Chairs: Anne Buvé (Belgium) and Kirilly De Polnay (Belgium)

8S7.1 Prevalence of paediatric chronic suppurative otitis media and hearing impairment in rural Malawi: A cross-sectional tele-otoscopy survey
Hunt L., Mulwafu W., Knott V., Ndamala C.B., Naunje W., Dewhurst S., Hall A., Mortimer K. (UK & Malawi)

8S7.2 Prevalence and incidence of schistosome infection and morbidity in pre-school children aged 6 months to 5 years
Osakunor D.N.M., Mduluza T., Midzi N., Woolhouse M.E.J., Mutapi F. (UK, Zimbabwe & South Africa)

8S7.3 Metabolic profiling of pre-school aged and school-aged children infected with Schistosoma mansoni and treated with praziquantel
Panic G., Keiser J., Coulibaly J.T., Silué K.D., Kovacs J., Harvey N., Holmes E., Swann J. (Switzerland, Côte d'Ivoire & UK)

8S7.4 Etiologies of fever episodes among children under 5 years in a seasonal malaria transmission area, Burkina Faso
Kiemde F., Tahtla M.C., Lompo P., Rouamba T., Some A.M., Tinto H., Mens P.F., Schallig H.D.F.H., Boele van Hensbroek M. (Burkina Faso & The Netherlands)

8S7.5 Incidence and characteristics of unintentional injuries among children in a resource limited setting in Kampala, Uganda
Ssemugabo C., Mukama T., Halage A.A., Paichadze N., Gibson D., Kobusingye O. (Uganda & USA)

15.00 Coffee Break

15.30 4S6 - NTD Control/Elimination through Preventive Chemotherapy
Chair: Marco Albonico (Italy)

4S6.1 Challenges for the control of strongyloidiasis in public health
Albonico M., Bisoffi Z., Montresor A., Savioli L. (Italy & Switzerland)

4S6.2 Predictive value of ov16 antibody prevalence in different sub-populations for elimination of African onchocerciasis
Coffeng L.E., Stolk W.A., De Vlas S.J., Golden A., De los Santos T., Domingo G.J. (The Netherlands & USA)

4S6.3 The impact of semi-annual mass drug administration for multi-species lymphatic filariasis in Indonesia: A modelling approach
Verkerk P.J., Kontourakis P., Supali T., Fischer P.U., de Vlas S.J., Weil G.J., Stolk W.A. (The Netherlands, Indonesia & USA)

4S6.4 High prevalence of epilepsy and onchocerciasis after 20 years of ivermectin use in four villages of the mahenge area in Tanzania
Mmbando B.P., Mnacho M., Makunde M., Kakorozya A., Matuja W., Greter H., Suykerbuij P., Colebunders R. (Tanzania & Belgium)

4S6.5 The long-term impact of preventive chemotherapy on the burden of soil-transmitted helminth infection
Joseph S.A., Montresor A. (Switzerland)
### 5S8 - Financing

**Chair:** Elisabeth Paul (Belgium)

**5S8.1** Do patients who incur informal payments really receive care of better quality? Evidence from Cameroon
  Kankeu Tchewonpi H. (UK)

**5S8.2** It takes two to own - The policy process behind the implementation of PBF in Uganda
  Rennmans D., Holvoet N., Criel B. (Belgium)

**5S8.3** Catastrophic health expenditure and care-seeking practices in Afghanistan: A mixed-methods study
  Jacobs E., Zaal F., Alba S. (The Netherlands)

**5S8.4** Financial access barriers for HIV patients in Kinshasa, DRC and possible mitigation by patient associations' managed vouchers
  Vinard P., Aventin L., Cartier N., Philips M. (France & Belgium)

**12.00** Lunch Break and Poster Tour (12.30 - 13.30)

### 5OS6 - Strategic Financing: Concept and Field Applications from 6 Partner Countries

**Organisers:**
BTC headquarters and 6 health projects in 6 different countries, including the national partners

**Chair:** Paul Bossyns (Belgium)

**5OS6.1** Keynote on strategic financing for more resilient health systems
  Bossyns P. (Belgium)

**5OS6.2** Strategic financing to increase system's performance in Senegal
  Ladrière F. (Senegal)

**5OS6.3** Strategic financing to increase system's performance in Niger
  Adamou H. (Niger)

**5OS6.4** Strategic financing to increase system's performance in Benin
  Sogbohossou P. (Benin)

**5OS6.5** Strategic financing to increase system's performance in Uganda
  Byakikka S. (Uganda)

**5OS6.6** Strategic financing to increase system's performance in Burundi
  Bosmans M. (Burundi)

**5OS6.7** Strategic financing to increase system's performance in DRC
  Iyeti A. (DRC)

**15.00** Coffee Break

### 5OS7 - Scratching beyond the Surface: Methods for and Cases of Under-documented Issues in Performance-Based Financing (PBF)

**Organisers:**
Institute for Development Policy and Management (IOB), Universiteit Antwerpen, Belgium
ARC Effi-Santé, Université de Liège, Liège, Belgium
Chaire Réalisme, Université de Montréal, Canada

**Chair:** Valéry Ridde (Canada)

**Round Table 1: Innovative approaches**

**5OS7.1** Using Causal Loop Analysis in a theory-based evaluation of performance-based financing: The case of Uganda
  Rennmans D. (Belgium)

**5OS7.2** Practitioners vs. researchers? Challenges and opportunities of engaging actors across silos in knowledge production processes on PBF
  Antony M. (Belgium)

**5OS7.3** Combining semantic discourse and social network analyses with qualitative data to explore the contribution of the PBF Community of Practice to policy diffusion in Africa
  Gautier L. (Canada)

**5OS7.4** Understanding the complex motivational mechanisms and consequences of PBF - A self-determination theory-based mixed methods approach
  Lohmann J. (Germany)

**Round Table 2: Under-Documented Issues**

**5OS7.5** PBF in Benin: Lack of ownership, capitalisation of experience, and sustainability
  Paul E. (Belgium)

**5OS7.6** Looking a gift horse in the mouth: When PBF subsidies eventually demotivate, the case of Senegal
  Bodson O. (Belgium)

**5OS7.7** Performed-Based Financing in Mali: Can it be called emergence?
  Coulibaly A. (Mali)

**5OS7.8** The unintended consequences of performance-based financing in Burkina Faso
  Turcotte-Tremblay A.M. (Canada)
6OS3 - Collaborative Initiatives for Capacity Building and Education

Organisers:
Marjan Pirard, Mieke Stevens, Maria Zolfo and Govert van Heusden
Institute of Tropical Medicine, Antwerp, Belgium

Chair:
Marjan Pirard (Belgium)

6OS3.1 Shaping tropEd, a higher education network in International Health, to meet contemporary needs
Reynolds R. (UK)

6OS3.2 Networking for quality in international health teaching and learning
van Heusden G. (Belgium)

6OS3.3 Amplifying influence: The West African Network of Emerging Leaders (WANEL) in health policy and systems
Kwamie A. (Ghana)

6OS3.4 Building sustainable capacity for operational research at a global level using the Structured Operational Research and Training Initiative (SORT IT) model
Zachariah R. (Switzerland)

6OS3.5 Virtual student mobility in international/global health
Gerstel L. (The Netherlands)

10.30

12.00 Lunch Break and Poster Tour (12.30 - 13.30)

13.30 6OS4 - Collaborative and Innovative Tools for Interactive Learning in Mobile Low-Bandwidth Context

Organisers:
Carlos Kiyan, Jan Kennis, Mieke Stevens and Maria Zolfo
Institute of Tropical Medicine, Antwerp, Belgium
Diljith Kannan and Harish H.N.
Institute of Public Health, Bangalore, Karnataka, India

Chair:
Diljith Kannan (India)

6OS4.1 Linking innovation, technology and collaboration to enhance teaching and learning
Kennis J. (Belgium)
Kiyan C. (Belgium)
Diljith K. (India)

15.00 Coffee Break

Journalism Session: The Impact of Science and Journalism on Global Health (‘Are Journalists and Scientists failing Global Health?’)

Organiser:
Roeland Scholtalbers (Institute of Tropical Medicine Antwerp)

Chair:
Andrew Jack (Financial Times)

Speakers:
Serusha Govender (Freelance journalist, South Africa; ITM Journalist-in-residence 2017)
Bharathi Ghanasyam (Journalists against TB, India; ITM Journalist-in-residence 2015)
Johan Van Griensven (Institute of Tropical Medicine Antwerp, coordinator Ebola-Tx trial in Guinea)
Emmanuelle Roure (Directorate-General Health & Food Safety, European Commission)

Recent outbreaks of Ebola and Zika have shown how important it is to communicate correctly about public health crises and scientific advancement. This session explores how science and journalism can foster a real dialogue for the benefit of global health.

This debate between journalists, scientists, policy-makers and the public will evolve around the question “Are journalists and scientists failing global health?”
2IPS1 - Interactive Poster Session Track 2: One Health Ecology
Chair: Sarah Gabriël (Belgium)

2P19 Erysipelothrix rhusiopathiae infection in pigs, pork and among raw pork handlers in Kamuli District, Eastern Uganda
Musewa A., Roesse K., Della G., Nakanjako D., Kawooya I., Ssenyonga R., Nangendo J., Erume J. (Uganda, Kenya & Germany)

2P26 Filarial parasites in cats and dogs represent a public health threat in Madampe, Sri Lanka
Mallawarachchi C.H., Chandrasena T.G.A.N., Wickramasinghe S., Samarasekara S.D., Mallawarachchi S.M.N.S., de Silva N.R. (Sri Lanka)

2P28 Zika virus dynamics in body fluids and risk of sexual transmission in a non-endemic area
Pou D., Sánchez-Montalvá A., Suleiro E., Salvador F., Bocanegra C., Treviño B., Rando A., Sere N., Molina I. (Spain)

2P44 Combining area-wide mosquito repellents and long-range attractants to create a “push-pull” system that protects against disease transmitting mosquitoes in Tanzania
Mmbando A., Okumu F., Ngowo H., Abbas S., Matowo N., Kiliangongongo M., Moore S. (Tanzania)

2P47 High prevalence of bed bug infestation in Ethiopian residential institutions; Its psychological, social and health impact: A cross-sectional study
Mekonnen D., Derbie A., Mulu W., Mekonnen Z., Abera B., Biadglegne F., Mihret A., Sack U. (Ethiopia & Germany)

2P48 Entomological studies to improve Chagas disease vector control in the Gran Chaco region
Gonzalves R., Bern C., Couneteny O. (UK & USA)

2P54 Lassa virus distribution and phylogeny in rodent populations in Bo district, Sierra Leone
Bangura U., Sondufu D., Buanie J., Dawson M., Lamin J., Bongo G., Ansumana R., Bocchert M., Sahr S., Fichet-Calvet E. (Germany & Sierra Leone)

10.30

1P16 Development of a point of care diagnostic test for the neglected tropical skin disease Buruli ulcer

1P21 Development of a nanobody-based amperometric immunocapturing assay for sensitive and specific detection of Toxocara canis excretory-secretory antigen
Morales-Yánez F.J., Sariego I., De Wael K., Polman K., Muyllems S., Trashin S. (Belgium & Cuba)

1P24 Optimization of the PAXgene Blood RNA system to store Salmonella cells for subsequent RNA analysis
Rutanga J.P., Van Puyvelde S., De Block T., Jacobs J., Muvunyi C.M., Deborggraewe S. (Rwanda & Belgium)

1P29 Characterization of a new maternal blood based illumigene® Malaria assay in a non-endemic region
Morales-Yánez F.J., Sariego I., De Wael K., Polman K., Muylperms S., Trashin S. (Belgium & Cuba)

15.00

LBP5 Mobile suitcase laboratory for rapid detection of Plasmodium DNA at low resource settings

15.30

LBP6 A novel diagnostic device for rapid quantitation of infectious disease in whole blood

LBP11 A low-cost, rapid diagnostic test for Trypanosoma cruzi II/IV/VI can replace ELISA for lineage specific serology in Chagas disease

Coffee Break

8OS2 - Crisis in the Mediterranean: Training Health Care Providers for Working with Refugees, Forced Migrants and Asylum-Seekers
Organisers:
Nathan Bertelsen, Koc University School of Medicine, Istanbul
Nuria Casamitjana, Institute for Global Health (ISGlobal), Barcelona
Federca Zamatto, Referent for Torture, Médecins Sans Frontieres, Rome and Athens

8OS2.1 The healing environment: Resilience factors for refugees in overcoming psychological trauma
Bertelsen N. (Turkey)

8OS2.2 Meeting the needs of torture victims along migration routes: The experience of MSF in Rome and Athens
Zamatto F. (Italy)

8OS2.3 Health and nutrition assessment of refugee children in the island of Chios, Greece
Furnadó V. (Spain)

8OS2.4 Refugee health training in Turkey: Medical student activities and reflections
Dedeoglu B.E., Bertelsen N. (Turkey)
## Programme at a glance - Thursday 19/10

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30 - 10.00</td>
<td>Coffee Break</td>
<td>Pelican</td>
</tr>
<tr>
<td>10.00</td>
<td>12.00</td>
<td>15.00</td>
</tr>
<tr>
<td>10.30 - 12.00</td>
<td>Lunch Break &amp; Poster Tour (12.30 - 13.30) / Satellite Symposia</td>
<td>Nightingale</td>
</tr>
<tr>
<td>12.30</td>
<td>13.30 - 15.00</td>
<td>15.30 - 17.00</td>
</tr>
<tr>
<td>15.00</td>
<td>15.30 - 17.00</td>
<td>17.00 - 18.30</td>
</tr>
</tbody>
</table>

### Session Details
- **Lunch Break & Poster Tour**: (12.30 - 13.30) / Satellite Symposia
- **Coffee Break**: 08.30 - 10.00, 10.30 - 12.00, 12.30, 15.00, 15.30 - 17.00, 17.00 - 18.30
- **Programme at a glance - Thursday 19/10**
- **Coffee Break**: 08.30 - 10.00, 10.30 - 12.00, 12.30, 15.00, 15.30 - 17.00, 17.00 - 18.30
- **Programme at a glance - Thursday 19/10**
- **Coffee Break**: 08.30 - 10.00, 10.30 - 12.00, 12.30, 15.00, 15.30 - 17.00, 17.00 - 18.30
- **Programme at a glance - Thursday 19/10**
- **Coffee Break**: 08.30 - 10.00, 10.30 - 12.00, 12.30, 15.00, 15.30 - 17.00, 17.00 - 18.30

### Additional Notes
- **Box 1**: Introduction to Health & Well-being
- **Box 2**: Universal Health Coverage and Health Equity
- **Box 3**: Health Systems and Governance
- **Box 4**: Health Research and Innovation
- **Box 5**: Health Workforce and Education
- **Box 6**: Health Systems and Financing
- **Box 7**: Health and Social Protection
- **Box 8**: Health and the Environment
- **Box 9**: Health and the Economy
- **Box 10**: Health and Society

---

**Coffee Break**: 08.30 - 10.00, 10.30 - 12.00, 12.30, 15.00, 15.30 - 17.00, 17.00 - 18.30
**Plenary Talks**

*Chairs:* Eduardo Gotuzzo (Peru) and Marleen Boelaert (Belgium)

**Bridging pharma and academia towards drug discovery for diseases of the developing world**
Julio Martín, GSK Spain

**Fieldworkers views of health research and why they fabricate data**
Patricia Kingori, Wellcome Trust Society, The Ethox Centre, University of Oxford, UK

**The information (and motivation) problem in global health**
Seye Abimbola, National Primary Health Care Development Agency, Nigeria and Sydney School of Public Health, University of Sydney, Australia

---

**7S1 - Health Inequalities**

*Chairs:* Seye Abimbola (Australia) and Button Ricarte (Belgium)

**7S1.1 State of inequality in malaria services in Sub-Saharan African countries**
Galactionova K., Smith T., de Savigny D., Penny M.A. (Switzerland)

**7S1.2 Reproductive and maternal health inequalities in Sub-Saharan Africa: Establishing a socioeconomic gradient based on data from Mozambique, Gabon and Tanzania**
Pons-Duran C., Islam M., Alonso S., Mtenga S.M., Agnandji S.T., Sicuri E., Menéndez C., Munguambe K. (Spain, Mozambique, Tanzania & Gabon)

**7S1.3 Inequities in global health: Easy to see, hard to define**
Ooms G. (UK)

**7S1.4 Inequities in Sub-Saharan African women’s and girls’ health opportunities and outcomes: Evidence from the demographic health surveys**
Pons-Duran C., Lucas A., Narayan A., Babale A., Menéndez C. (Spain & USA)

---

**5OS8 - Patient Fees in Times of Universal Health Coverage: Old Demons Roaring their Head (again)? The Specific Role of Social Health Assistance to Protect Vulnerable People**

*Organisers:* Bart Criel, Equity and Health Unit, Public Health Department, Institute of Tropical Medicine, Antwerp, Belgium
Valéry Ridde, Université de Montréal, Canada
Mit Philips, Médecins Sans Frontières (MSF), Brussels, Belgium
Anna Marriott, OXFAM-UK, Oxford, UK

*Chairs:* Kerstin Akerfeldt (Sweden)

**Patient perspectives - Sub-session 1: The revival of user fees?**

**Patient perspectives - Sub-session 2: The complex case of the ‘destitute’**

**3OS10 - New Tools and Initiatives to combat Antimicrobial Resistance (AMR)**

*Organisers:* Marco Albonico (SIMET), Centre for Tropical Diseases, S. Cuore Hospital, Verona, Italy
Françoise Gay-Andrieu (SPE), bioMérieux, Medical Affairs and Public Health, Marcy l’Etoile, France

*Chairs:* Herman Goossens (Belgium) and Alessandro Bartoloni, Italy
17.00  
**7OS3 - Global Observatory on Health R&D**

**Organisers:**
Malaria Eradication Scientific Alliance (MESA), WHO Department of Information, Evidence and Research

**Chairs:**
Alistair Robb (Switzerland) and Taghreed Adam (Switzerland)

7OS3.1 Understanding R&D needs for better global health  
Moorthy V. (Switzerland)

7OS3.2 Research and development (R&D) priority setting processes for tuberculosis: How are they structured and how should they be structured?  
Khan M. (UK)

7OS3.3 R&D needs and perspectives in TB  
Lienhardt C. (Switzerland)

7OS3.4 Malaria R&D: Developing tools to accelerate control and elimination  
Schellenberg D. (Switzerland)

---

10.30  
**3S5 - Mycobacterial Diseases**

**Chairs:** Dissou Affolabi (Benin) and Chris Kenyon (Belgium)

**3S5.1**  
IP-10 kinetics in the first week of therapy are strongly associated with subsequent bacteriological confirmation of tuberculosis in HIV-infected patients  

**3S5.2**  
New diagnostic tests for tuberculosis: Performance of LAM and Xpert MTB/RIF in urine of hospitalized patients on intensive phase of TB treatment, and its association with TB dissemination and HIV status - Preliminary results from an observational cohort study in Kigali, Rwanda  
Bitunguhiari L., Nkundibiza S., Dukundane A., Clerinx J. (Rwanda & Belgium)

**3S5.3**  
Association between *rpob* mutations and probe profiles, and potential application of who-endorsed rapid diagnostic tests for rifampicin resistant-TB control  
Ng K.S., Meehan C.J., Torres G., Goeminne L., Diels M., Rigouts L., de Jong B., André E. (Belgium)

**3S5.4**  
Effectiveness and safety of long-term versus short-term treatment regimen of multidrug-resistant pulmonary tuberculosis in Burkina Faso  
Ouédraogo A.R., Badoum G., Ouédraogo G., Boncoungou K., Maiga S., Nacanabo R., Kunakey E.K., Ouédraogo M. (Burkina Faso)

**3S5.5**  
Identification of non-tuberculous mycobacteria isolated from clinical specimens at Dr George Mukhari tertiary laboratory, South Africa, using the genotype mycobacterium cm/as assay and 16s RNA gene sequencing  
Makhado N.A., Colebunders R., Nchabeleng M., de Jong B.C. (South Africa & Belgium)

12.00  
Lunch Break and Poster Tour (12.30 - 13.30)
13.30  
**4OS4 - Towards Improved Tuberculosis Control – Why Small Countries matter**

**Organiser:** Martin P. Grobusch, Center of Tropical Medicine and Travel Medicine, Academic Medical Center, University of Amsterdam, The Netherlands, Centre des Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon and Institute of Tropical Medicine, University of Tuebingen, Germany

**Chairs:** Martin P. Grobusch (The Netherlands & Gabon) and Akim A. Adegnika (Gabon & Germany)

---

**4OS4.1 Enhanced TB laboratory diagnosis and treatment in resource-limited settings – The Lambaréné experience**
Alabi A. (Gabon)

**4OS4.2 Tuberculosis treatment outcome and drug resistance in Lambaréné, Gabon – A prospective cohort study**
Béalard S. (Germany)

**4OS4.3 Multidrug-resistant *Mycobacterium tuberculosis* outbreak strains in Gabon**
Beckert P. (Germany)

**4OS4.4 Implementation of multidrug resistant tuberculosis (MDR-TB) treatment in Gabon: Lessons learnt from the field**
Edoa R.J. (Gabon)

**4OS4.5 Fostering programmatic uptake and implementation of research data for improved TB control in Gabon**
Adegnika A.A. (Gabon)

**4OS4.6 Towards improved tuberculosis control – Why small countries matter**
Grobusch M.P. (The Netherlands)

15.00  
**Coffee Break**

---

15.30  
**4OS5 - Interrupting Leprosy Transmission – The Unfinished Task**

**Organisers:** Arielle Cavaliero, Novartis Foundation, Basel, Switzerland
Peter Steinmann, Swiss Tropical and Public Health Institute, Basel, Switzerland, and University of Basel, Basel, Switzerland

**Chairs:** Arielle Cavaliero (Switzerland) and Peter Steinmann (Switzerland)

---

**4OS5.1 Achievements of multidrug therapy in the control of leprosy**
Smith W.C.S. (UK)

**4OS5.2 Emerging evidence from the Leprosy Post-Exposure Prophylaxis (LPEP) program**
Richardus J.H. (The Netherlands)

**4OS5.3 Toward a global partnership for zero leprosy transmission**
Cavaliero A. (Switzerland)

**4OS5.4 Integration of leprosy post-exposure prophylaxis into drives for retrospective active case finding in Cambodia**
Steinmann P. (Switzerland)

**4OS5.5 Stop the transmission of leprosy: The PEP++ project**
Mieras L.M. (The Netherlands)

17.00  
**6OS5 - Preparing for the Next Epidemic: The Need for Global Collaboration**

**Organiser:**
European Commission – DG Research and Innovation – Unit E3, Fighting Infectious Diseases and Advancing Public Health

**Chairs:**
Line Matthiessen (European Commission) and Yazdan Yazdanpanah (France)

---

**6OS5.1 A long-term research agenda for infectious disease research funders**
Koopmans M.P. (The Netherlands)

**6OS5.2 Data sharing in public health emergencies**
Littler K. (UK)

**6OS5.3 A social science network for infectious disease preparedness**
Hongoro C. (South Africa)

**6OS5.4 Creating links between clinical trial networks**
Goossens H. (Belgium)
Tuesday, Thursday

15.30 4S8 - Vaccination Strategies
Chairs: Maria Eugenia Toledo (Cuba) and Marianne Van der Sande (Belgium)

4S8.1 Extracting the incentives: Vaccination behavior as a multi-criteria decision
Verelst F., Willem L., Kessels R., Beutels P. (Belgium & Australia)

4S8.2 Field challenges to measles elimination in the Democratic Republic of Congo
Coutborn R.M., Nackers F., Panunzi I., Bachy C., Porten K., Vochten H., Van Herp M., Bibala-Faray E., Cohuet S. (France, Belgium & Democratic Republic of Congo)

4S8.3 WHO gap III roadmap to compliance for poliovirus-essential facilities
De Kesel T., Rüdelsheim P. (Belgium)

4S8.4 The value and unexpected by-product of a community engagement strategy aimed at addressing the immunisation gap in Northwest Ethiopia

4S8.5 Understanding girls’ preference for human papilloma virus vaccination in Ethiopia: A study protocol for Discrete Choice Experiment
Hailu A., Assefa R. (Ethiopia & Norway)

8OS3 - Human Papilloma Virus Vaccines and Cervical Cancer Mortality in Sub-Saharan Africa: Evidence and Lessons learnt from Mozambique

Organiser: Barcelona Institute for Global Health (ISGlobal) - Initiative for Maternal, Child and Reproductive Health. Hospital Clinic, University of Barcelona, Spain
Centro de Investigación en Salud de Manchúcia (CISM), Maputo, Mozambique

Chairs: Azucena Bardají (Spain) and Graça Matsinhe (Mozambique)

8OS3.1 Overview of GAVI human papillomavirus (HPV) vaccine support and lessons learnt from HPV demonstration programmes in GAVI countries
Khanduri A. (Switzerland)

8OS3.2 Cancer of the uterine cervix in Maputo, Mozambique: Incidence, trends and HPV infection distribution
Carrilha C. (Mozambique)

8OS3.3 HPV vaccination of pre-adolescents in Mozambique: Main outputs and lessons learnt from the HPV demonstration project in three districts
Matsinhe G. (Mozambique)

8OS3.4 Awareness of cervical cancer and willingness to be vaccinated against HPV among Mozambican adolescent girls
Bardají A. (Spain)

8OS3.5 Community views on cervical cancer and HPV vaccination in Mozambique –A qualitative study
Cambaco O. (Mozambique)

8OS3.6 Operationalization and costs involved in the implementation of an HPV demonstration program in Mozambique
Munguambe K. (Mozambique)
10.30  **SS9 - Governance of Health Systems Managing Complexity, Managing Accountability**
**Chairs:** Peter Eerens (Belgium) and Bruno Marchal (Belgium)

*Health systems: social systems, complex systems*
Marchal B. (Belgium)

**Performance of community health workers: Situating their intermediary position within complex adaptive health systems**
Kok M.C., Taegtmeyer M., Broerse J.E.W., Dieleman M., Theobald S. (The Netherlands & UK)

**Translation of multiple health systems flows in the language of complex networks**
Eerens P. (Belgium)

12.00  **Lunch Break and Poster Tour (12.30 - 13.30)**

13.30  **SS9 - Complex Adaptive Governance in Local Health Systems- When Implementation Instruments interact with Local Politics and Shift Accountability**

**Organiser:** Sara Van Belle, Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium

**Chair:**
Sara Van Belle (Belgium)

**5OS9.1 The politics of implementation: An exploration of local dynamics shaping health worker incentives and service delivery in three districts of Sierra Leone**
Bertone M.P. (UK)

**5OS9.2 Enhanced horizontal and public accountability within the local health system: Effects of the preparation for Universal Health Coverage in Senegal**
Bossyns P. (Belgium)

**5OS9.3 Complex adaptive health system governance: Sierra Leone case study of epidemic response**
Mayhew S. (UK)

Round-up of the panel discussion
Kwamie A. (Ghana)

15.00  **Coffee Break**

15.30  **5OS10 - Strengthening Comprehensive and Integrated First Line Care for Health & Well-being - Exchange of Approaches from Low, Middle and High Income Countries, aiming at launching a Community of Practice**

**Organiser:**
Pol De Vos, Institute Tropical Medicine, Antwerp Belgium

**Chair:**
Pol De Vos (Belgium)

**5OS10.1 Developing integrated social and health care centres in Brussels: Are the questions and answers generalizable?**
Heymans I. (Belgium)

**5OS10.2 Integration of medical and psychosocial care for stigmatized and vulnerable groups into primary health services in Senegal**
Sow A. (Guinée)

**5OS10.3 Latin American experiences on ‘health and well-being’ – An overview**
Torres-Tovar M. (Colombia)

**5OS10.4 Primary care development in El Salvador: A comprehensive strategy towards Health and well-being**
Espinoza E. (El Salvador)

17.00  **6S1 - International Funding Mechanisms**

**Chairs:** Gorik Ooms (UK) and Lisa Forman (Canada)

**6S1.1 The love-hate relationship between European donors and the global health initiatives**
Steurs L., Delputte S., Orbie J. (Belgium)

**6S1.2 Behind the scenes: International NGOs, global-national policy transfer and the politics of concealment**
Storeng K.S., Palmer J., Kloster M.O., Judy D. (Norway, UK & Australia)

**6S1.3 European donors and health system strengthening: A distinct approach?**
Steurs L., Delputte S., Orbie J. (Belgium)
10.30  **6OS6 - Innovative Training Programmes for Local Health Systems**
**Staff**

**Organisers:**
Valéria Campos da Silveira and Bart Criel
Equity and Health Unit, Dept. of Public Health, Institute of Tropical Medicine, Antwerp, Belgium

**Chair:**
Valéria Campos da Silveira (Belgium)

**6OS6.1** Context-based learning within and for the district health system in Thailand
Tawaytibhongs O. (Belgium)

**6OS6.2** Swasthya Karnataka: An intervention to strengthen local health systems through training in Tumkur district, Karanataka, India
Bhojani U. (India)

**6OS6.3** Fellowship in health systems management: A work-based action-oriented training programme in Uganda
Kirunga Tashobya C. (Uganda)

**6OS6.4** Understanding Local Health Systems (LHS): Innovative ways to acquire a core competency in the Antwerp Master in Public Health (MPH)
Criel B. (Belgium)

**6OS6.5** A strategy to support the development of inter-organizational and inter-disciplinary governance of Belgian local health and social care systems: The case of the innovative ‘Integreo’ program
Macq J. (Belgium)

12.00  Lunch Break and Poster Tour (12.30 - 13.30)

13.30  **6S2 - Training and Capacity Building**
**Chairs:**
Christine Kirunga Tashobya (Uganda) and Emmanuel Bottieau (Belgium)

**6S2.1** Medical electives – A risky business for all?
Hookham L., Smith K., Schmid M. (UK)

**6S2.2** Learning curve characteristics for caesarean section among associate clinicians: A prospective study from Sierra Leone
Waalewijn B.P., van Duinen A.A., Bolkan H.A. (Norway & The Netherlands)

**6S2.3** WikiTropica: A concept for a knowledge management platform in the field of tropical medicine and travel health
Kennis J., Van Den Broucke S., Clerinx J., Huits R., Zolfo M., Bottieau E. (Belgium)

**6S2.4** Evidence-based guidelines and training materials for first aid by laypeople: The example of India
De Buck E., Van Remoortel H., Vande vegaete A., Singhal M., Vandekerckhove P., Agarwal S.P. (Belgium & India) *Deceased November 17, 2015*

15.00  Coffee Break

15.30  **6OS7 - From Tropical Medicine to Global Health: Presenting an Educational Evolution, responding to Human Resources for Health Needs in Low Resource Settings**
**Organisers:**
Sanne Jongma (TROIE), Annelieke Hulzebosch (TROIE), Jan Henk Dubbink (TROIE), Barend Gerretsen (OIGT), NVTG (Nederlandse Vereniging voor Tropische Geneeskunde en Internationale Gezondheidszorg)

**Chairs:**
Sanne Jongma (The Netherlands) and Annelieke Hulzebosch (The Netherlands)

**6OS7.1** From tropical medicine to global health – Past
Jongma S.Y (The Netherlands)

**6OS7.2** From tropical medicine to global health – Present
Various speakers

**6OS7.3** From tropical medicine to global health – Future
Gerretsen B. (The Netherlands)

**6OS7.4** From tropical medicine to global health – Discussion
Jongma S.Y. (The Netherlands)

17.00  **9S4 - Transglobal Health Programme**
**Chairs:**
Nuria Casamitjana (Spain) and Anne Buvé (Belgium)

**Introduction:**
Gerrets R. (The Netherlands)

**9S4.1** If they bring the new Ebola vaccine, will I take part in it again?: Paid participation in clinical trials as concealed labor
Alenichev A. (The Netherlands)

**9S4.2** Micro-epidemiology of malaria in three villages in a low-transmission setting in north-eastern Cambodia
Bannister-Tynell M. (Belgium)

**9S4.3** Using quasi-experimental methods and routine surveillance data to evaluate the short-term impact of a malaria elimination initiative in Southern Mozambique
Brew J. (Spain)

**9S4.4** The perceived social aetiologies and solutions of perinatal common mental disorders in rural Uganda
Sarkar N. (Belgium)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.30</td>
<td>7S2 - Migrant Health</td>
<td>A crisis of protection and humane treatment: Violence, physical trauma and deaths among migrants/refugees travelling along the Western Balkan corridor to Northern Europe</td>
<td>Willem van de Put (The Netherlands) and Clara Afun (Belgium)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Migrants’ journey, vulnerabilities, access to information and endured violence during the journey and in refugee camps in Ioannina, Attica, Athens and Samos, Greece</td>
<td>(The Netherlands) and Clara Afun (Belgium)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Needs versus rights: Moral understandings of healthcare workers and undocumented migrants in Belgium regarding access to healthcare</td>
<td>Lafaut D. (Belgium)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Family health Doctors Beyond Borders</td>
<td>Cacciotella L., Bernardi A., D’Agostino F., Fascendini M., Montanari A. (Italy)</td>
</tr>
<tr>
<td></td>
<td>7S2.5</td>
<td>Comprehensive care for migrants and refugees who have suffered torture and other forms of ill-treatment – The MSF experience in Athens</td>
<td>Kotsioni I., Kastrissianaki A., Haziri I., Papachristou A., Kokkiniotis M., Zerva E., Vallanou A., Zamatto F., Van den Bergh R., Gionakis N., Sarantou E. (Belgium &amp; Greece)</td>
</tr>
<tr>
<td>12.00</td>
<td>Lunch Break and Poster Tour</td>
<td>Early diagnosis of acute schistosomiasis by schistosome DNA detection in serum in a cluster cohort of 34 travelers exposed in South Africa</td>
<td>Cnops L., Maniewski U., Soentjens P., Huyse T., Bottleau E., Clerinx J., Van Esbroeck M. (Belgium)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Travel-related disease and antibiotic use in immunocompromised travelers</td>
<td>Van Aalst M., van Ruisien M.C.E., Stijns C., van Vught M., de Bree G.J., Grobusch M.P. (The Netherlands)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Epidemiology of travel-related health events among HIV infected migrants living in France and visiting their country of origin in sub-Saharan Africa: The ANRS-VHVO Morbidity sub-Study</td>
<td>Pistone T., Agbrii S., Ouattara E., Lele N., Gabillard D., Malvy D., Bouchaud O. (France)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Epidemiological and clinical profile of imported strongyloidiasis from the REDIVI network</td>
<td>Salvador F., Treviño B., Herrera-Martínez J.M., Rodríguez-Guardado A., Turría D., Goikoetxea J., Zubero Z., Velasco M., Chamorro S., on behalf the REDIVI Collaborative Network (Spain)</td>
</tr>
<tr>
<td>15.00</td>
<td>Coffee Break</td>
<td>Polymerase chain reaction for the diagnosis of Clostridium difficile infection in patients with persistent digestive disorders and asymptomtatic conditions in Côte d’Ivoire</td>
<td>Bub F., Chatigre J.K., Yao J.A., Coulibaly J.T., von Müller L., Polman K., Boelaert M., N’Goran E.K., Utzinger J., Becker S.L. (Germany, Côte d’Ivoire, Switzerland &amp; Belgium)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No association between Salmonella intestinal carriage and Schistosoma mansoni infection in healthy individuals, Democratic Republic of the Congo</td>
<td>Mboyi Kalouni L., Barbé B., Madinga J., Roucher C., N’kiki G., Polman K., Luimputa P., PhoYa M.-F., Luimputa O., Jacobs J. (Democratic Republic of Congo &amp; Belgium)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Use of antibiotics prior to blood culture sampling in Nepal</td>
<td>Koirala K.D., Verdónk K., Barbé B., Khanal B., Bhattachar N.R., Pradhan B., Bhatta N.K., Karki P., Rijal S., Boelaert M., Chappuis F., Jacobs J. (Nepal, Belgium &amp; Switzerland)</td>
</tr>
<tr>
<td>17.00</td>
<td>Lunch Break and Poster Tour</td>
<td>Causes of non-traumatic paraplegia in Malawi</td>
<td>Zijistra, E.E., van Hellemont J., Mwandawire N., Katchanov J., Rothe C. (The Netherlands, Malawi &amp; Germany)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prevalence of neglected infectious diseases in patients with persistent fever in Sihanouk Hospital Center of HOPE, Cambodia</td>
<td>Phe T., Lim K., Leng L., Verdónk K., Barbé B., Jacobs J., Parda P., Rijal S., Boelaert M., Chappuis F. (Cambodia, Belgium, France, Nepal &amp; Switzerland)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Epidemiology of onchocerciasis and epilepsy in Ituri province in the Democratic Republic of the Congo (DRC)</td>
<td>Lengaerts, M., Mukendi D., Mando M., Dolo H., Ucima Wonya'Rossi D., Ngave F., Colebunders R., Suikerbury P. (Belgium, DRC &amp; Mali)</td>
</tr>
<tr>
<td>17.00</td>
<td>Lunch Break and Poster Tour</td>
<td>Intestinal helminthiasis as a determinant of response to pentavalent antimony treatment in Peruvian patients with cutaneous leishmaniasis: A case-control study</td>
<td>Martínez D.Y., Verdonck K., Adaui V., Jara M., Alba M., Arevalo J., Polman K., Lunguya O., Jacobs J. (Democratic Republic of the Congo &amp; Belgium)</td>
</tr>
</tbody>
</table>
10.30 3S9 - All about Leishmaniasis

Chairs: Jean-Claude Dujardin (Belgium) and François Chappuis (Switzerland)

3S9.1 Accuracy of antigen detection in urine using katex for non-invasive visceral leishmaniasis diagnosis and treatment monitoring in HIV-infected patients

Vogt F., Mekonnen T., Fikke H., Takele Y., Adem E., Mohammed R., Ritmeijer K., Adriaensen W., Dero E., Van Griensven J. (Belgium & The Netherlands)

3S9.2 Evaluation of point-of-care tests for cutaneous leishmaniasis diagnosis in Afghanistan


3S9.3 Post-Kala-Azar Dermal Leishmaniasis (PKDL) treated with ambulatory short course AmBisome

Ritmeijer K., Burza S., Das A.K., Mahajan R., Das P., Be-Nazir A., den Boer M. (The Netherlands, India, Bangladesh & UK)

3S9.4 South Sudan: A clinical severity scoring system for visceral leishmaniasis in HIV negative patients

Kärnink S., Collin S.M., Harrison T., Gatiau K., Mullahzada A.W., Ritmeijer K. (The Netherlands, UK & South Sudan)

3S9.5 Prevalence and risk factors of asymptomatic leishmaniasis infection in HIV-infected individuals in Northwest Ethiopia

van Griensven J., Van Henten S., Mengesha B., Endris M., Van Den Bossche D., Cnops L., Adriaensen W., Gedamu Y., Vogt F., Dero E. (Belgium & Ethiopia)

3S9.6 Visceral leishmaniasis and HIV co-infection in Northwest Ethiopia: Uptake of antiretroviral treatment and burden of disease amongst patients enrolled in HIV care

van Griensven J., Simegn T., Endris M., Diro E. (Belgium & Ethiopia)

12.00 Lunch Break and Poster Tour (12.30 - 13.30)

13.30 4S9 - Control of Leishmaniasis

Chair: Albert Picado (Switzerland)

4S9.1 Cluster randomised trial and development of a sandfly sex pheromone lure to reduce Leishmania infantum infection

Courtney O., Dilger E., Carter V., Bray D., Bell M., Gonzalez de Heredia M., Borges-Alves G., Nunes C., Brazil R., Hamilton G. (UK & Brazil)

4S9.2 Efficacy of commercial systemic insecticides in dogs at killing blood-fed sand flies


4S9.3 Update on Leishmaniasis Control in Suriname


4S9.4 Suffering in silence: A qualitative study on reasons of delay in seeking care for visceral leishmaniasis in Southern Gedaref, Sudan

Sunyoto T., Atia A.M., Khalid G., Alcoba G., den Boer M., Boelaert M. (Belgium, Switzerland & Sudan)

4S9.5 What are the true outcomes of patients declared lost to follow up in a visceral Leishmaniasis program in Sudan?

Atia A.M., Den Boer M., Mousab Siddig Elhag, Ahmed R., Alcoba G., Chappuis F., van Griensven J., Rony Z. (Sudan, Luxembourg, Switzerland, Belgium & UK)
10.30 3OS11 - Unsolved Issues in the Clinical Management of Imported Tropical Infections: A TropNet Contribution

Organiser:
TropNet
Swiss Tropical Institute of Public Health, Basel, Switzerland

Chairs:
Christophe Hatz (Switzerland) and Jan Clerinx (Belgium)

3OS11.1 Refractory giardiasis – an appraisal of second-line treatment options
Neumayr A. (Switzerland)

3OS11.2 Early diagnosis and treatment of acute schistosomiasis (Katayama syndrome) in travelers
Clerinx J. (Belgium)

3OS11.3 Management of cystic echinococcosis in the non-endemic setting: Is harmonization of practices feasible?
Chiodini P. (UK)

3OS11.4 PCR-controlled management of cutaneous and mucocutaneous leishmaniasis
Blum J. (Switzerland)

12.00 Lunch Break and Poster Tour (12.30 - 13.30)

13.30 8S8 - Obstetric Care

Chairs: Vincent De Brouwere (Belgium) and Alexandre Delamou (Belgium)

8S8.1 Maternal near miss morbidity and mortality in hiwot fana specialized university hospital, Eastern Ethiopia: A prospective cohort study
Tura A.K., van der Akker T., van Roosmalen J., Stekelenburg J., Zwart J., Scherjon S.A. (Ethiopia & The Netherlands)

8S8.2 Indications for caesarean sections in a rural hospital in Malawi
Bakker W., Bakker E., Huigens A.C., Kaunda E., Beltman J.J., van der Akker T.H. (Malawi & The Netherlands)

8S8.3 Feasibility of mobile phone data collection via within a longitudinal study of Ugandan women treated for obstetric fistula

8S8.4 The effect of improved trends in use of the partograph to actively monitor labor on newborn outcomes in southwestern Uganda
Ndageire K.G., Kirunda I., Kaguru P., Mudope P. (Uganda)

8S8.5 Task-shifting of foetal heart rate monitoring during labour in low-resource settings: Perceptions of skilled birth attendants, mothers and policymakers

15.00 Coffee Break

15.30 8OS4 - Measuring Progress of Safe Motherhood Programs: Only a Matter of International Organizations?

Organisers:
Vincent De Brouwere and Thérèse Delvaux
Maternal & Reproductive Health Unit, Institute of Tropical Medicine, Antwerp, Belgium

Chair:
Véronique Filippi (UK)

8OS4.1 Measuring progress for safe motherhood: An overview of the issue
Filippi V. (UK)

8OS4.2 Maternal deaths surveillance system: A tool to guide action at regional level in Morocco?
Abouchadi S. (Morocco)

8OS4.3 Trend in unmet obstetric needs in rural Guinea from 2011 to 2016
Delamou A. (Belgium & Guinea)

8OS4.4 Tracking facility capability to provide abortion services: An application of abortion signal functions to central province, Zambia
Cresswell J. (UK)

8OS4.5 Strengthening the availability and quality of maternal health services by supporting the use of globally defined indicators at local level – Case study of Togo
Monet J.P. (USA)

17.00 8OS5 - Burden of Maternal Morbidity in Low and Middle Income Countries: Knowns and Unknowns - Measuring and addressing Maternal Morbidity: The next 5 Years

Organisers:
Véronique Filippi, London School of Hygiene and Tropical Medicine, UK
Lale Say, World Health Organization

Chair:
Vincent De Brouwere (Belgium)

8OS5.1 Maternal morbidity measurement: Roadmap for the next 5 years
Filippi V. (UK)

8OS5.2 Maternal morbidity measurement tool: Pilot study results
Chou D. (Switzerland)

8OS5.3 Improving detection and initial management of gestational diabetes through the primary level of care in Morocco
Utz B. (Belgium)

8OS5.4 Severe maternal morbidity at the time of delivery and in the postpartum in Morocco: Magnitude, causes and consequences
Assarag B. (Morocco)

8OS5.5 The atlas of maternal morbidity: a systematic review of systematic reviews
Gon G. (UK)
10.30  **1S6 - Therapeutic Innovations**
**Chairs:** Julio Martin (Spain) and Raffaella Ravinetto (Belgium)

**1S6.1** Discovery and lead-optimisation of two new antileishmanial pre-clinical candidates within an academic-industry partnership
De Rycker M. on behalf of the DDU/GSK Kinetoplastid Drug Discovery Team (UK & Spain)

**1S6.2** Modelling the antimalarial activity of SJ733, a novel promising investigational antimalarial using early phase human pharmacokinetic and efficacy data

**1S6.3** The effect of oral administration of antibiotics on *Schistosoma Mansoni* egg-induced pathology in mouse models
Kildemoes A.O., Schramm G., Pakkenberg B., Hansen A.K., Skov S., Nielsen D.S., Vennervald B.J. (Denmark & Germany)

**1S6.4** Antiviral treatment efficiently inhibits Chikungunya virus replication in the joints of mice during the acute but not during the chronic phase of infection
Abdelnabi R., Jochmans D., Verbeken E., Delang L., Neyts J. (Belgium)

13.30  **3S10 - Management of Helminthiases**
**Chairs:** Juerg Utzinger (Switzerland) and Tom van Gool (The Netherlands)

**3S10.1** Comparison of single Kato-Katz, duplicate Kato-Katz, mini-FLOTAC and FECPAKG2 for the assessment of anthelmintic efficacy of single dose albendazole

**3S10.2** Egg excretion indicators for the measurement of soil-transmitted helminth response to treatment

**3S10.3** Landscape of studies generating individual participant data on the efficacy of drugs for treating soil-transmitted helminthiasis and the case for data sharing

**3S10.4** Evolution of anthelmintic resistance in the era of preventive chemotherapy
Coffeng L.E., Stolk W.A., de Vlas S.J. (The Netherlands)

**3S10.5** Hot topics in the diagnosis and management of strongyloidiasis
Buonfrate D., Bisoffi Z. (Italy)

15.00  **Coffee Break**

**15.30  6OS8 - Development, Validation and Implementation of Diagnostic Tools in Resource-Limited Settings**
**Organisers:** Michelle Helinski and Ana Lucia Cardoso & Developing Countries Clinical Trials Partnership (EDCTP), The Hague, The Netherlands

**6OS8.1** Rapid diagnosis of *Taenia solium* taeniasis and (neuro)cysticercosis in resource-poor areas
Gabriel S. (Belgium)

**6OS8.2** Syndromic approach to the diagnosis of neglected infectious diseases
Boelaert M. (Belgium)

**6OS8.3** Towards the development of a field-friendly point-of-care screening test for the diagnosis of TB disease in resource constrained settings
Chegou N. (South Africa)

**6OS8.4** Missed opportunities for early access to infant diagnosis of HIV-exposed infants and care of HIV-infected infants in Burkina Faso
Coulibaly M. (Burkina Faso)

**17.00  3OS12 - Point-of-Care Ultrasound in Infectious Diseases in Resource-Poor Areas: Where are We and which Way to go?**
**Organisers:** Francesca Tamarozzi, University of Pavia, Department of Clinical Surgical Diagnostic and Paediatric Sciences, WHO Collaborating Centre for Clinical Management of Cystic Echinococcosis, Pavia, Italy
Maria Teresa Giordani, San Bortolo Hospital, Infectious and Tropical Diseases Unit, Vicenza, Italy
Sabine Belard, Department of Pediatric Pneumology and Immunology, Charité-Universitätsmedizin Berlin, Germany
Joachim Richter, Institute of Tropical Medicine and International Public Health, Charité-Universitätsmedizin Berlin, Germany
Daniel Karnstein, Medical College of Georgia at Augusta University, Georgia, USA

**Chair:**
Francesca Tamarozzi (Italy)

**3OS12.1** The increasing role of lung ultrasound in HIV
Giordani M.T. (Italy)

**3OS12.2** Point-of-care ultrasound for extra-pulmonary tuberculosis in India: A prospective cohort study in HIV-infected and HIV-uninfected tuberculosis patients
Weber S.F. (Germany)

**3OS12.3** Proposed improvement of the WHO protocol for focused assessment of ultrasound abnormalities due to schistosomiasis
Richter J. (Germany)

**3OS12.4** Ultrasound classification of cystic echinococcosis: Where are we 15 years after?
Tamarozzi F. (Italy)

**3OS12.5** The challenges of teaching ultrasound in low-resourced settings
Karnstein D. (USA)
10.30  
**8IPS1 - Interactive Poster Session Track 8: Maternal Health**
Chair: Bettina Utz (Belgium)

8P66  
Prevalence of latent tuberculosis (LTB) among pregnant women in high burden setting in Sudan using Interferon gamma (IFN-ɣ) releasing assay (IGRA)  

8P68  
Low birth weight or prematurity in teenage mothers from rural areas of Burkina Faso  

8P69  
Impact of maternal STH infection on infant height and weight gains at 24 months of age  
Gyorkos T.W., Sarker H., Mofid L.S., Montresor A., Razuri H., Casapia M. (Canada, Switzerland & Peru)

8P70  
Prevalence, associated factors and evolution of gestational diabetes mellitus in Ouagadougou  

13.30  
**TMIH Workshop 1: Elements of Text**
Main objective:  
To learn how to write clearly and simply.

Topics:
(a) using the right kind of vocabulary (avoiding jargon, colloquial expressions, pomposity);
(b) constructing clear, unambiguous sentences; pitfalls to avoid in English;
(c) paragraphs (structuring them such that they form a „skeleton“ of the paper; weighting information within).

15.00  
Coffee Break

15.30  
**TMIH Workshop 2: Structure of Quantitative Medical Research Papers & Ethical Issues of Authorship**
Main objective:  
To understand the IMRD format; plagiarism, authorship and other issues authors need to be aware of.

Topics:
(a) recognising that IMRD has a „dramatic“ form, like a story
(b) function and contents of introduction, materials & methods, results, conclusion;
(c) formulating and using titles and abstracts;
(d) plagiarism – what constitutes it and how to avoid it, with iThenticate demo
(e) ethical presentation of one’s work;
(f) conflict of interest;
(g) authorship.

12.00  
Lunch Break and Poster Tour (12.30 - 13.30)
10.30  **4OS6 - The Role of Multi-Sectoral Approaches for the Prevention and Control of Malaria and Emerging Arboviral Diseases**

*Organisers:* Florence Fouque, The Special Programme for Research and Training in Tropical Diseases, World Health Organization, Geneva, Switzerland  
Karin Gross, Swiss Agency for Development and Cooperation, Bern, Switzerland  
Zee Leung, International Development Research Centre, Ottawa, Ontario, Canada  
Konstantina Boutsika, Swiss Tropical and Public Health Institute, Basel, Switzerland

*Chair:* Florence Fouque (Switzerland)

**4OS6.1** Multi-sectoral approach for prevention and control of malaria and vector-borne diseases  
Fouque F. (Switzerland)

**4OS6.2** Strategic partnerships at national and sub-regional levels in Asia  
Hii J. (Thailand)

**4OS6.3** The impact of industrial activities on vector-borne disease transmission  
Jones R. (UK)

12.00  Lunch Break and Poster Tour (12.30 - 13.30)

13.30  **3OS13 - International Networks for Travel Medicine**

*Organiser:* TropNet, Swiss Tropical Institute of Public Health, Basel, Switzerland

*Chairs:* Leo Visser (The Netherlands) and Jan Clerinx (Belgium)

**3OS13.1** An overview of GeoSentinel  
Hamer D. (USA)

**3OS13.2** Activities and goals of TropNet, the largest 'European Network for Tropical and Travel Medicine'  
Hatz C. (Switzerland)

15.00  **8OS6 - The Power of the Image: Use of Multimedia in Health Research, Advocacy and Dissemination**

*Organisers:* Caroline Masquillier, Department of Sociology, University of Antwerp, Antwerp, Belgium  
Radhika Arora, Freelance Consultant, New Delhi, India  
Werner Soors, Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium  
Upendra Bhojani, Institute of Public Health, Bangalore, India  
Leanne Brady, Health Policy and Systems Division, School of Public Health and Family Medicine, Cape Town, South Africa  
Ary Rogerio Silva, Pan American Health Organization; International Development – Global Affairs Canada and the Government of Colombia, Washington, USA  
Sabine van Elsland, Stellenbosch University, Dept. Paediatrics and Child Health, Cape Town, South Africa and Desmond and Leah Tutu Legacy Foundation, Cape Town, South Africa

*Chairs:* Caroline Masquillier (Belgium) and Arora Radhika (India)

**Video/photo screening part 1: The use of multimedia in data collection**

**8OS6.1** Photovoice as a research methodology: Research on social inclusion of children with special needs in Uganda  
Masquillier C. (Belgium) and Musoke D. (Uganda)

**8OS6.2** Ships of hope: Mobile boat clinics in the riverside areas of Assam  
Radhika A. (India)

**Video/photo screening part 2: The use of multimedia in dissemination, communication and conveying messages**

**8OS6.3** Making hope and despair  
Soors W. (Belgium) and Bhojani U. (India)

**8OS6.4** River of Hope  
Rogerio Silva A. (USA)

**Video/photo screening part 3: The use of multimedia in agenda setting**

**8OS6.5** Life on the road  
Brady L. (South Africa)

**8OS6.6** Victim testimonies for tobacco control advocacy  
Bhojani U. (India)
8OS7 - Social and Economic Impact of Cutaneous Leishmaniasis (CL) in Latin America: A patient's Perspective to Inform better Treatments and Study Design

Organisers:
Dalila Martínez Medina, Instituto de Medicina Tropical “Alexander von Humboldt”, Universidad Peruana Cayetano Heredia, Lima, Peru
Astrid Erber, University of Oxford, NDMRB, Centre for Tropical Medicine and Global Health, Headington Oxford, UK

Chair:
Piero Olliaro (Switzerland)

8OS7.1 Protocol and selected results of an international study exploring Cutaneous leishmaniasis patients’ disease experiences and preferences
Erber A. (UK) and López L. (Colombia)

8OS7.2 Access and economic impact of Cutaneous Leishmaniasis in Colombian patients: A qualitative study
Castro M.M. (Colombia)

8OS7.3 Assessment of the quality of life and economic impact of Cutaneous Leishmaniasis in Brazil: An exploratory approach
Cota G. (Brazil)

8OS7.4 Social and economic impact of Cutaneous Leishmaniasis in Peruvian patients: A qualitative study
Martínez Medina D. (Peru)

Summary and discussion
- Personal, social and economic impact of CL on patients across Latin America (Panel)
- Using patients’ perspectives for designing better trials and interventions (all)
Programme at a glance - Friday 20/10

08.30 - 10.00
- Gorilla 4
  LBS3 – Health Systems and Ethics

10.00
- Coffee Break

10.30 - 12.00
- Pelican
  5OS11 Quality improvement and patient safety in low and middle income countries
- Toucan
  5OS12 Asset management in LMICs: A challenge with multiple answers
- Gorilla 5
  6OS10 The secrets of effective networks -5 case studies focusing on structure and functioning of multi-stakeholder platforms

12.45
- Farewell Lunch
10.30  **Plenary Talks**  
**Chairs:** Steve Ahuka (DR Congo) and Christian Lengeler (Switzerland)  

**Malaria elimination: Challenges and opportunities**  
Umberto D’Alessandro, MRC Unit The Gambia, Banjul, The Gambia  

**Achieving impact at scale - Lessons from Africa**  
Sodzi Sodzi-Tettey, Institute for Healthcare Improvement, Ghana  

**Closing Session**  
12.00  
ECTMIH2017 wrap-up through a journalistic lens  
Serusha Govender (Broadcast Journalist from South Africa, ITM Journalist-in-residence 2017)  

12.25  
Introduction of ECTMIH2019  
Karel Gyselinck (Chair of FESTMIH)  

12.35  
Closing of the Congress  
Bruno Gryseels (Congress Chair, ITM Director)  

12.45  
Farewell Lunch  

08.30  
**4OS7 - Switzerland’s Contribution to Research and Control of Malaria and the Neglected Tropical Diseases**  

**Organiser:**  
Swiss Society of Tropical Medicine and Parasitology (SSTMP)  

**Chairs:**  
Christoph Hatz (Switzerland) and Jürg Utzinger (Switzerland)  

4OS7.1 The Swiss Society of Tropical Medicine and Parasitology – 75 years shaping global health  
Utzinger J. (Switzerland)  

4OS7.2 Switzerland’s successful contribution to the global fight against malaria  
Lengeler C. (Switzerland)  

4OS7.3 Snake bites – and the fight to bring them on the neglected tropical disease list  
Alcoba G. (Switzerland)  

4OS7.4 Neglected tropical disease interventions in a conflict zone: Schistosomiasis at Lake Chad  
Greter H. (Switzerland) and Alcoba G. (Switzerland)  

4OS7.5 The Swiss Alliance against neglected tropical diseases  
Steinmann P. (Switzerland)  

10.00  
Coffee Break
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 08.30 | **6OS9 - Give-and-Take: Sharing and using Health Research and Programme Data for Improved Impact**  
Organisers: Piero Olliaro, Special Programme for Research and Training in Tropical Diseases (WHO/TDR), Geneva, Switzerland  
Alessandro Bartoloni, University of Florence and SIMET, Italy  
Chairs: Piero Olliaro (Switzerland) and Amadou Garba (Switzerland)  
**6OS9.1** Sharing and using health research and programme data for improved impact – good practice in governance arrangements  
Terry R.F. (Switzerland)  
**6OS9.2** Data Sharing In Schistosomiasis: beginning the discussion and Experience gained from CONTRAST: A comprehensive multidisciplinary schistosomiasis research network in sub-Saharan Africa  
Kabaterine Bujun N. (Uganda)  
**6OS9.3** Clinical data management in the European Register of Cystic Echinococcosis (ERCE), the HERACLES project  
Tamarozzi F. (Italy)  
**6OS9.4** Clinical trial data platforms: Lessons from malaria applied to a range of infectious diseases  
Guerin P.J. (UK)  
**6OS9.5** A special case: Sharing data in infectious disease outbreaks and emergencies  
Littler K.L. (UK)  
| 10.00 | Coffee Break |
| 08.30 | **LBS1 – Health Problems and Disease Control (1)**  
Chairs: Jan Vanden Abeele (Belgium) and Katja Polman (Belgium)  
**LBS1.1** Full protection from fatal Zika virus infection by a novel chimeric live-attenuated Zika virus vaccine  
Buh Kum D., Mishra N., Schmid M.A., Boudewijns R., Kaptein S., Neyts J., Dallmeier K. (Belgium)  
**LBS1.2** Targeted proteomics identifies novel candidate antigens for the diagnosis of invasive salmonellosis  
Saleh S., Staes A., Van Puyvelde S., Kuipers L., Barbé B., Jacobs J., Gevaert K., Deboggraeve S. (Belgium)  
**LBS1.3** Characterisation of anti-Rhamnose antibody in Cutaneous Leishmaniasis (CL)  
Mesri M., Austin V., Subramanian K., Acosta-Gerrano A. (UK)  
**LBS1.4** Efficacy and safety of moxidectin plus albendazole, moxidectin plus tribendimidine, and moxidectin alone versus albendazole plus oxantel pamoate against Trichuris trichiura and concomitant soil-transmitted helmint infections: A randomised controlled trial  
Barda B., Albonico M., Ame S.A., Said A., Puchkov M., Huwyler J., Hattendorf J., Keiser J. (Switzerland, Italy & Tanzania)  
**LBS1.5** Preliminary results of an intensified praziquantel treatment regimen aiming to eliminate schistosomiasis on Ijinga Island, Lake Victoria, Tanzania  
Mueller A., Fuss A., Kaatano G., Kasang C., Mazigo H. (Germany & Tanzania)  
**4S5.6** Impact of mass drug administration on clinical malaria in a setting of seasonal transmission and high coverage of control interventions  
| 10.00 | Coffee Break |
**LBS2 – Health Problems and Disease Control (2)**

**Chair:** Anne Buvé (Belgium)

**LBS2.1** Interactively exploring the global Dengue phylogeny with PhyloGeoTool

**LBS2.2** Time to harmonize Dengue nomenclature and classification

**LBS2.3** Insecticide-impregnated dog collars reduce human visceral Leishmaniasis under operational conditions in NW Iran: A community–wide cluster randomised trial
Courtenay O., Gavgani S.M., Bazmani A., Cameron M., Davies C.R. (UK & Iran)

**LBS2.4** Can forest malaria be addressed with community-based interventions? Evidence from a multidrug resistance region in Western Cambodia
Gryseels, G., Bannister-Tyrrell M., Suon S., Set S., Uk S., Silling K., Lek D., Peeters Grietens K. (Belgium & Cambodia)

**LBS2.5** Congenital malformations and trace metals: A case-control study from Lubumbashi, DR Congo

**08.30** Coffee Break

---

**LBS3 – Health Systems and Ethics**

**Chairs:** Jean-Paul Dossou (Belgium) and Raoul III Bermejo (Philippines)

**LBS3.1** Health systems, context and frontline provider decision making for maternal and newborn health – Multi-disciplinary perspectives: The Accelerate Project

**LBS3.2** Globalization of clinical trials for breast cancer with innovative and highly priced drugs: Ethical implications in resource-limited settings
Payedimarri A.B., Dierickx K., Gaidano G., Ravinetto R. (Italy & Belgium)

**LBS3.3** Comparative cases of abortion laws and access to safe abortion services in sub-Saharan Africa
Blystad A., Moland K.M. (Norway)

**LBS3.4** Are we missing pregnant women with gestational diabetes? Evidence from a diagnostic accuracy study comparing glycosuria, glycated haemoglobin, random and fasting glucose to oral glucose tolerance test
Agbozo F., Abubakari A., Narh C., Jahn A. (Germany & Ghana)

**10.00** Coffee Break
08.30  5OS11 - Quality Improvement and Patient Safety in Low and Middle Income Countries: Considerations on Feasibility, Challenges and Success Factors
Organiser:
Michael Marx, University of Heidelberg, Institute of Public Health, Heidelberg, Germany
In collaboration with evaplan GmbH at University Hospital Heidelberg, Germany
Chair:
Michael Marx (Germany)
5OS11.1 Rubber stamp templates improve clinical documentation and patient safety: A mixed-methods evaluation in private sector primary healthcare facilities in Kenya
Kleczka B. (Germany)
5OS11.2 How can we measure patient safety? A literature review based 'gold standard' of patient safety indicators
Nitschke C. (Germany)
5OS11.3 Framework for quality improvement of health systems in an outbreak setting based on priority intervention areas
Brugnara L. (Germany)
5OS11.4 Systemic approach to improve service quality in health facilities - A break-through in 10 health facilities in Kenya
Paul –Fariborz F. (Germany)
5OS11.5 Is the indicator based approach a reliable and effective strategy to develop a quality assurance program? Lessons from the Benin quality assurance initiative
Sogbohossou P. (Belgium)
5OS11.6 Is quality equal to safety? The reflection of patient safety in a Kenyan quality improvement project
Marx M. (Germany)

10.00  Coffee Break

08.30  5OS12 - Asset Management in LMICs: A Challenge with Multiple Answers
Organisers:
FESTMIH member: Platform of Be-cause Health & HUMATEM & AZV/MSV
Chair:
Lieven D’haese (Belgium)
5OS12.1 Sharing of good practices through a collaborative network
Blanc-Gonnet C. (France)
5OS12.2 Relevant training of users and maintenance staff
Ntambwe A. (Belgium)
5OS12.3 Feasibility and perspectives of introducing a GMAO in the Ministry of Health in Benin
Verbeke F. (Belgium)

10.00  Coffee Break
08.30 6OS10 - The Secrets of Effective Networks - 5 Case Studies Focusing on Structure and Functioning of Multi-Stakeholder Platforms

Organisers:
FESTMIH members: Platform of Be-cause Health & Irish Forum of Global Health

Chair:
Christine Kirunga Tashobya (Uganda)

6OS10.1 Networking for health and development: Core concepts, challenges and evaluation
Van Steirteghem S. (Belgium & UK)

6OS10.2 Panellists: Basu B. (India) Gyselinck K. (Belgium) Matthews A. (Ireland) Ravinetto R. (Belgium)

10.00 Coffee Break

Poster List Tuesday

1P1 Screening the pathogen box and the stasis box to identify compounds inhibiting Madurella mycetomatis growth in vitro and in vivo
Konings M., Meise Y., van de Sande W. (The Netherlands)

1P2 Action of HIV and tuberculosis medication on CatSper Ca+2 channels in human sperm
Schneider F., Brecker C., Schlatt S., Strünker T. (Germany)

1P3 Diagnostic performance of the Loop-Mediated Isothermal Amplification (LAMP) based illumigene® Malaria assay in a non-endemic region
De Koninck A.-S., Crops L., Hofmans M., Jacobs J., Van den Bosche D., Philippé J. (Belgium)

1P4 Targeting the arginine permease 3 (aap3) coding sequence for rapid identification of Leishmania through high resolution melting (HRM) analysis

1P5 Evaluation of the Leishbox compounds on Nepalese clinical isolates of Leishmania donovani, an industrial/ academic collaboration
Hefnawy A., Cantizani J., Peña I., Dujardin J.C., de Muylder G., Martin J. (Belgium & Spain)

1P6 Human stem cell-derived hepatocyte-like cells support Zika virus replication and provide a relevant model to assess efficacy of potential antivirals
Tricot T., Helsen N., Kaptein S., Neyts J., Verfaillie C. (Belgium)

1P7 The ESBL NDP test: A tool for rationale use of antibiotics in low resource countries
Affolabi D., Sogbo F., Laley G., Orekan J. (Benin)

1P8 Induced pluripotent stem cell-derived neuronal cultures as a model to study Zika virus infections and antivirals
Lanko K., Kaptein S., Eggermont K., Patel A., Claes C., Guo W., Van Damme P., Van Den Bosch L., Delang L., Verfaillie C., Neyts J. (Belgium)

1P9 An immunomics approach detects promising candidate antigens for Ascaris Serodiagnosis in pigs and humans
Vlaminck J., Dana D., Derney L., Mekonnen Z., Weil G.J., Geldhof P., Levecke B. (Belgium, Ethiopia & USA)

1P10 Diagnosis of Trypanosoma cruzi infection status in saliva of infected subjects
Cortes-Serra N., Pinazo M.J., De la Torre L., Galizzi M., Gascon J., Bustamante J.M. (Spain & USA)

1P11 Performance evaluation of a rapid diagnostic test for simultaneous diagnosis of malaria and screening for gambiense human African trypanosomiasis using archived samples
Matovu E., Lumbala C., Sendagire H., Kazibwe A.J.N., Biéler S., Ndung’u J.M. (Uganda, Democratic Republic of Congo & Switzerland)

1P13 Serological tests for gambiense human African trypanosomiasis detect antibodies in cattle
Matovu E., Kitiwba A., Picado A., Biéler S., Bessell P.R., Ndung’u J.M. (Uganda, Switzerland & UK)

1P14 In vitro and in vivo anti-malarial activity of extracts from Terminalia mantaly (Combretaceae)

103 www.ectmih2017.be
1P15 Loop-mediated isothermal amplification of DNA is a rapid and accurate diagnostic for canine Leishmaniasis
Ibarra-Meneses A.V., Sánchez C., García E., Nieto J., Ortega S., Chicharro C., Moreno J., Ndung’u J.M., Cruz I., Camillo E. (Spain & Switzerland)

1P16 Development of a point of care diagnostic test for the neglected tropical skin disease Buruli ulcer

1P17 Diagnosis of schistosomiasis without a microscope: A community-based survey using PCR and CCA-CAA detection on banked stool and urine samples from DR Congo

1P18 Can a Zika IGM and IgG immunoblot replace the virus neutralisation test to confirm screening test results?
Van den Bossche D., Foque N., Michiels J., Arín K.K., Van Esbroeck M. (Belgium)

1P19 The challenge in serodiscordant Chagas Disease: The role of two confirmatory techniques in inconclusive cases
Moure Z., Sulleiro E., Niesta L., Guillen C., Molina I., Alcover M.M., Riera C., Pumarola T., Fisa R. (Spain)

1P20 Analysis of the specificity of a Mycobacterium leprae diagnostic qPCR
Braet S., Vandelannoote K., Meehan C., Rigouts L., Brum Fontes A., Rosa P., Suffys P., De Jong B. (Belgium & Brazil)

1P21 Development of a nanobody-based amperometric immunocapturing assay for sensitive and specific detection of Toxocara canis excretory-secretory antigen
Moraes-Yánez F.J., Sariego I., De Wael K., Polman K., Muylermans S., Trashin S. (Belgium & Cuba)

1P22 Anti-cancer potential of Fasciola hepatica extracts
Ferreira S., Fernandes R., Alves H., Richter J., Botelho M.C. (Portugal & Germany)

1P23 Could Estradiol be used as a biomarker of infection in Schistosoma haematobium infected patients?
Botelho M.C., Cardoso R., Bordalo A., Alves H., Richter J. (Portugal & Germany)

1P24 Optimization of the PAXgene Blood RNA system to store Salmonella cells for subsequent RNA analysis
Rutanga J.P., Van Puyvelde S., De Block T., Jacobs J., Muvunyi C.M., Deborggraeve S. (Flanders & Belgium)

1P25 Shotgun metagenomics as a tool for the rapid diagnosis and genotyping of Dengue

1P26 Usefulness of Toxocara canis larval low molecular weight excretory-secretory products for diagnosis of human toxocariasis
Sariego I., Rojas L., Cantillo J., Falcón R., Polman K. (Cuba & Belgium)

1P27 MRDT (Malaria Rapid Diagnostic Test): Pfvivax pLDH cross react with Denguevirus (DENV)?

1P28 Neutrophil activation and enhanced release of granule products in HIV-TB immune reconstitution inflammatory syndrome

1P29 Influence of age, IPTp-SP, malaria infection and anaemia on naturally acquired antibodies levels to DBL5 and ID1-ID2A and the antibodies’ dynamic during postpartum in a rural setting of Burkina Faso
Traoré O., Yerbanga W.L., Sorgho H., Rouamba T., Ouedraogo N.I., Traoré-Coulibaly M., Velaá I., Tinto H., Belem A.M.G., Traoré Y. (Burkina Faso)

1P30 Low levels of soluble CD40 ligand in asymptomatic leishmanias donovanii co-infected HIV patients
Adriaenssen W., Diro E., Abdellati S., Groupe Y., Mengersha B., Adeem E., Vogt F., van Henten S., Kestens L., Van Griensven J. (Belgium & Ethiopia)

1P31 Distribution of Duffy blood group (FY) phenotypes among Plasmodium vivax-infected patients in Nouakchott, Mauritania

1P32 Killer-cell immunoglobulin-like receptor genotyping by MULTIPLEX PCR-SSP in a Venezuelan population infected with cutaneous Leishmaniasis
Sanjuan-Pacheco W.A., Goncalves L., Fennin G. (Venezuela)

1P33 Platelet-activating factor mediates endotoxin tolerance by regulating indoleamine 2,3-dioxygenase-dependent expression of the suppressor of cytokine signaling 3
Kyung Tae Noh (South Korea)

1P34 Decrease of serological markers of Th2 activity in a context of decreasing intestinal helminth prevalence: Chaco Region, Plurinatal State of Bolivia

1P35 Parasitic exosomes as biomarkers for diagnosis in infectious diseases
Morales G., Cardenas D., Arroyo C., Ayala L., Sesquet R., Torres M. (Ecuador)

1P36 Recent uptake of intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine is associated with selection of Pfdhfr mutations in Bobo-Dioulasso, Burkina Faso

1P37 Variable-Number-Tandem-Repeat Typing for Madurella mycetomatis isolates
Lim W., Eadie K., van de Sande W. (The Netherlands)
1P38 Trypanosoma cruzi analysis by Next Generation Sequencing reveals an important genetic expansion
Callejas-Hernández F., Gironés N., Fresno M. (Spain)

1P39 High prevalence of Pfhrp2 and Pfhrp3 genes mutations in pregnant women in Bobo-Dioulasso, Burkina Faso
Soulama A., Cissé M., Awandare A.G., Hayette M.-P., Guiguemde T.R. (Burkina Faso, Ghana & Belgium)

1P40 Analysis of the Ubiquitin-conjugating (E2) gene, over-expressed in metacyclic promastigotes of Leishmania infantum extracted from Phlebotomus perniciosus
Larraga J., Alonso A., Acolea P.J., Larraga V. (Spain)

1P41 Genome-wide analysis of gene expression in a knock-in cell line of Leishmania infantum over-expressing the elongation factor 2 gene
Acolea P.J., Alonso A., Martínez E., Valldares B., Larraga V. (Spain)

1P42 Molecular subtyping of Blastocystis from symptomatic patients and healthy individuals from the southwestern Iran
Beiromvand M., Hardanipasand L. (Iran)

1P43 Expression analysis of Iron Super Oxide Dismutases (FeSOD A/ B) genes in sensitive and resistant field isolates of L. tropica to meglumine antimoniate using Real-Time RT-PCR
Hajilaran H., Bahram P., Kazemi-Rad E., Mohebali M., Raoofian M., Oshaghi M.A. (Iran)

1P44 Pharmacogenetic profile of P450 2B6, 2C8 and 3A4 genetic variants and the clinical association with malaria recurrent infections in DR Congo
Baraka V., Hansson H., Mavoko H.M., Nabasumba C., Francis F., Rutumba P., Alifrangis M., Van Geertuymen J.P. (United Republic of Tanzania, Belgium, Democratic Republic of Congo, Uganda & Denmark)

1P45 Molecular epidemiology of hepatitis D virus in Togo

1P46 Molecular characterization of Trypanosoma cruzi in 4 Chagas disease patients infected by different routes of transmission
Moure Z., Suleiro E., Ibáñez I., Rubio J.M., Martín A., Nieto J., Pumarola T., Flores Chávez M. (Spain)

1P47 Exploring the genetic basis for human trypanotolerance in African populations
Matovu M., the TrypanoGEN Network (Uganda)

1P48 Complexity of infection and parasite relatedness of Plasmodium falciparum parasites populations in patients administered artemether-lumefantrine (AL) in Kenya

1P49 Role of mTOR in invasion, proliferation and egress of Toxoplasma gondii tachyzoites
González-del Carmen M., Rosas-Luna M., Ramírez-Salazar D.I., Fernández-Vázquez C.A., Jiménez-Patillo J.N., Varela-Cardoso M., Caníno-Calvo L. (México)

1P50 First genome of Salmonella concord, a highly resistant and virulent Salmonella serotype in the Horn of Africa
Cuyper W.L., Dougan G., Jacobs J., Laukens K., Deborggraev S., Van Puyvelde S. (Belgium & UK)

1P51 Antifolate resistance mutations in Plasmodium falciparum isolates from the Central African Republic
Djale D., Ipero J., Serengbe Bobossi G., Kazani M., Manirakiza A. (Central African Republic & France)

1P52 Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the Schistosoma mansoni Mouse Model: Possible clinical implications
Abla N., Keiser J., Vargas M., Reimers N., Haas H., Spangenberg T. (Germany & Switzerland)

1P53 Moderate and severe LFT elevations in controlled human Plasmodium falciparum malaria infection model: Recent experience, literature review and mechanistic hypotheses
Akakpo S., Chalon S., Duparc S., Shapiro T., Griffin P., McCarr J. (Switzerland, USA & Australia)

1P54 Cellulose filtration of blood from malaria patients for improving ex vivo growth of Plasmodium falciparum parasites

1P55 The establishment of an Enterovirus 71 (EV71) infection model with robust lethal neuro-pathogenicity in adult mice
Sun L., Tijm J., Thibaut H.J., Mirabelli C., Delang L., Neys J. (Belgium)

1P56 Steroid hormones in murine schistosomiasis mansoni
Olivera K.C., Cardoso R., Dos Santos A.C., Alves H., Richter J., Botelho M.C. (Portugal, Brazil & Germany)

1P57 Expression of angiogenic and inflammation markers in murine schistosomiasis mansoni

1P58 Rabies antibody response after boosting 10 years or more after pre-exposure prophylaxis
De Pijper C.A., Langedijk A.C., Grobusch M.P., Stijns C. (The Netherlands)

1P59 Pneumococcal Vaccine Immunogenicity following allogeneic hematopoietic stem cell transplantation
Langedijk A.C., Van Aalst M., Meek B., Grobusch M.P., Gooihrus A. (The Netherlands)

1P60 The new Cuban pneumococcal vaccine pipeline: Clinical evaluation status and future considerations

1P61 Measuring the burden of nasopharyngeal colonization in Cuban children: Prevalence and expected changes after pneumococcal vaccine introduction
1P62 Suspected cases of Adverse Event Following Immunization (AEFI) in pregnant women vaccinated after the last yellow fever mass immunization campaign in Kinshasa/Lomba

1P63 Growth inhibition of Peruvian Amazon p. falciparum isolates by antibodies against N-terminal and central MSP10 domains
Villasis E., Bendezú J., Nolasco O., Garro K., Maldonado Y., Torres K., Infante B., Gamboa D., Vinetz J. (Perú & USA)

1P64 Is early measles vaccination associated with stronger survival benefits than later measles vaccination?
Hansen J.S., Thyssen S.M., Rodrigues A., Martins C., Fisker A.B. (Denmark, Guinea-Bissau & Denmark)

1P65 Wing sexual dimorphism in species and subspecies of Tsetse flies
Ebthodaghe F.I., Jaramillo-O.N. (Ghana & Colombia)

1P66 Preparation of colloidal gold immunochromatographic test to detect dog exposure to Phlebotomus perniciosus in endemic settings of canine leishmaniasis
Willen L., Mertens P., Volf P. (Czech Republic & Belgium)

3P1 Discussion of two infection prevention and control training approaches to enhance biosafety in primary healthcare facilities during an outbreak of Ebola virus disease
Kratz T., Verbeek L. (Germany)

3P2 Impact of integrating a pre-referral treatment of severe malaria with rectal artesunate at the community level: A non-inferiority trial in the Democratic Republic of Congo

3P3 A training curriculum for conducting clinical research during outbreaks
Horby P., Denis E., Kaynen N.D., Reis A., Rojek A., Salam A.P., Olliaro P. (UK & Switzerland)

3P4 Sample size calculation in malaria non-inferiority treatment trials with outcome assessed by product-limit estimates of failure
Vailant M., Olliaro P. (Luxembourg, Switzerland & UK)

3P5 Validating and promoting ‘rapid ethical assessment’ as a practical method for enhancing ethical conduct of tropical disease research in developing countries
Addisie A., Mitiku I. (Ethiopia)

3P6 Usefulness of PET-CT for the diagnosis of tuberculosis

3P7 Herbal antimalarial, Azadirachta indica, decreases blood pressure and heart rate in Sprague Dawley rats
Kabits D.E., Angibogu C.N. (Nigeria)

3P8 Biological confirmation of a Cholera epidemic in the Democratic Republic of the Congo, 2016

3P9 Implication of using the GeneXpert for the detection of STIs in pregnant women in Kisantu Health Zone, DRC

3P10 Safety of rVSV ebola vaccine, after 6 months follow-up, in adults: A phase 1 trial conducted in Lambaréné, Gabon

3P11 Introducing single dose liposomal amphotericin b for the treatment of visceral leishmaniasis in Nepal: An experiences to support ongoing elimination programme
Karki P., Urasaw S., Kattel V., Acharya B., Singh N. (Nepal)

3P12 The potential impact of splenectomy in treatment of visceral leishmaniasis in a multi-experienced HIV-coinfected patient
Chiappetta S., Guiffanti M., Cernuschi M., Bossolasco S., Maillard M., Ceserani N., Boeri E., Racca S., Castagna A., Gaiera G. (Italy)

3P13 Low probability for Zika virus (ZIKV) circulation in pregnant women from Madagascar in 2010 and evidence for cross-reactivity in malaria infected individuals leading to false positive anti-ZIKV IgG ELISA tests
Schwarz N.G., Mertens E., Winter D., Maiga-Ascofaré O., Dekker D., Jansen S., Tappe D., Randriamampionona N., May J., Rakotozandrainy R., Schmidt-Chanasit J. (Germany, Ghana & Madagascar)

3P14 rHA T-Sero-Strip, a new rapid diagnostic test for gambienne sleeping sickness using recombinant antigens
Büschler P., Mertens P., Gilleman Q., Rooney B., Rogé S. (Belgium & UK)

3P15 Optimization of the dna extraction and real-time PCR for low parasitemia leishmania infections

3P16 Cost-effectiveness analysis of new diagnostic tools for cutaneous leishmaniasis in Afghanistan
Aerts C., Vink M., Picado A., Pashtoon S.J., Hazrat S., Cruz I., Sicuri E. (Spain, The Netherlands, Switzerland & Afghanistan)

3P17 Accuracy of a rapid test for the diagnosis of cutaneous leishmaniasis in patients with suggestive skin lesions in Morocco
Bennis I., Verdonck K., Riyad M., el Khalfaoui N., Fellah H., Sahibi H., Van der Auwera G., Dujardin J.C., Boelaert M. (Morocco & Belgium)

3P18 Comparison of two Zika virus serological techniques and the influence of previous Dengue infection for the screening of asymptomatic pregnant women in a reference centre in Barcelona

3P19 Diagnostic performance of the InBiOS rapid diagnostic test for the detection of Burkholderia pseudomallei in blood culture broth: results of a phase II evaluation study
Peeters M., Chung P., Lin H., Mortelmans K., Phe C., San C., Kuljers L., Teav S., Phe T., Jacobs J. (Belgium, Cambodia & USA)
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>3P21</td>
<td>Formulation and evaluation of quinine hydrochloride loaded ethosomes</td>
<td>Agbo C.P., Nwabueze H.U., Offor E.N., Attama A.A. (Nigeria)</td>
</tr>
<tr>
<td>3P22</td>
<td>Antibiotic Stewardship Programs in Hospitals in Low-and Middle Income Countries: Current Status, Priorities and Barriers</td>
<td>Cox J.A., Jacobs J., Vlieghe E. (Belgium)</td>
</tr>
<tr>
<td>3P23</td>
<td>Improving basic hygiene among health care workers through ebola-training: A field perspective</td>
<td>Kaboré R.P., Kaboré D.S.R., Zida S., Ouedraogo N.W., Verbeek L., Gies S. (Burkina Faso &amp; Germany)</td>
</tr>
<tr>
<td>3P24</td>
<td>Clinical mentoring via mobile teams - a new approach to visceral leishmaniasis care in resource-constrained settings in Africa</td>
<td>den Boer, Moerkerk M., Lado M., Atiaby A., Ochol A., Alvar J., Mekonnen B., Ritmeijer K. (UK, Switzerland, South Sudan, Sudan, Ethiopia &amp; The Netherlands)</td>
</tr>
<tr>
<td>3P25</td>
<td>Chronic multi-morbidity among bangladesh adult population</td>
<td>Khan N., Rahman M., Afsana K. (Bangladesh)</td>
</tr>
<tr>
<td>3P26</td>
<td>Prevalence of selected cardiovascular risk factors in ART-naive HIV infected patients in Lillonge, Malawi</td>
<td>Neuhamn F., Phili S., Helft T., Chaweza T., Tweya H., Fäktkenheuer G., Demir M., Steffen H.M. (Germany &amp; Malawi)</td>
</tr>
<tr>
<td>3P27</td>
<td>Epidemiology and Clinical Presentation of MERSCOV in Saudi Arabia: A Systematic Review</td>
<td>Alqaihtani S.H., Aldawsari M.N. (Saudi Arabia)</td>
</tr>
<tr>
<td>3P28</td>
<td>Correlation between cytokine profile and left ventricular function in chronic chagasic patients</td>
<td>Sousa R.C., Bernardino D., Silva M.V., Costa T.A., Rodrigues V., Correia D. (Brazil)</td>
</tr>
<tr>
<td>3P29</td>
<td>Cross-sectional analysis in young non-pregnant and pregnant women in Burkina Faso of associations between biomarkers of iron status and effect modification by inflammation and <em>P. falciparum</em> infection</td>
<td>Diazlo S., Gies S., Ki A., Pagbelguem J.G., Tinto H., Ouedraogo G.A., Brabin B.J. (Belgium, Germany, UK &amp; Burkina Faso)</td>
</tr>
<tr>
<td>3P30</td>
<td>The Global Point Prevalence Survey of antimicrobial consumption and resistance (Global-PPS): First results of antimicrobial prescribing in a tertiary care hospital in Guinea</td>
<td>Sow M.S., Versporten A., Goossens H., Sylla A.O. (Guinea &amp; Belgium)</td>
</tr>
</tbody>
</table>
3P45 Histoplasmosis in Europe an uncommon condition, associated with HIV infection

3P46 Dermatophytosis in patients with Podocnosis in the Ethiopian highlands

3P47 Diagnosis of cutaneous anthrax with the naked eye in resource poor settings

3P48 Pathogenic fungal species associated with digestive system of Periplaneta americana L. (Blattaria: Blattidae) trapped from residential dwellings in Ahvaz city, Southwestern Iran
Kassiri H., Zarrin M., Veys-Behbahani R. (Iran)

3P49 Intra-articular virus RNA shedding in Zika virus (ZIKV) and Chikungunya virus (CHIKV)
Co-infection correlates with long-lasting infection, higher severity and systemic poor viral clearance

3P50 Prevalence and risk factors of CTX-M Enterobacteriaceae in hospitalised patients at a tertiary hospital in Kilimanjaro, Tanzania

3P51 Autochthonous cases of Strongyloidiasis in the Czech Republic
Stejskal F., Polívková S., Pytlík R., Stížek M., Richterová L. (Czech Republic)

3P52 Factors associated with indeterminate cause of death in rural Southern Mozambique

3P53 Safety and tolerability of two regimens used to treat multi-drug resistant Tuberculosis in Kinshasa: A prospective cohort

3P54 Safety and tolerability of artesunate and armodudino combination in the treatment of uncomplicated malaria in Kinshasa: A pilot cohort event monitoring study
Lula Y., Nsima G., Nzigou D., Nsima G., Tona G., Van geerven J.P. (Democratic Republic of Congo & Belgium)

3P55 The epidemiology of Taenia Saginata and Taenia Solium in Western Europe: A systematic review
Laranjo-González M., Develleaschauer B., Trevisan C., Aleupz A., Sotiraki S., Dorny P., Gabriël S., Dermauw V. (Spain, Belgium, Denmark & Greece)

3P56 Long term evolution of the clinical complications of Ebola virus disease: Results of the Postebogu cohort

3P67 Systematic literature review of antibiotic stewardship interventions in hospitalized patients in low- and middle-income countries
Van Dijck C., Vlieghé E., Cox J.A. (Belgium)

3P68 Clinical patterns of tetanus and HIV co-infection in a referral hospital in Ethiopia: A case series
Lomencha A., Fantaye H., Azash A. (Ethiopia)

3P69 Clinical management and outcomes of alveolar echinococcosis in a tertiary care centre in Prague
Stejskal F., Trojanek M., Kolarova L. (Czech Republic)

3P60 Zika Virus Infection on human umbilical vein endothelial cells induces cell death and activation of secondary hemostasis

Wilmes D., Losert H., Antweiler E., Tilienthö K., Rickerts V. (Germany)

3P62 Prevalence of hepatitis C virus co-infection among patients enrolled in routine HIV care in three outpatient departments with varying risk profiles in Phnom Penh, Cambodia
Iwamoto M., Kim S.C., Suonsopehek M., Sangky J., Dimanche H., Heang S., Islam S., Chikwani I., Balkan S., Maman D. (Cambodia)

3P63 Infectious aetiology of persistent digestive disorders (>2 weeks) in Niono, Mali, and implications for treatment
Saye R., Becker S.L., Fofana H.K.M., Mama Nélè Doumba, Polman K., Boelaert M., Chappuis F., Traoré M.S., Utzinger J., Sacko M. (Mali, Switzerland, Germany & Belgium)

3P64 Digestive disorders in Mali: Assessment of a neglected public health issue
Saye R., Landoués A., Mama Nélè Doumba, Becker S.L., Polman K., Boelaert M., Chappuis F., Utzinger J., Sacko M., Traoré M.S. (Mali, Switzerland, Germany & Belgium)

3P65 Multicenter surveillance of bloodstream infections in Kisangani, Oriental Province, Democratic Republic of the Congo: Quality indicators from blood cultures
Falay D., Peeters M., Mapendo B., Hasivirwe E., Phoba M-F., Lungyu O., Devlieger H., Van Geet C., Ngbonda D., Jacobs J. (Republuc of the Congo & Belgium)

3P66 The influence of Dengue virus serotype on disease severity
Mulyaningrum U., Rochmah F.S.N. (Indonesia)

3P67 Investigation of markers of arsenicmin resistance at selected intervals during the 72-hour period after arsenicmin based combination therapy dosing in Kisumu western Kenya

3P68 SMS photograph-based external quality assessment of reading and interpretation of malaria rapid diagnostic tests in the Democratic Republic of the Congo

3P69 Effect of additional instructions for sputum sampling on microscopic tuberculosis detection in Kinshasa, Democratic Republic of Congo
Kupa S.M., Aloni M., Bakoko B., Sabi L., Mukadi D., Nkuba A., Mujangi B., Musala S., Kaswa M., Ahuka M. (Democratic Republic of the Congo)
3P0 Posters

3P70 Photo-based external quality assessment of malaria rapid diagnostic tests in a non-endemic setting
Vernelen K., Barbé B., Gillet P., Van Estbroeck M., China B., Jacobs J. (Belgium)

3P71 Rethinking the approach of medicine stability testing
Grech J., Robertson J., Thomas J., Cooper G., Naunton M., Mutambuze, I., Kelly T. (Australia & Uganda)

3P72 A systematic review and meta-analysis of the risk of transfusion transmitted malaria from blood donors in sub-Saharan Africa
Fiamaña S., Buffet P., Guérin P.J. (UK & France)

3P73 Pre-travel guidelines needed for travelers with an Immunocompromised status or chronic disease
Van Aalst M., Verhoeven R., Omar F., Stjinis C., van Vugt M., de Bree G.J., Goorhuis A., Grobusch M.P. (The Netherlands)

3P74 Lobomycosis in an Italian traveler acquired during 5-days-honeymoon in the Amazon region of Venezuela
Beltrame A., Danesi P., Farina C., Orza P., Perandín F., Capelli G., Rodari P., Staffolani S., Bisoffi Z. (Italy)

3P75 Cardiovascular disease risk prediction in sub-Saharan African migrant and home populations – Comparative analysis of risk algorithms in the Rodam study

3P76 An unusual case of leprosy from Germany – Just an exception of the rule?
Saar M., Beissner M., Hanus I., Huber K., Löschter T., Bretzel G. (Germany)

3P77 The challenge of persistent parasitic and viral infections among prisoners from sub-Saharan Africa and Latin America: A cross-sectional study in Geneva, Switzerland
Getaz L., Chappuis F., Wolff H., Albajar-Vinas P., Vitoria M., Tran N.-T., Da Silva Santos L. (Switzerland)

3P78 “He doesn’t seem to understand it as an illness”: Mental health interventions for migrant victims of torture and other forms of ill treatment
Womersley G., Klotzter L., Van den Bergh R., Verabendes E., Kotsioni I., Kokkiniotis M., Zamatto F. (Switzerland & Greece)

3P79 Epidemiological, microbiological and clinical data of traveller women returning from vector-borne endemic areas for Zika virus
Rodó C., Soriaño-Arandes A., Suy A., Sulleiro E., García I., Frick A., Rando A., Arévalo S., Pumarola T., Carreras E. (Spain)

3P80 Human filariasis: Transversal study on imported cases at an International Health Reference Unit in Barcelona

3P81 Delayed Plasmodium falciparum malaria in three migrants
Figueiredo Ferreira M., Dauby N., Konopiński D., Nguyen V.T.P., Cantinieaux B., Martin C. (Belgium)

3P82 Colonisation of German soldiers returning from deployment with enterobacteriaceae with resistance against 3rd generation cephalosporins
Rojak S., Frickmann H., Maassen W., Wiener D. (Germany)

3P83 TRIP (Travel Remote Information Platform), a platform for monitoring traveler's health
Rodríguez-Valero N., Ledesma Carbayo M.J., Cuadrado Sanchez D., Vladimirov A., Vera I., Roldan M., De Alba T., Sanz S., Luengo Oroz M., Muñoz J. (Spain)

3P84 Epidemiological and clinical characteristics of imported chagas disease in a hospital in Madrid

3P85 Risk factors of imported malaria in a non-endemic country
Rodríguez-Toro A., Cabrera Rodríguez I., Prieto-Pérez L., Herrero Martínez J.M., Cabanuz C., Fernández Roblas R., Cabello A., Pérez De Ayala A., Carrillo Acosta I., Górgolas M. (Spain)

3P86 Serological screening for cystercercosis in internationally adopted children in Italy
Zammarilli C., Fantoni T., Chiappini E., Angheben A., Galli L., Marchese V., Zavarise G., Bisoffi Z., Bartolini A. (Italy)

3P87 Impact of antimalarial chemophrophylaxis on clinical presentation of imported malaria in children: A retrospective study in a Parisian university hospital
Cavasino T., Bourayou R., Craiu I., Federci L., Regnard D., Zenkhi F., Angoulvant A., Pham L.L. (France)

3P88 Artemisin-based combination therapy for the treatment of non-severe imported malaria in children: A retrospective study in a Parisian university hospital
Matczak S., Cavasino T., Bourayou R., Craiu I., Bissiere B., Angoulvant A., Pham L.L. (France)

3P89 Severe cases of imported plasmmodium ovale malaria in a french university hospital center: A 2015-2017 retrospective cohort study
Méchain M., Lambert Y., Duvinraud A., Pitstone T., Millet P., Gabriel F., Augis V., Receveur M-C., Malvy D. (France)

3P90 Zika virus infection – The experience of a reference laboratory for its surveillance in Catalonia

3P91 First results of an HIV counselling and testing project in the irregular migrant population of Doctors of the World, Antwerp
Couderé K., Wouters K., Erven G., Van Den Heuvel A., Fransen K. (Belgium)

3P92 Cystic echinococcosis in refugees from Syria and Iraq
Richter J., Trebesch I., Gertler M. (Germany)

3P93 MYHEALTH: Models to engage migrants and refugees in their health, through community empowerment
Esteban Serna E., Qureshi A., Oliveira-Souto I., Collazo P., Ouazarab H., Gomez I Prat J., Molina Romero I., Serre-Delcor N., MyHealth Project group (Spain)
8P1 The public health and economic implications of infant male circumcision in rural Ghana; A community level population based study
Gyan T., McAuley K., Stoebel A.N., Newton S., Owusu-Agyei S., Edmond M.K. (Australia & Ghana)

8P2 Caring practises of mothers with low birth weight infants in the neonatal period; a retrospective qualitative study in the Hoohoe municipality, Ghana
Schuler C., Notw G. E., Agbozo F. (Switzerland, Ghana & Germany)

8P3 An evaluation of continued cognitive and motor decline in Congolese Kongo children during four-year follow-up

8P4 Community acquired pneumonia in Cuban children under five, 2009-2015

8P5 Childhood tuberculosis in a rural hospital in southeast Ethiopia: A seventeen-year retrospective study
Ramos J.M., Pérez-Blugagüeno M., Comche B., Tesfamariam A., Reyes F., Gorgolas M. (Ethiopia & Spain)

8P6 Severe malaria and risk factors associated to the lethality in children admitted in Jason Sendwe hospital, Democratic Republic of the Congo

8P7 Home-based management of presumptive malaria in children under 5 years old in an urban health area, Democratic Republic of the Congo

8P8 Prevalence and determinants of under and overnutrition among under five children in Bengo province, Angola
Brito M., Gaimberri S., Fançony C., Soares A., Centro de Investigação em Saúde de Angola (CISA), Cahito, (Angola & Portugal)

8P9 Prevalence of Helicobacter pylori antigens and antibodies in asymptomatic children in Kinshasa, DR Congo

8P10 Etiology of fever in hospitalized children in Gabon: Preliminary results
Fernandes J.F., Held J., Dorm M., Agnandji S.T., Adgekina A.A., Kremsner P.G., Mordmüller B., Grobusch M.P. (Germany, Gabon & The Netherlands)

8P11 Neonatal hyperbilirubinemia in hospitalized neonates on the Thai-Myanmar border: An audit of neonatal medical records from 2009 to 2014

8P12 Clinical and neurodevelopmental outcome of newborns with excessively high levels of serum bilirubin in a limited-resource setting: A matched case-control study

8P13 Comparative post-rainy season surveys of malaria-associated morbidity among febrile pediatric patients in Nouakchott, Mauritania

8P14 Associated factors to double burden of malnutrition stunting of child and obesity or overweight in mother in a secondary city of Benin
Saizounou J., Sossa-Jérôme C., Dembé B., Moubo G., Ouendo E.-M. (Benin)

8P15 Does the deployment of HIV diagnostic assistants in Malawi improve early infant HIV Diagnosis and enrollment to care?

8P16 Clinico-epidemiological profile and outcome of snake bites victims: A pilot project to monitor and accelerate the reduction of snake bite mortality - Touboro health district Cameroon - 2016
Djikeussi K.T., Nko’Ayissi G., Etoundi G.A., Matheiu E. (Cameroon & USA)

8P17 Integrating nutrition into local development plans: A challenge for Burkina Faso
Ouedraogo O., Doudou M.H., Drabo K.M., Ouaro B., Donnin P. (Belgium & Burkina Faso)

8P18 Impaired child development in the Amazon region of Peru: Describing the current situation and identifying early-life targets for intervention
Blouin B., Casapia M., Gyorkos T.W. (Canada & Peru)

8P19 Uptake of HIV Testing and Counselling (HTC) among acutely malnourished children in rural and urban Blantyre, Southern Malawi: A retrospective comparative review
Kalumbi L.R., Kamanga F. (Malawi)

8P20 Mental health among private high school students in Hanoi, Vietnam
Linh T.D. (Vietnam)

8P21 Malnutrition associated to uncomplicated malaria in sub-Saharan African adults: Socio-demographic factors, clinical and biological impact
Zango S.H., Valea I., Nakarabo D.S., Rouamba T., Tinto H. (Burkina Faso)

8P22 Geographical variations in nutritional status of children in India: A fresh evidence based on NFHS 2015-16
Kumar A. (India)

8P23 Emergence of dancing and singing in infants and toddlers
Richter J., El-Scheich T., Akpata R., Ostovar R. (Germany & Benin)

8P24 Evaluation of RSV and hMPV viruses in respiratory samples of children under 5 years by Real-time PCR in Arak, Iran
Rahimi E., Sarmadian R., Salehi F., Khansarinejad B., Mehrparvar B., Mondanizadeh M., Fotouhi F. (Iran)

8P25 Determinants of stunting and severe stunting among Burundian children aged 6-23 months: Evidence from a national cross-sectional household survey, 2014
Nkurunziza S., Meessen B., Van geertruyden J.-P., Korachais K. (Belgium & Burundi)

8P26 Associated factors to double burden of malnutrition stunting of child and obesity or overweight in mother in a secondary city of Benin
Saizounou J., Sossa-Jérôme C., Dembé B., Moubo G., Ouendo E.-M. (Benin)
8P27  Gastro-intestinal parasitic infection amongst primary school children in Ogiobo and Eresoyen primary schools in Benin city, Edo state, Nigeria
Ezieful C.M., Okaka C.E. (Ghana & Nigeria)

8P28  Prevalence and associated risk factors of intestinal parasites among children in a referral hospital in Northern Tanzania
Janzen A., van Eckert R., Fuss A., Kahima J., Kasang C., Kalluya S., Mueller A. (Germany & Tanzania)

8P29  Stunting in extreme nutritional vulnerability: Eastern of Democratic Republic of Congo crisis case

8P30  Pediatric tuberculosis in a hospital in Lima Peru, 2005-2015
Otero L., Hernández H., Sedanamo J., Baye A., Lovatón N., Gotuzzo E. (Peru)

8P31  Malnutrition is dominant in boys less than two-years-old in rural Cambodia
Iwamoto A., Matsui M., Koto K., Nogami Y., Taniguchi N., Miyazaki A., Tung R. (Japan & Cambodia)

8P32  Parental knowledges, attitudes and practices regarding childhood fever in the health district of n'sele in Kinshasa, Democratic Republic of The Congo
Zola T., Mateso D., Vulu C., Company J.P., Matoka T., Nkanza P., Mbaya F., Muhindo H., Matangila J., Mitashi P. (Democratic Republic of Congo & Belgium)

8P33  Reaching the underserved: Taking stock of child health days' with a mixed methods impact evaluation
Alba S., van der Veen A., Bakker M.I., van den Broek A., Baatsen P. (The Netherlands)

8P34  Causes of severe febrile illnesses in hospitalized children, Nouna Burkina Faso
Dah C., Seynou M., Lesikan A., Sozou A., Souares A. (Burkina Faso & Germany)

8P35  Impeding factors regarding appropriate feeding of infants and young children in Burkina Faso: Infant colic is a forgotten problem to manage
Somassé Y.E., Savadogo L.G.B., Donnen P. (Belgium & Burkina Faso)

8P1  A molecular survey on Babesia and Thiliera species parazitizing tick of camels in borderline of Iran-Pakistan

8P2  Molecular identification and genetic characterization of tick-borne zoonotic anaplasma species in dogs in Lusaka, Zambia
Chitanga S., Vlahakis P.A., Changula K., Simulundu E., Simununza M.C. (Zambia)

8P3  The tsetse fly (Glossina) challenge at wildlife/people/livestock interface of Akagera National Park, Rwanda
Gashururu S.R., Musafiri E., Munyampuhwe S., Tukey E.M (Rwanda)

8P4  Important foodborne bacteria and their antimicrobial resistances in Ecuadorian poultry
Vinueza C., De Zutter L. (Ecuador & Belgium)

8P5  Gastro-intestinal parasites infections in mountain gorillas (Gorilla beringei beringei) of Rwanda Volcanoes National Park: One Health Implications
Gashururu S.R., Umurerwa A.G., Tukey E.M (Rwanda)

8P6  A one health approach to taenia solium control in sub-Saharan Africa
Johansen M.V., Braae U.C., Trevisan C., Lekule F., Magnussen P., Ngowi H. (Denmark, West Indies, Belgium & Tanzania)

8P7  Minyoo Mata: The vicious worm – A Taenia solium taeniosis/cysticercosis health education tool – in Swahili
Trevisan C., Fèvre E.M., Owinyi M., Ngere I., Johansen M.V. (Belgium, Kenya & Denmark)

8P8  Experience of a Peruvian University using the “One Health (UnaSalud)” concept
Ormea V.C., Mejía F., Gotuzzo E. (Peru)

8P9  Systemic insecticide treatment of the canine reservoir of Trypanosoma cruzi induces high levels of lethality in Triatoma infestans, a principal vector of Chagas disease
Villanucci A., Fascendini M., Cristofori E.I., Demarchi A., Pecchioni V., Salza A. (Italy)

8P10  Gaps in the control of zoonoses in Nepal

8P11  One health to enhance the health status of nomadic pastoralists and their livestock
Villanucci A., Fascendini M., Cristofori E.I., Demarchi A., Pecchioni V., Salza A. (Italy)

8P12  Prevention of emerging zoonoses in central Africa: An overview from a veterinary perspective
Assana E., Van Wettere A., Chepnda V., Awah Ndukum J., Tarbel B. (Cameroon & USA)

8P13  Knowledge and preventive practices of toxocariosis in school children and their parents trained on the disease in 2006 - District of San Juan de Lurigancho, Lima, Peru, 2010
Ormea V.C. (Peru)

8P14  Seroprevalence of toxoplasmosis in pregnant and infants in Lubumbashi, Democratic Republic of Congo
2P15 Rabies outbreak in village livestock and lack of post exposure vaccine seeking behavior in South Oromia Pastoralist, Ethiopia
Gurni B., Girma S., Mohamed H., Desera A. (Ethiopia)

2P16 Evaluating milk handling processes in smallholder dairy farms in Rombo district, Tanzania
Hyera E., Minja M.G., Marwa L.J., Mng’anya P. (Tanzania)

2P17 Use of One Health approach for anthrax outbreak response in Northern Tanzania - A case study of Selela Ward in Monduli District, November 2016

2P18 Epidemiology of human brucellosis in Durood city, Iorestan province, Iran
Nazar N., Bohlooli N. (Iran)

2P19 Erysipelothrix rhusiopathiae infection in pigs, pork and among raw pork handlers in Kamuli District, Eastern Uganda
Musewa A., Roesel K., Delia G., Nakanjako D., Kawooya I., Ssenyonga R., Nangendo J., Erume J. (Uganda, Kenya & Germany)

2P20 Evaluation of post-mortem detection techniques for bovine cysticercosis in Belgium
Jansen F., Dorny P., Makay C., van den Broeck N., Berkers D., Gabriël S. (Belgium)

2P21 Participatory-based surveillance and detection of viral zoonotic pathogens in the Democratic Republic of Congo

2P22 Pattern spatio-temporal of buruli ulcer in the rural health area of Kimpese, central Kongo province, in the Democratic Republic of the Congo from 2009-2015
Mulongo P.M., Luzolo E.K., Matondo J.B., Mazamayi S.K., Bompangue D.N., Phanzu D.M. (Democratic Republic of Congo)

2P23 Seroprevalence of toxoplasmosis among premarital women in Banguntapan, Bantul, Indonesia
Agustiningsih L., Fitriani Y., Mulyaningrum U. (Indonesia)

2P24 Hemato-biochemical analysis of natural PPR outbreaks in Black Bengal goats showed marked anemia, leukocytosis and electrolyte imbalance
Begum S., Nooruzzaman M., Murshida M.M., Mohanto N., Parvin R., Islam M.R., Chowdhury W.E., Mohanta N. (Bangladesh)

2P25 Serological evidence and risk factor of spotted fever group and typhus group rickettsiae exposure in humans from Madagascar

2P26 Filarial parasites in cats and dogs represent a public health threat in Madampe, Sri Lanka
Mallawarachchi C.H., Chandrasena T.G.A.N., Wickramasinghe S., Samarasekara S.D., Mallawarachchi S.M.N.S., de Silva N.R. (Sri Lanka)

2P27 Brugian filariasis in Sri Lanka: A preliminary report on survey in Gampaha District
Mallawarachchi C.H., Chandrasena T.G.A.N., Samarasekara S.D., Mallawarachchi S.M.N.S., de Silva N.R. (Sri Lanka)

2P28 Zika virus dynamics in body fluids and risk of sexual transmission in a non-endemic area

2P29 Trans placental transmission of visceral leishmaniasis - Looking for the evidence – A case series
Basher A., Nath R.N. (Bangladesh)

2P30 Extensive serological survey in multiple African monkey species reveals complex reactivity patterns to four ebola virus species

2P31 Anopheles mosquitoes and transmission of malaria in the mountainous region of Rutshuru, in eastern Democratic Republic of Congo

2P32 Chagas disease transmission: Importance of humans as triatomine blood source in an endemic area
Ocaña-Mayorga S., Bustillos J.J., Brenière S.F., Villacís A.G., Grijalva M.J. (Ecuador, France & USA)

2P33 The mosquito borne West Nile Virus infection: Is it threatening to Egypt or a neglected endemic disease?
El-Bahnasawy M.M., Morsy T.A. (Egypt)

2P34 New methods to identify Leishmania super-spreaders in modeling targeted control
Lison A., Reed S., Courtenay O. (UK & USA)

2P35 Examination of influencing factors and high-risk regions of Dengue in Nicaragua, using spatiotemporal compartmental simulations
Theodorakos K., Broeckhove J., Willem L. (Belgium)

2P36 Transmission dynamics of loiasis over twenty-three years in three communities of the Mbalmayo health district (central Cameroon)
Mogoun-Walo A.E., Nana-Djeunga H.C., Domche A., Fossou-Thotchum F., Bopda J., Mbickmen-Tchana S., Karrino J. (Cameroon)

2P37 Change in diversity and risk of rodent-borne diseases along a gradient of anthropogenic habitat perturbation in Yasuni National Park, Ecuador
Ocaña-Mayorga S., Innico N., Bonté D., Sanchez-Montalvá A., Muyembe J.J., Delaporte E., Grijalva M.J. (Ecuador, France & USA)

2P38 Higher tuberculosis transmission potential in South African compared to Tanzanian schools: Using carbon dioxide levels and re-breathed shared air to estimate airborne transmission
Hella J., Morrow C., Hella J., Chitnis N., Gagneux S., Mutayoba B., Ginsberg S., Wood R., Fenner, L., Reither K. (Tanzania, Switzerland & South Africa)
<table>
<thead>
<tr>
<th>Monday</th>
<th>Tuesday</th>
<th>Wednesday</th>
<th>Thursday</th>
<th>Friday</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2P40</strong></td>
<td></td>
<td>Rats as a potential reservoir of invasive non-Typhii Salmonella: A field study in Kisangani, Province of Tshofo, Democratic Republic of the Congo</td>
<td>Falay D., Peeters M., Tarztito J., Akaibe D., Lunguya O., Mathews W., Bertrand S., Van Geet C., Ngbonnda D., Jacobs J. (Democratic Republic of the Congo &amp; Belgium)</td>
<td></td>
</tr>
<tr>
<td><strong>2P42</strong></td>
<td></td>
<td>Bio ecological characteristic of malaria vectors in southeast part of Iran</td>
<td>Edalat H., Khairandish S., Mahmoudi M. (Iran)</td>
<td></td>
</tr>
<tr>
<td><strong>2P43</strong></td>
<td></td>
<td>Biodiversity and medically important ticks in northeast of Iran</td>
<td>Telmadarraiy Z., Arzamani K., Saghafipour A., Faghihi F., Arzamani N., Rahimeh A. (Iran)</td>
<td></td>
</tr>
<tr>
<td><strong>2P44</strong></td>
<td></td>
<td>Combining area-wide mosquito repellents and long-range attractants to create a &quot;push-pull&quot; system that protects against disease transmitting mosquitoes in Tanzania</td>
<td>Muhando A., Okumu F., Ngowo H., Abbas S., Matowo N., Kililangongono M., Moore S. (Tanzania)</td>
<td></td>
</tr>
<tr>
<td><strong>2P46</strong></td>
<td></td>
<td>Expansion in the distributional range of ixodid ticks parasitising cattle in Zimbabwe</td>
<td>Sungai M., Moyo D.Z., De Clercq P., Madder M. (Zimbabwe, Belgium &amp; South Africa)</td>
<td></td>
</tr>
<tr>
<td><strong>2P47</strong></td>
<td></td>
<td>High prevalence of bed bug infestation in Ethiopian residential institutions: its psychological, social and health impact; A cross-sectional study</td>
<td>Melkonnen D., Derbie A., Mulu W., Melkonnen Z., Aberra B., Bladstegfne F., Mihret A., Sack U. (Ethiopia &amp; Germany)</td>
<td></td>
</tr>
<tr>
<td><strong>2P48</strong></td>
<td></td>
<td>Entomological studies to improve Chagas disease vector control in the Gran Chaco region</td>
<td>Goncalves R., Bern C., Courtenay O. (UK &amp; USA)</td>
<td></td>
</tr>
<tr>
<td><strong>2P50</strong></td>
<td></td>
<td>First report of pyrethroid resistance in Rhipecephalus (Boophilus) annulatus (Say, 1821) from Iran</td>
<td>Ziapour S.P., Kheiri S., Aasgarian F., Faezeli-Dinah M., Yazi F., Mohammadmour R.A., Aarabi M., Enayat A. (Iran)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Monday</th>
<th>Tuesday</th>
<th>Wednesday</th>
<th>Thursday</th>
<th>Friday</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2P52</strong></td>
<td></td>
<td>Bioepidemiology of intermediate host and Schistosoma haematobium infection in Angolan rural areas - Systematic review</td>
<td>Cardoso S.M., Grácio A.J.S., Grácio M.A. (Portugal &amp; Angola)</td>
<td></td>
</tr>
<tr>
<td><strong>2P53</strong></td>
<td></td>
<td>Comparative entomological study on ecology and behaviour of malaria vectors in Badar- Abbas district, southern of Iran</td>
<td>Basseri H.R., Mojahedi A.R., Safari R., Yarian M., Raesi A., Edalat H., Beniardelam M. (Iran)</td>
<td></td>
</tr>
<tr>
<td><strong>2P54</strong></td>
<td></td>
<td>Lassa virus distribution and phylogeny in rodent populations in Bo district, Sierra Leone</td>
<td>Bangura U., Sondufu D., Buanie J., Dawson M., Lamin J., Bongo G., Ansunama R., Borchert M., Sah S., Fichtel-Calet E. (Germany &amp; Sierra Leone)</td>
<td></td>
</tr>
<tr>
<td><strong>2P55</strong></td>
<td></td>
<td>Manipulation of sandyfly distribution within the peridomestic environment, and implications for the control of vector-borne disease</td>
<td>Dilger E., Carter V., Gonzalez de Heredia M., Borges-Alves G., Nunes C., Garcez L.M., Brazil R., Hamilton G., Medley G., Courtenay O. (UK &amp; Brazil)</td>
<td></td>
</tr>
<tr>
<td><strong>2P57</strong></td>
<td></td>
<td>Don’t overlook the snail: The role of the intermediate snail host in the dynamic epidemiology of schistosomiasis in Northern Senegal</td>
<td>Huyse T., Boon N., Smitz N., De Sciscio A., Kanage B., Polman K., Volckaert F., Van den Broeck F. (Belgium)</td>
<td></td>
</tr>
<tr>
<td><strong>4P1</strong></td>
<td></td>
<td>Economic and disease and burden of Dengue from the perspective of the patients and their families</td>
<td>Baly A., Abadi A., Cabrera P., Van der Stuyft P. (Cuba &amp; Belgium)</td>
<td></td>
</tr>
<tr>
<td><strong>4P2</strong></td>
<td></td>
<td>Yellow fever in Brazil: Report of 2 cases</td>
<td>Figueiredo L.T.M. (Brazil)</td>
<td></td>
</tr>
<tr>
<td><strong>4P3</strong></td>
<td></td>
<td>Micro costing of an Aedes aegypti control programme</td>
<td>Baby Gil A., Fonseca V., Figarola R., Cabrera P., Van der Stuyft P. (Cuba &amp; Belgium)</td>
<td></td>
</tr>
<tr>
<td><strong>4P4</strong></td>
<td></td>
<td>Towards knowledge translation of community empowerment strategies in Dengue prevention: A fresh look at a Cuban experience</td>
<td>Pérez D., Castro M., Lifkin S.B., Lloyd L.S., Zabala M.C., Van der Stuyft P., Ridve P., Lefèvre P. (Cuba, USA, Belgium &amp; Canada)</td>
<td></td>
</tr>
<tr>
<td><strong>4P5</strong></td>
<td></td>
<td>Insecticide-treated curtains and residual spraying for Dengue control: Disappointing effects on disease incidence in a cluster randomized controlled trial in Santiago de Cuba</td>
<td>Enayatat M.E., Varanberghie V., Popa J., Mirabal M., Cabrera P., Fonseca V., Gómez T., Pérez M., Montadta D., Van der Stuyft P. (Cuba &amp; Belgium)</td>
<td></td>
</tr>
<tr>
<td><strong>4P7</strong></td>
<td></td>
<td>Community intervention against Dengue in Ouagadougou: Theory and implementation fidelity</td>
<td>Sarr D., Pérez D., Somé P.A., Barro A., Kafando Y., Ridde V. (Canada &amp; Burkina Faso)</td>
<td></td>
</tr>
</tbody>
</table>
4P8 Clinical and biological characteristics of Yellow Fever suspect patients in Nsona-Mpangu Hospital, NSona-Mpango Health Zone, DRC

4P9 Tuberculosis treatment outcomes among TB/HIV co-infected cases treated under directly observed treatment of short course in Nekemte, Western Ethiopia
Ejeta E., Birhanu T., Wolde T. (Ethiopia)

4P10 Prevalence of pulmonary tuberculosis among prison inmates: Across-sectional survey at the Correctional and Detention Facility of Abidjan, Côte d’Ivoire
Receiver M.C., Sél B., Koffi A., Ouassa T., Assemien J., Laurent A., MalvY D., Domoua S.K., Anglaret X. (France & Côte d’Ivoire)

4P11 Twenty years studying latent tuberculosis infection in Cuban health Care workers: Implications toward TB elimination

4P12 Determinants of mortality among MDRTB patients: A cross-sectional study
Molli E.W., Chilongola J. (Tanzania)

4P13 Current profile of new HIV infections among adults in northern Benin in 2016

4P14 Exploratory results of intensification of the use of the Genexpert® MTB/RIF as support in the tracking the TB and RR in Kinshasa
Bele A., Musala S., Okenge L., Kasereka J.C., Baleka J.F., Bakoko B., Van Deun A., Kaswa M. (DRC & Belgium)

4P15 Detection of Rifampicine resistance mutations in the 81bp RRDR of rpoB gene in Mycobacterium tuberculosis using Xpert MTB/RIF in Kinshasa, DRC: A retrospective study
Musala S., Bele A., Okenge L., Kasereka J.C., Ailoni M., Van Deun A., Kaswa M. (DRC & Belgium)

4P16 Directly Observed Treatment Short-course (DOTS) for Tuberculosis Control Program in Gambella Regional State, Ethiopia: Ten years experience
Solomon S., Belete M., Woldargay E., Desalegne W. (Ethiopia)

4P17 TB SEQUEL: Pathogenesis and risk factors of long-term pulmonary sequelae defining the individual outcome and public health impact of TB disease
Rachow A., Prieto-Pérez L., Tefasmariam A., Górgolas M. (Ethiopia & Spain)

4P18 Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: A systematic review and meta-analysis
Eshete S., Gizachew M., Dagnaw M., Kumea G., Woldie H., Ambaw F., Tessema B., Moges F. (Ethiopia & Switzerland)

4P19 The Effect of HAART on tuberculosis incidence among HIV infected patients in Bale Zone Hospitals
Bekele T., Eshmel K.J., Kaso M. (Ethiopia)

4P20 Gender differences in tuberculosis in adults in a rural area in Africa

4P21 Impact of prompt MDR-TB treatment initiation: Significant reduction of MDR-TB mortality rate in Rwanda
Ngabonziza J.C.S., Habimana M.Y., Migambi P., Mazarati J.B., de Jong B.C., Torrea G. (Rwanda & Belgium)

4P22 Enhancement of TB research: A regional approach with the West African regional network for TB control (WARN-TB)
Merle C.S., Affolabi D., Wachinou PA., Bonsu F., Olliaro P.L. (Switzerland, Benin & Ghana)

4P23 Integrated approaches for intensifying tuberculosis active case finding: Lessons learned from pilot projects in West Africa

4P24 Renal dysfunction in HIV-positive patients on tenofovir-based therapy: A case control study
Nayan N., Sashindran V.K. (India)

4P25 Risk factors associated with TB co-infection in HIV/AIDS patients taking antiretroviral therapy (ART) in one of the public hospitals in Ethiopia
Megersa O.A., Phaladze N.A. (Ethiopia & Botswana)

4P26 Health resource management for TB in post-war Okinawa, Japan
Uechi M., Ogawa S. (Japan)

4P27 Perception of people living with HIV/AIDS (PLWHA) on the attitude of health care workers towards PLWHA in Calabar Metropolis, Cross River State, Nigeria

4P28 Performance of community tracing system of people affected by Tuberculosis during ebola epidemic in Conakry, Guinea
Ortuño-Gutiérrez N., Cherif G.-F., Loua F., Souleymiane H.H., Bangoura A., Camara L.-M. (Belgium & Guinea)

4P29 Biomedical and social support to vulnerable people affected by Tuberculosis in Guatemala: An effective governmental and non-governmental partnership implementation
Sánchez-Bustamante L., Bailón Z., Bongaerts T., Ortuño-Gutiérrez N. (Guatemala & Belgium)

4P30 Successful integrated biomedical and social support to vulnerable people affected by Tuberculosis in Nicaragua
Bravo Reyes M., Perez M., Bongaerts T., Ortuño-Gutiérrez N. (Belgium)
4P31 Attitude of health care workers towards people living with HIV/AIDS (health care workers perspective) in Calabar Metropolis, Cross River State, Nigeria

4P32 Impact of BCG vaccination on global survival of children up to 1 year in rural Burkina Faso
Ouedraogo S., Diallo A.H., Meda N. (Burkina Faso)

4P33 Assessment of tuberculosis under-reporting through inventory studies in 3 European Union Member States
Stratemans M., Mengenthaler C., Andersen P.H.S., Schimmel H., Carvalho C., Alba S., Rood E., van Hest R., Abubakar I., Bakker M.I. (The Netherlands, Portugal & UK)

4P34 Household contact tuberculosis investigation under re-engineered primary health care in the Free State Province, South Africa
Kigozi N.G., Heunis J.C., Engelbrecht M.C., Janse van Rensburg A.P., Van Rensburg H.C.J. (South Africa)

4P35 Elimination of tuberculosis in Cuba: Chimera or social reality for the XXI century
González-Ochoa E.R., Armas-Pérez L., Martínez-Rodríguez A., Baly-Gil A. (Cuba)

4P36 Research towards improved tuberculosis control in the free state, South Africa – A narrative review
Heunis J.C., Chikobvu P., Kigozi N.G., van der Spoel-van Dijk A., Van Rensburg H.C.J., Janse van Rensburg A.P., Engelbrecht M.C. (South Africa)

4P37 Protective effectiveness of seasonal malaria chemoprevention
Coldiron M.E., Assao B., Koscalova A., Quere M., Langendorf C., Grais R.F. (France, Nigeria & Switzerland)

4P38 Prevalence of parasitemia in an area receiving SMC
Coldiron M.E., Assao B., Koscalova A., Quere M., Langendorf C., Grais R.F. (France, Nigeria & Switzerland)

4P39 Coverage rate of the optimal dose of intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy in the rural district of Houndé, Burkina Faso
Cisse M., Ouattara O., Soulama A., Sombié I. (Burkina Faso)

4P40 Risk factors for persisting malaria among the Jarai ethnic minority along the Vietnam-Cambodia border
Xuan Xa N., Thi Thuan N., Thanh Duong T., Truc Quynh N., D’Umberto A., Erhart A., Peeters Grietens K. (Vietnam, Belgium & The Gambia)

4P41 Characteristics of malaria infection among the Jarai ethnic minority in central Vietnam
Thanh Duong T., Xuan Xa N., Thi Thuan N., Truc Quynh N., D’Umberto A., Erhart A., Peeters Grietens K. (Vietnam, Belgium & The Gambia)

4P42 Fine scale mapping of malaria infection clusters by using routinely collected health facility data in urban Dar es Salaam, Tanzania
Miacha Y.P; Chaki R.P; Mwalakilinga V.M.; Govella N.J.; Limwagwa A.J.; Msellenu D.F.; Magedi Z.D.; Terfou D.J.; Kiilene G.F.; Dongus S. (Tanzania, South Africa, Malawi & Switzerland)

4P43 Housing improvement intervention reduce indoor malaria transmission in spite of pyrethroid resistant malaria vector
Massebo F., Getawen S.K., Ashine T., Lindtjorn B. (Ethiopia & Norway)

4P44 Community perception and acceptance of environmental larviciding against malaria with BTI formulations in Burkina Faso: A mixed-methods study
Dambach P., Beersmann C., Mendes Jorge M., Traoré I., Savadogo H., Zabré P., Sé A., Sauerborn R., Becker N., Phaley R. (Germany, Burkina Faso & UK)

4P45 Environmental characteristics and evolution of malaria hotspots in a rural area, Burkina Faso
Rouamba T., Nakarabo-Diallo S., Derra K., Rouamba E., Kankoe S., Yaka P., Vaïla I., Tinto H., Krakoya-Samandoulou F., Gaudart J. (Burkina Faso, France & Belgium)

4P46 Sulfadoxine-pyrimethamine versus Cotrimoxazole in pregnant women: Effect on birth weight-findings from a randomized, open-label, non-inferiority trial in Zambia

4P47 Risk factor assessment for malaria among forest-goers in a pre-elimination setting – Phu Yen province, Vietnam
Thuan V.H., Canavati S.E., Quintero C.E., Khanh L.T., Ohrt C., Ngo T.D., Tran D.T., Martin N.J. (Vietnam, Finland, Australia & Singapore)

4P48 Targeted-reactive case detection at sleeping sites to interrupt malaria transmission in Vietnam II: Reported and observed malaria prevention, treatment and risk behaviors
Thuan V.H., Canavati S.E., Khanh L.T., Ohrt C., Ngo T.D., Tran D.T., Martin N.J. (Vietnam, Finland, Australia & Singapore)

4P49 Net use and preference among those who slept in a forest or farm in the context of malaria multidrug resistance and elimination
Thuan V.H., Canavati S.E., Khanh L.T., Ohrt C., Ngo T.D., Tran D.T., Martin N.J. (Vietnam, Finland, Australia & Singapore)

4P50 Community participation as part of formative research to design innovative malaria elimination strategies in The Gambia

4P51 Malaria incidence in the area of seasonal malaria chemoprevention
Koscalova A., Tenessadoufouo F., Gignoux E., Azman A., Quere M., Ciglenecki I., Sterk E. (Switzerland & USA)

4P52 Targeted-reactive case detection at sleeping sites to interrupt malaria transmission in Vietnam I - Risk behaviors associated with malaria cases sleeping in a farm or forest
Canavati S.E., Thuan V.H., Khanh L.T., Ohrt C., Ngo T.D., Tran D.T., Martin N.J. (Vietnam, Finland, Australia & Singapore)

4P53 A malaria indicator survey in a malaria elimination area of Phu Yen Province, coastal Vietnam
Canavati S.E., Thuan V.H., Khanh L.T., Ohrt C., Ngo T.D., Tran D.T., Martin N.J. (Vietnam, Australia, Finland & Singapore)

4P54 The Kwahu-South malaria situation: Towards tailor-made interventions
Owusu E.D.A., Arko-Boham B., Mens P.F., Grobusch M.P. (Ghana & The Netherlands)
4P55 Knowledge, perceptions and practices of community health workers regarding the use of long-lasting insecticide-treated nets for malaria control in Burundi
Nyabenda F., Nizigiyimana D., Aoun O., Lahaye F.M., Rapp C. (Egypt, Burundi & France)

4P56 Prevalence of mdr1 and k13 polymorphisms in Plasmodium falciparum after a decade of using artemisinin-based combination therapy in mainland Tanzania

4P57 Repeated Artemisinin-based combination treatment and dynamics of Plasmodium falciparum strains in Uganda and the Democratic Republic of the Congo

4P58 Assessment of glucose-6-phosphate dehydrogenase (G6PD) deficiency in Plasmodium vivax malaria endemic setting in Mauritania

4P59 Defining the unit of intervention for targeted treatment of asymptomatic malaria carriers: A transdisciplinary approach

4P60 Feasibility of intermittent preventive treatment in infants: Experience of the Democratic Republic of Congo
Matangila J.R., Likwela J., Tisasa E., Gasigwa D. (DRC)

4P61 Role of community participation in malaria elimination interventions in south of Iran
Shahandeh K.H., Basseri H.R. (Iran)

4P62 Factors limiting the effectiveness of standardized malaria control strategies in forested highlands of Vietnam: A qualitative study

4P63 Efficacy and user acceptability of transfluthrin-treated sial and hessian decorations for protecting against mosquito bites in outdoor bars
Masalu J., Finda M., Okumu F., Minja E., Mbitindo A., Sikulu M., Ogoma S. (Tanzania & Kenya)

4P64 Dynamics of Plasmodium vivax infections during a 2-year monthly follow up within the Peruvian Amazon

4P65 Characterization of the human malaria reservoir throughout the dry season in a forested area of central Vietnam: A pilot study

4P66 A nationwide school malaria parasitaemia survey for routine surveillance at district level in mainland Tanzania
Runge M., Chacko F., Mandike R., Rumisha S., Chaki P., Massaga J., Mohamed A., Molteni F., Snow R.E., Lengeler C. (Switzerland, Tanzania, Kenya & UK)

4P67 Increasing the time between incident malaria episodes in Ugandan children: Repeated application of IRS
Ziniszer, K. Morrison K., Bakir, N. Nannad J., Arinaitwe E., Nankabirwa J., Kamya M.R., Dorsey G. (Canada, Uganda & USA)

4P68 Historical review of malaria control in Morocco: Disease and vectors
Laboudi M., Saksak A., Ah Hamou S., Faraj C. (Morocco)

4P69 The burden of malaria infection among 0-6 month old African infants in settings with low to high intensity of malaria transmission
Nahum A.M., Ceessy S., Bohissou F., Kolovogui L., d’Alessandro U. (Benin, The Gambia, Guinea)

4P70 Health beliefs of school-age rural children in podocyoniasis affected families: A qualitative study in Southern Ethiopia
Tora A., Tadele G., Asea A., McBride C.M., Davey G. (Ethiopia, USA & UK)

4P71 Population-wide administration of single dose rifampicin for leprosy prevention in isolated communities: A feasibility study in Indonesia
Tiwari A., Dandel S., Miears L., Richardus J.H. (The Netherlands & Indonesia)

4P72 The development of an application for digital recording of DIGEIIH-T study participant data, including macroscopic and microscopic images
Büsscher P., Hasker E., Lejon V. (Belgium & France)

4P73 Diagnostic tools for human African trypanosomiasis elimination and clinical trials
Lejon V., Mumba D., Njagi P., Camara M., Camara O., Kone D., Koné M., Lumbala C., Makabuza J., Ilboudo H., Dama E., Faye E., Amouneveu V., Bucheton B., Büsscher P. (France, RDC, Guinea, Côte d’Ivoire, Burkina Faso, UK & Belgium)

4P74 Visceral leishmaniasis cases in the non-endemic districts: Challenges to ongoing elimination programme in Nepal

4P75 Epilepsy perceptions and experiences of different stakeholders prior to the implementation of an epilepsy treatment programme in an onchocerciasis endemic region in Ituri, Democratic Republic of the Congo (DRC)
Dolo H., Ucima Wonya Rossi D., Mandro N.M., Ngave F., Fraeyman J., Sykuybuckuy P., Colebunders R. (Belgium, DRC, Mali & Belgium)

4P76 Healthy homes for healthy living: Home improvement to control vectorial transmission of Chagas disease in Loja Province, Ecuador
Nieto-Sanchez C., Grijalva M.J. (USA & Ecuador)

4P77 Improved access to diagnostics for rhodesiense sleeping sickness around a conservation area in Malawi enables early detection of cases and reduced mortality
Lemerani M., Jumah F., Bessell P., Bieler S., Ndung’u J.M. (Malawi, Scotland & Switzerland)
4P78 Mobile technology improves management of a gambiense human African trypanosomiasis (gHAT) elimination programme in Uganda
Warnoga C., Picado A., Matovu E., Bieler S., Bessell P.R., Ndung’u J.M. (Uganda, Switzerland & UK)

4P79 Costing of large scale strategies for active case finding of Human African Trypanosomiasis (HAT) in the Democratic Republic of the Congo

4P80 Quality assurance of active screening for Human African Trypanosomiasis elimination in the Democratic Republic of the Congo

4P81 The Human African Trypanosomiasis (HAT) Platform
Mbo F., Valverde O. (DFC & Switzerland)

4P82 Kala-Azar outbreak management in Bangladesh: A new initiative in the Kala-Azar elimination program

4P83 Tracking the progress: Visceral leishmaniasis elimination in Nepal
Cloots K., Urwan S., Rijal S., Boelaert M. (Belgium & Nepal)

4P84 Visceral leishmaniasis in the indigenous community in Bangladesh: A wake up call
Huda M.M., Chowdhury R., Mondal D. (Bangladesh)

4P85 A cross sectional study of Post Kala-Azar Dermal Leishmaniasis (PKDL) with Visceral Leishmaniasis (VI) cases in Surja Kanta Kala-Azar Research Center (SKKRC), Bangladesh
Maruf S., Basher A., Nath P., Mondal D. (Bangladesh)

4P86 Accelerating control of visceral leishmaniasis in Turkana County, Kenya, through improved access to diagnostics
Ebei S.E., Murali G., Shamalla O., Lorumia K., Wachira D., Bessell P.R., Magiri C., Cruz I., Ndung’u J.M. (Kenya & Switzerland)

4P87 Epidemiology and burden of visceral leishmaniasis in sub-Saharan Africa: Evidence from a systematic review
Sunyoto T., Verdonck K., el Saifi S., Potet J., Picado A., Boelaert M. (Belgium, Switzerland & Spain)

4P88 The potential impact of visceral leishmaniasis vaccines: Explorations with different deterministic age-structured transmission models
Le Rutte E.A., Colfeng L.E., De Vlas S.J. (The Netherlands)

4P89 Cutaneous leishmaniasis control in Morocco: Vertical analysis
Laboudi M. (Morocco)

4P90 Persistence of Mycobacterium ulcerans disease (Buruli ulcer) in the historical foci of Kongo Central Province, the Democratic Republic of Congo

4P91 Feasibility of integration of activities of human African trypanosomiasis control in basic health services in the Democratic Republic of the Congo: Preliminary results from an action research
Mulenga F., Chenge F., Mpanya A., Criel B., Lutumba P., Lobuyo O., Lumbula C., Coppieters Y., Boelaert M. (DRC & Belgium)

4P92 Perception of the integration of activities of African human trypanosomiasis control into basic health services: A qualitative study
Mulenga P., Vander Kelen C., Lutumba P., Coppieters Y., Chenge F., Lumbula C., Lobuyo O., Boelaert M., Mpanya A. (DRC & Belgium)

4P93 Schistosomiasis and Soil-Transmitted Helminths prevalence in school-aged children and opportunities for integration of control in health services in Kwilu province, Democratic Republic of the Congo
Inocencio da Luz R., Linsuke S., Lutumba P., Hasker E., Boelaert M. (Belgium & DRC)

4P94 Environmental monitoring of Schistosoma mansoni infection rate in Biomphalaria sudanica – Results of the Ifjina Island Schistosomiasis Elimination Pilot Study, Mwanza, North-western Tanzania
Fus A., Mafungu H., Kasang C., Mueller A. (Tanzania & Germany)

4P95 Temporal trends in schistosomiasis in Burundi, from 2011 to 2015
Bizimana P., Van Geertuytten J.P., Polman K., Nyongabo P., Munezero F., Ortu G. (Burundi, Belgium & UK)

4P96 Preliminary assessment of the computer-based Taenia solium educational programme ‘The Vicious Worm’ in rural primary school children in eastern Zambia

4P97 Knowledge, attitude and perception about onchocerciasis and ivermectin in the onchocerciasis endemic health zone of Retby in Ituri, Democratic Republic of the Congo (DRC)
Dolo H., Ucinia Wonye/Rossi D., Mandro N.M., Ngave F., Fraeyman J., Suykerbuyk P., Colebunders R. (Belgium, DRC & Mali)

4P98 Projected number of people with onchocerciasis-loiasis co-infection in Africa, 1995–2025

4P99 Neglected diseases in a marginalized population: Priorities of intestinal parasitic infections in mobile pastoralists at Lake Chad
Greter H., Batil A.A., Hattendorf J., Moto D.D., Marti H.-P., Utzinger J., Zinsstag J. (Switzerland & Chad)

4P100 Koko et les lunettes magiques – An educational entertainment tool to prevent intestinal worms and diarrheal diseases in Côte d’Ivoire
Koffi A.V., Essé C., Kouamé A., Kouassi D., Yapi B.R., Moro M.H., Bonfòh B., N’Goran K.E., Gabrielli S. (Belgium, Switzerland & Côte d’Ivoire)

4P101 Important progress towards elimination of onchocerciasis in the West Region of Cameroon
Kamga G.-R., Dissak-Delon F.-N., Nana-Djoungia H.C., Bholon B.D., Ghogomu S.M., Souopgui J., Kambjo N., Robert A. (Cameroon & Belgium)
4P102 Still mesoendemic onchocerciasis in two Cameroonian community-directed treatment with ivermectin projects despite more than 15 years of mass treatment

4P103 A call for podocerosis, a neglected tropical disease

4P104 Strongyloides stercoralis a call for revising soil transmitted helminthiasis programmes

4P105 Impact of anthelmintic treatment on the burden of schistosomiasis and soil transmitted helminths in primary schoolchildren in Biyela health zone in Kinshasa, Democratic Republic of the Congo

4P106 The need of placing schistosomiasis into context
Amor A., Aneagrie M., Zewdie D., Benito A. (Spain & Ethiopia)

4P107 Onchocerciasis control in the Democratic Republic of Congo (DRC): Challenges in a post-war environment
Makenga Bol J.-C., Maketa V., Bakajika D.K., Ntumba F., Mpunga D., Murdoch M.E., Lutumba P., Coppetiers Y. (Belgium)

4P108 Trachoma elimination in Agago District, northern Uganda: District health system role in planning and implementation of mass drug administration for neglected tropical diseases
Omony O.E., Turayguma P., Kirunga C.T., Orach C.G. (Uganda)

4P109 Evidence of negligible soil-transmitted helminth prevalence in the Bolivian Chaco triggers interruption of preventive chemotherapy and calls for strengthening of surveillance

4P110 Seropidemiological trend of strongyloidiasis in the Bolivian Chaco (1987-2012) in the absence of disease-specific control measures

4P111 Rabies the deadly disease - How much we aware?
Basher A. (Bangladesh)

4P112 Modeling the mass use of systemic insecticides in dogs to control zoonotic visceral leishmaniasis
Gómez S.A., Courtenay O., Chapman L.A.C., Dilger E., Marcotty T., Picado A. (Spain, UK & Belgium)

4P113 Echinococcosis, a global economic and health burden
Menschaert D., Hoyoux M., Moerman F., Daron A., Frere J. (Belgium)

4P114 The control of zoonotic visceral leishmaniasis in Europe: A survey among Spanish and French veterinarians
Le Rutte E.A., van Straten R., Overgaauw P.A.M. (The Netherlands)

4P115 Economic implications of the whole genome sequencing technology to control Salmonella
Mukhopadhyay K., Jain S., Thomassin P.J. (Canada & India)

4P116 Assessment of the level of awareness and knowledge of Middle East Respiratory Syndrome (MERS Cov) among Saudi population
Aldawarsi M.S., Alqhtani S.H. (Saudi Arabia)

4P117 An interventional program on selected mass gathering infectious diseases at Hajj
El-Bahmasawy M.M. (Egypt)

4P118 Raising awareness for different concepts of personal protective equipment on a trainer-level
Staub J., Lee M.-H., Meerbach A., Gies S., Verbeek L. (Germany)

4P119 Evaluation and analysis of Acute Flaccid Paralysis (AFP), surveillance system data in the N’djamena regional health delegation, Chad, 2012-2014
Nadougo D.H., Dissia F., Mbaihol T., Mathieu E. (Cameroon & Chad)

4P120 Meneningitis surveillance in four health districts of the north-west region of Cameroon
Esso Endalle L., Mboke Ekoun E., Pedoum Mofola E., Tchualeu Kameni A.B., Okorno Assouverou M.C., Mathieu E., Seukap E.C., Etoundi Mballa G.A. (Cameroon)

4P122 Assessment of exposure and serostatus of contacts persons to ebola virus disease cases in Guinea (Contactebogui study)

4P123 Sentinel surveillance of flu in the Central African Republic

4P124 Evaluation of vaccine coverage and its determinants in children aged from 12 to 23 months in the Democratic Republic of Congo
Kazongo J., Aoun O., Lahaye F.M., Rapp C. (Egypt & France)

5P1 How patients navigate diagnostic ecosystem in a fragmented health system:
A qualitative study from India
Yellappa V., Devadasan N., Knromeich A., Pant P.N., Vadhana C., Pai M., Engel N. (India, The Netherlands & Canada)

8P36 OpenHDS: Evidence for improved quality/timeliness and cost in demographic surveillance systems
Di Pasquale A., Derra K., Tinto H., Maire N. (Switzerland & Burkina Faso)

8P37 Estimating the risk of non-communicable diseases: A case study of Canada
Alhashmi M., Thomassini P.J., Mukhopadhyay K. (Canada & India)

8P38 Implementation of mobile medical e-learning for higher medical education in Zambia – A Zambian-German-Swiss cooperation
Bartell S., Bowa A., Lüders S., Marimo C., Phiri Y., Wolter S., Neuhann F. (Zambia)

8P39 Trends in HIV infection in sentinel sites from 2007 to 2016 in Burkina Faso
Yonii B.P.C., Quere A., Kouna S. (Burkina Faso)
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Country/Region</th>
</tr>
</thead>
<tbody>
<tr>
<td>8P43</td>
<td>Epidemiological, clinical and biological features of onychomycosis in Tunisia area, Tunisia</td>
<td>Boudaoura Y., Bettiaieb J., Ben Abda I., Siala E., Boulehmni N., Aoun K., Bouratbine A. (Tunisia)</td>
<td>Tunisia</td>
</tr>
<tr>
<td>8P44</td>
<td>Predicative criteria of onychomycosis causative agents’ dermatophytes and Candida</td>
<td>Boudaoura Y., Ben Abda I., Bettiaieb J., Siala E., Boulehmni N., Aoun K., Bouratbine A. (Tunisia)</td>
<td>Tunisia</td>
</tr>
<tr>
<td>8P45</td>
<td>Seroprevalence of Hepatitis C Virus infection among general population in Central-Ouest Tunisia</td>
<td>Bettiaieb J., Chouikha A., Khamroubi G., Khedhiri M., Aissi W., Bel Hajhmida N. Gharbi A., Salah Alif B., Triki H. (Tunisia)</td>
<td>Tunisia</td>
</tr>
<tr>
<td>8P46</td>
<td>Steeplly increasing HIV prevalence among young men in Zambia past 12 years - Data from Demographic and Health Surveys</td>
<td>Nakazwe C., Michelo C., Sandoy I., Fylkesnes K. (Norway &amp; Zambia)</td>
<td>Zambia, Norway</td>
</tr>
<tr>
<td>8P48</td>
<td>Maternal and child health among the Okinawan diaspora in Hawaii in the early 20th century</td>
<td>Ogawa S. (Japan)</td>
<td>Japan</td>
</tr>
<tr>
<td>8P49</td>
<td>Systematic review and meta-analysis of risk factors for epilepsy and nodding syndrome in sub-Saharan Africa</td>
<td>Siling K., Peeters Griestens K., O'Neil S., verdonck K. (Belgium &amp; UK)</td>
<td>Belgium, Africa</td>
</tr>
<tr>
<td>8P50</td>
<td>Trends in socioeconomic inequalities in obesity and overweight among women in Cameroon, 2004 – 2011</td>
<td>Kankeu Tchewonpi H. (UK)</td>
<td>Cameroon</td>
</tr>
<tr>
<td>8P51</td>
<td>Epidemiological, clinical characteristics and outcome of scorpion envenomation in Abdanan County, Western Iran: An analysis of 780 cases</td>
<td>Kassiri H., Lotfi M., Ebrahimi A. (Iran)</td>
<td>Iran</td>
</tr>
<tr>
<td>8P52</td>
<td>Epidemiological pattern of pediculosis capitis in the eastern area of Ahvaz, Southwestern Iran</td>
<td>Kassiri H., Mardani M., Ebrahimi A. (Iran)</td>
<td>Iran</td>
</tr>
</tbody>
</table>
**Poster List Thursday**

**5P2** Improving access to HIV services for key population groups in achieving the 90:90:90 goals in Nigeria  
Etsetowaghan A.A., Konopka S. (Nigeria)

**5P3** Improving HIV service delivery in Nigeria: A review of the 2014 national task shifting policy  
Etsetowaghan A.A., Phiri M.M. (UK)

**5P4** Factors affecting use of generics drugs in the Philippines  
Ku G.M.V. (Belgium)

**5P5** Exploring resilience in a complex crisis: Iraq’s health system response to a triple security, financial and ecological shock  
Mangouri Z., Zangana G.A. (Iraq)

**5P6** A systematic literature review of effective strategies for delivery of child health interventions using the private sector in low and middle income settings  
Awor P. (Uganda)

**5P7** Economic burden of malaria and predictors of cost variability to rural households in South Central Ethiopia  
Hailu A., Lindtjorn B., Desessa W., Gari T., Loha E., Robberstad B. (Norway & Ethiopia)

**5P8** The side effects of the 2014/15 ebola epidemic: A review  
Strauss R., Schuster V., Lee M.H., Sasse J., Schwarz N.G. (Germany)

**5P9** Factors influencing the family planning service availability and utilization in Blue Nile state, Sudan  
Elhassan M., Elfaddil L.E., Basheir I.A. (Sudan)

**5P10** Improving health system capacity to address healthcare disparities: A systematic review of the role of academic health centres in contributing to equitable health systems  

**5P11** Implementation and results of an indigents' healthcare exemption scheme in the district of Lokossa-Athieme (Benin)  
Deville C., Poncelet M., Vancolen O. (Belgium)

**5P12** Determining factors in the use of health services in a metropolitan area of Havana, Cuba  
Rodriguez Salva A., Díaz Piñera A.M., Hernández Grifán D., García Roche R., Balcindes (Cuba)

**5P13** The influence of price variability on the use of prenatal counseling services in the city of Lubumbashi  
Ntambue M.A., Musuva A.M., Matungulu M.C., Ilunga M.T., Malonga K.F. (Democratic Republic of Congo)

**5P14** Assessing cost of illness among type 2 diabetic patients with complications in a tertiary health facility in North-west, Nigeria  
Mohammed S., Bani E.K., Sani-Bello F., Aliyu S., Ezikeanyi, B.C., Zayyad M.A., Grys P. (Nigeria & Germany)

**5P15** Visceral leishmaniasis treatment access - The reality on the ground in Sudan  

**5P16** The alternative called Rashtriya Swasth Bima Yojana: Care access and the quality of hospitals panelled under RSBY in Palakkad district in Kerala  
Toms T., Satish K. (India)

**5P17** Does Bacillus Calmette-Guerin vaccine protect against infection with Mycobacterium tuberculosis ascertained by tuberculin skin testing?  
Pelzer P.T., Cobelens F.G.J. (The Netherlands)

**5P18** Cross-sectional surveys in Bangladesh, India, Ethiopia & Sudan to understand visceral leishmaniasis treatment seeking, diagnosis, treatment and household economic burden  

**5P19** Cost of postpartum services for mothers and of infant immunization services in Kaya health district (Burkina Faso)  
Yugbare Belemmsaga D. (Burkina Faso)

**5P20** The Kenyan malaria market after AMFm  
Musuva A.M., Ngigi J., Mwambi D. (Kenya)

**5P21** Systems effectiveness and patient adherence to dihydroartemisinin piperaquine in northern Ghana  
Oduro A., Ayamba E., Anyorigiya T., Beeri P., Chatio S., Amenga-Etego L., Baiden R., Binka F. (Ghana)

**5P22** Evaluating access barriers to visceral leishmaniasis diagnostic and drugs in 6 endemic countries in Eastern Africa: Is regional approach the solution?  
Sunyoto T., Potel J., Picado A., Boelaert M. (Belgium, Switzerland & Spain)

**5P23** Improving financial security and access to maternal health services in a rural setting: An assessment of community health insurance in Uganda  
Mirembe J., Mwesigwa J., Tumwesigye T., Balikitenda D., Dabira E.D. (Uganda & Gambiya)

**5P24** Willingness to pay for HPV vaccines among married women aged 15-49 years in 2 locations in Vietnam  
Ha D.T., Huong N.T., Le N.H., Thuy H.T., Van T.T., Anne B. (Vietnam & Belgium)

**5P25** Evaluating the effect of PMTCT-focused structured SMS messaging and calls in improving service uptake in Suleja, North Central Nigeria  
Etsetowaghan A.A., Nwokedi N., Norma O. (Nigeria)

**5P26** Does Bacillus Calmette-Guerin vaccine protect against infection with Mycobacterium tuberculosis ascertained by tuberculin skin testing?  
Pelzer P.T., Cobelens F.G.J. (The Netherlands)

**5P27** Sexual education and data inquiry about sexual behavior through mobile phone services in Uganda  
Schneider F., Salibrown E., Nabembezi R. (Germany & Uganda)
5P28 Connecting the unconnected in sub-Saharan Africa: Non-discriminating access for Digital Inclusion with an emphasis on health (DiGl)

5P29 Innovative on-line approach though eLearning to health agents on the field
Carrion C., Garcia-Lorda P., Aymerich M., Casabona J., Reyes-Ureña J., Cardona P.J., Mokni M., Ruiz-Postigo J.A. (Spain, Tunisia & Switzerland)

5P30 Design of a technology platform for knowledge sharing among health professionals to improve maternal and child healthcare
Megersa O.A., Bekele R., Seifu A. (Ethiopia)

5P31 Personalised management of health and health expenditure: Role of technology - Experiences of patients using iDecide digital health platform
Thomas Toms K., Jari R., Satish K. (India & South Africa)

5P32 Scope of leveraging mHealth for routine immunization strengthening in India
Ashish K. (India)

5P33 Information technology in health Vs provider accountability to patients: The experience of iDecide a patient managed clinical care platform
Toms K.T., Denny J., Satish K., Jari R. (India & Finland)

5P34 Mobile health care - A review of Indian mobile health initiatives
Toms K.T., Denny J., Satish K., Jari R. (India & Finland)

5P35 eLearning in public health education in India

5P36 Improving contraceptives supply management by addressing the human factor
Vermandere H., Galles A., Griffin S., de Melo M., Machaieie L., Van Braeckel D., Degomme O. (Belgium)

5P37 A qualitative analysis of the Northern Ugandan catholic health system
Engl M., Orach S., Shumba C., Ogwang D.M., Prugger C. (UK, Italy, Uganda & Germany)

5P38 Do under-resourced health systems have the ability to offer financial risk protection for primary healthcare? A baseline study of outpatient expenditure to inform health financing and universal coverage reform in the Democratic Republic of Congo (DRC)
Laokri S., Soelaeman R., Hotchkiss D. (Belgium & USA)

5P39 Assessing health equity in the Democratic Republic of Congo (DRC) - A focus on financial protection
Laokri S., Eozouenou P., Eloko G., Minga G., Miteo R., Samaha H. D. (Belgium, USA & DRC)

5P40 Performed-based financing in Mali: Can it be called emergence?
Coulibaly A., Touré L., Ridde V. (Mali & Canada)

5P41 An experience of health education in a primary health care project with a community in Colombia: Preliminary findings
Villa L. (Colombia)

5P42 Improving attraction and retention of rural health workers: Building up a sustainable and cost-effective housing cooperative in Zambia
Thieme K., Weber M. (Zambia)

5P43 Knowledge, coverage and usage patterns of health insurance in rural South India
Hegde R., Kran K.G. (India)

5P44 Equipment for essential surgical care in Africa: Availability, barriers and need for novel redesign
Oosting R.M., Wauben L.S.G.L., Groen R.S., Dankelman J. (The Netherlands & USA)

5P45 Impact of short term clinical training on tropical and infectious disease to medical doctors working at remote part of Nepal
Rijal S., Karak P., Bhatta N., Sharma S.K., Uranw S., Koira P., Chhetri R., Boelaert M., Marasini B., Kattel V. (India, Nepal & Belgium)

5P46 Measuring quality of care as a result - The example of RBF (Results Based Financing)
Toonen J., Habineza C. (The Netherlands & Rwanda)

5P47 Budget support to Peru's health sector: A PFM perspective
Haghebaert G.V., Giussani B. (Peru)

5P48 Performance based financing for mother and new-born health in Peru: A focused development cooperation
Haghebaert G., Huamani Huamani N., Velkeneers E., Niño de Guzman J., Gonzáles Camaicho H. (Peru)

5P49 Inside the black box: Administration of the Tanzanian Community Health Fund and its interaction with other health financing mechanisms
Renggli S., Maryamuna I., Mshana C., Mbaya D., Kesey F., Tediosi F., Pfeiffer C., Aerts A., Lengeler C. (Switzerland & United Republic of Tanzania)

5P50 Between marketing and universal coverage of obstetric and neonatal care: What about determinants of the variability of expenditures in Lubumbashi, Democratic Republic of Congo
Mbamue Mukengeshayi A., Musau Nicola A., Matungulu Matungulu C., Ilunga Mpoyi T., Mundongo Tshamba H., Malonga Kaj F. (Democratic Republic of Congo)

5P51 Postgraduate training in tropical medicine and International Health – Results of an alumni survey on career development and implications for course content needs
De Vos P., Apers L., Zolfo M., Vuyisteke B. (Belgium)

5P52 Complex leadership in health
Belhiti Z., Ariadna N.G., Marchal B. (Morocco & Belgium)

5P53 Impact of community-level factors on the volunteers services in rural Nepal: A qualitative study
Panday S., Paul B., Simkhada P., Teijlingen E.V. (UK)

5P54 A prime vendor system to complement public sector supply - A public-private partnership in Tanzania
Wiedenmayer K., Mfuko W., Chilunda F., Mbwasi R. (Switzerland & Tanzania)
5P55 Performance for universal health coverage – Efficiency analysis of sub-national health systems in Pakistan
Khulid F., Petro Brunial M.T., Sattar A., Hotchkiiss D.R. (Pakistan, Switzerland & USA)

5P56 Factors influencing the distribution of health care workers to rural areas in a Nigerian state in an era for Universal Health Coverage

5P57 What keeps community health workers in Kenya going? A qualitative study
Muturi N., Mireku M., Karuga R., Taegtmeyer M., Otiso L. (Kenya & UK)

5P58 Community expectations of community health volunteers in Kenya: Bridging community and health systems
Achieng M.A., Muturi N., Karuga R., Taegtmeyer M., Otiso L. (Kenya & UK)

5P59 Impact of the Lesotho maternal and newborn health performance-based financing system on reproductive health indicators
Mofoka N., Uzamukunda C., Sued I., Meidany F., Mc Leod K., Vink M. (Lesotho, The Netherlands & USA)

5P60 Health surveillance assistants remain critical to fill health workforce gaps in Malawi
Chinsakaso B., Jackson N., Banda A., Kestens W., Philips M., Berelmans M. (Malawi, South Africa & Belgium)

5P61 In post-Ebola era, still waiting for the strengthening of health workforce in Sierra Leone
Berelmans M., van Adrichem E., Rehfeld R., Makere J., Philips M. (Belgium & Sierra Leone)

5P62 Gender dimensions of the ASHA programme: Programme design, evolution, and implementation truths
Ved R., Gupta G., Singh S., Scott K., George A. (India & South Africa)

5P63 A solidarity fund to improve emergency obstetric and neonatal care in Mirirah department, Niger

5P64 Cost-effectiveness of first-line antiretroviral regimens in a Nigerian HIV clinic: A 5-year retrospective study
Asoke S., Ovosi J.D., Bello-ovosi B.O., Iyanda M., Bernsah L.D. (Nigeria)

5P65 Enhancing chronic condition care for urban poor: Role of the local health systems
Bhojani U., Devadasan N., Koisteren P., DeHenaux S., Criet B. (India & Belgium)

5P66 Assessing quality of HIV counselling services offered in public health facilities in Kampala
Kyobutungi V., Seebagereka A., Muwumuza C., Matovu J. (Uganda)

5P67 Integrating nutrition products into health system supply chains: Making the case
Sorensen S., Coddia P., Vreeke E., Jilie-Traas I. (Kenya & Belgium)

5P68 Effect of primary health care worker training on identification of child- and adolescent mental health conditions: a randomised controlled trial in Uganda
Askol A., Babirye J.N., Makumbi F., Engebretsen I.M.S. (Norway & Uganda)

5P69 Factors associated with poor glycaemic control among diabetic patients in primary health care services in Morocco
Idrissi A., Leveque A. (Morocco & Belgium)

5P70 Kira Mama! A continuum of care for neonatal health
Conayisayne A., Bordigonii A., Fascondenii M., Rosmini A., Pecchioni V. (Italy)

5P71 Quality determinants of diabetes mellitus services in Sudan: A descriptive study
Elfaki S.O.S., Batta S.A., Elhassen M. (Sudan & Sierra Leone)

5P72 A task-shifting mental health program: Integration of primary health care and social care on depression

5P73 Gaps in the access, diagnosis, treatment and control of hypertensive patients in a metropolitan area of Centro Habana, Cuba
Díaz Piñera A.M., Rodríguez Salvá A., Piña Alonso A.C., García Roche R., Balcindes Acosta S. (Cuba)

5P74 Gaps in the management of type 2 diabetic patients in a metropolitan area of Havana Rodríguez Salvá A., Díaz Piñera A.M., Céspedes Hernández L., García Roche R., Balcindes Acosta S. (Cuba)

5P75 Non-pharmaceutical factors associated with control of hypertension among older persons in Uganda: A cross-sectional survey
D肚umba I., Wandera S.O., Kawooya I., Musinguzi G., Islam S.M.S., Nuwaha F. (Uganda, Bangladesh & Australia)

5P76 Integrating mental health care (MHC) to the district health system: Action-research in Niger
Yamien I. (Niger)

5P77 Health system preparedness and access to medicines for non-communicable diseases at primary care: Experience from a south Indian district
Elias M.A., Pati M.K., Aivalli P., Munegowda C.M., Bhanupraksh S., Prashanth N.S. (India)

5P78 The global point prevalence survey of antimicrobial consumption in one Costa Rican hospital
Ramirez C., Villalobos J., Versporten A., Goossens H., Pelaez M. (Costa Rica & Belgium)

5P79 Strengthen digestive surgical emergency care: Experience of an action-research in Zinder National Hospital, Niger

5P80 Preventing infectious disease by sensitization
Kaboré R.P., Ouédraogo I., Ouédraogo P., Gniminou S., Roamba G., Reuleck M., Gies S. (Burkina Faso & Germany)

5P81 Issues and challenges of integrating essential packages of high-impact services into the prevention, surveillance and adequate management of cases of neglected tropical disease in Guinea
Diola A.A. (Guinea)
5P83 Community engagement, personal responsibility and self help in Cuba’s health system reform

5P84 Improving prison health governance: The Zambian Prisons Health System Strengthening (ZAPPHS) project
Topp S.M., Moonga C.M., Chileshe C., Magwende G., Henstrooza G. (Australia, Zambia & USA)

5P85 “From Helsinki with love” - An evaluation of health in all policies strategy in Kenya
Mauli J., Tosun J., Jahn A. (Germany)

5P86 Understanding factors that influence the implementation of the Performance-Based Financing scheme at community level for nutrition services in Burundi
Nkurunziza S., Van Geertruyden J.P., Korachais C., Anthierens S. (Burundi & Belgium)

5P87 Stakeholders schematic mapping for implementing a policy to improve Healthcare Worker’s distribution to rural area in a sub-national area in Nigeria

5P88 Strategies to institutionalise patient engagement in the public health sector
Ku G.M.V., Dalmacion G., Baja M. (Belgium & Philippines)

5P89 Healthcare think tanks in India: Challenges, needs, and recommendations
Arora R., Shekar V., Shukla S., Bhattacharya S. (India)

5P90 Knowledge, attitudes and practices towards schistosomiasis among school-aged children in Kisantu health zone / Democratic Republic of Congo
Khone K.R. (Democratic Republic of Congo)

5P91 Contribution of community health workers towards estimating the global mortality rate in rural Eastern DR Congo: A household-based survey
Ndongozi B., Nabugobe S., Cikomola M., Biembre M., Bahati M. Bashonja M., Bwenge M., Ntambwe M., Bisimba M. (Democratic Republic of Congo)

5P92 Interdisciplinary team work in primary health care: Experience of Belgian community health center
Dispas H., Marganne P., Drielsma P., Somassè Y.E. (Belgium)

5P93 Development of an international External Quality Assurance (EQA) scheme for malaria Nucleic Acid Amplification Techniques (NAAT)
Shrivastava J., Saez A., Murugappillai S., Cunningham J., Chiodini P. (UK & Switzerland)

5P94 Assessment of quality of health care in 4 health districts of South Tajikistan
Karimova G., Ilhom B., Mengliboeva Z., Abdujabborov N., Matthys B., Prytherch H. (Tajikistan & Switzerland)

5P95 Global Point Prevalence Survey on antimicrobial use and resistance (Global-PPS): Implications for antibiotic stewardship programme for Komfo Anokye teaching hospital in Ghana

5P96 Towards improved health service quality in Tanzania: An approach to strengthen routine supportive supervision
Renggilly S., Mayamana I., Mboya D., Charles C., Maeda J., Mahana C., Kessy F., Tediosi F., Pfeiffer C., Schulte A., Aerts A., Lengeler C. (Switzerland, United Republic of Tanzania & Ethiopia)

5P97 Perceived quality of care: Clients’ aspect upon antenatal, delivery and postnatal care at health facilities in primary health care level
Mon N.O., Han W.W., Saw S., Mon S.W., Phyo A.P., Khaing H.L.Y., Latt M.T., Kentpser M., Eindia H.M.T. (Myanmar)

5P98 Accreditation at district level in Cote d’Ivoire: Are the actors informed enough to mobilize their capacity?
Bassalia D., Porignon D.G., Teya K., Kouakou B.I., Aka E.J., Kouassi D., Dosso M.,-Sondag-Thuli D. (Belgium & Côte d’Ivoire)

5P99 Integrated eDiagnosis approach: Assessing the quality of the management of children illnesses in Burkina Faso
Some S.A., Blanchet K., Somda A.S., Lewis J., Sarrassat S., Cousens S. (Burkina Faso & UK)

5P100 Inventorying and accuracy assessment of HIV/AIDS rapid diagnostic tests in DR Congo

5P101 Regulation of medicines storage for health system resilience in Nigeria
Mohammed S., Jibo I.A., Aliyu S., Grys P., Awaisu A., Umar N. (Nigeria, Germany, Qatar & UK)

5P102 Use of drugs in management of uncomplicated malaria in Public Health facilities in DR Congo
6P1 Gender equality in healthcare access during international health crises
Osorio V., Oliver S. (UK)

6P2 Improving emergency medicine training in resource-limited settings, experiences from a piloting project in Zanzibar
Cohen D., Ferguson J., Wilson E., Mann C. (UK)

6P3 Evolving governance options to enhance equitable data sharing

6P5 NCD monitoring: A challenge and a chance for global public health cooperation
Fehr A., Ziese T. (Germany)

6P6 Cooperation between biomedical training programs: A challenge for healthcare
Armrouche M., Corne B., Waiz R. (France)

6P7 Measuring behavioral outcomes in development aid: A call for standardization to improve the evidence synthesis
Van Remoortel H., Van Deegaete A., Naidoo S., Avau B., Govender T., Vandekerckhove P., Young T., De Buck E. (Belgium & South Africa)

6P8 Continued agents of change? Follow-up of graduates from MPH program
Zwanikken P.A.C., Gerstel L. (The Netherlands)

6P9 HERACLES collaborative and translational project on cystic echinococcosis funded by the European Commission
Casulli A. (Italy, Romania, Bulgaria, Turkey & Spain)

6P10 Extended ultrasound surveys for cystic echinococcosis in Bulgaria, Romania and Turkey: Results from HERACLES project
Tamarozzi F., Cretu C.M., Vutova K., Akhan O., Siles-Lucas M., Pezzotti P., Fabiani M., Brunetti E., Casulli A. (Italy, Romania, Bulgaria, Turkey & Spain)

6P11 Building training and research capacities in Ebola affected countries: The case of the Belgian cooperation in Guinea
Delamou A., Delvaux T., Beavogui A.H., Sow A., Van Bastelaere S., Criel B., Van Damme W. (Guinea & Belgium)

7P1 Rates and causes of death in women of reproductive age (12-49 years) in 12 rural communities from Maputo and Gaza province, southern Mozambique

7P2 The impact of urbanization and population density on childhood Plasmodium falciparum parasite prevalence rates in Africa
Kabaria C.W., Gilbert M., Noor A.M., Snow R.W., Linard C. (Kenya, Belgium & UK)

7P3 Urban health interventions and vector-borne and other infectious diseases of poverty: An international collaboration to analyse knowledge gaps

7P4 Prevalence and management of acute pesticide poisoning in public and private hospitals in Kampala, Uganda
Charles Semugaba, Abdullah Ali Halage, Ruth Mubeze Neebye, Victoria Nabankema, Massy Moses Kasule, Deogratius Sekirmp, Erik Jors (Uganda & Denmark)

7P5 Climate change and schistosomiasis: A global synthesis of research findings, knowledge gaps and new research directions
Stensgaard A.S., Vounatsou P., Utzinger J. (Denmark & Switzerland)

7P6 Responsive to who/what? A review of conceptualisations of ‘responsiveness’ in health systems literature
Whyte E.B., Oliver. J. (South Africa)

7P7 Expanded access to second-line TB treatment at risk in Eastern Europe and Central Asia (EECA) as global fund policies accelerate transition to national funding
Akerfeldt K., Lynch S., Ismayilov A. (UK, USA & Kyrgyz Republic)

7P8 Travel-related leptospirosis in the Netherlands 2009 - 2016
de Vries S.G., Bekedam M.M.I., Goorhuis A., Grobusch M.P., Goris M.G. (The Netherlands)

8P60 Knowledge, attitude and practices: Assessing maternal and child health care handbook intervention in Vietnam

8P61 Determinants of intermittent preventive treatment use among pregnant women attending antenatal care at three levels of care in Oyo State: A comparative cross sectional study

8P62 Policymaker, health provider and community perspectives on male involvement in maternal health in Mozambique: A qualitative study
Galle A., Degomme O., Roelens K., Griffin S., Osman N. (Belgium & Mozambique)

8P63 Socio-cultural aspects of vaginal practices: A systematic and cross-cultural review of qualitative research
Dierickx S., Rahbari L., Longman C., Coene G. (Belgium)

8P64 Descriptive epidemiology of prevalence and factors associated with anemia among pregnant women initiating antenatal care in rural northern Ghana
Nonterah E.A., Ademola E., Yidana A., Dogo I., Ayamba E., Atindama S., Ahassan M. (Ghana & South Africa)

8P65 Maternal and perinatal outcomes of visceral leishmaniasis (kala-azar) treated with sodium stibogluconate in eastern Sudan
Gamal K. Adam, Mohamed A. Abdulla, Ahmed A.A., Ismaily S., Ahassan M. (Ghana & South Africa)

8P66 Prevalence of latent tuberculosis (LTB) among pregnant women in high burden setting in Sudan using Interferon gamma (IFN-γ) releasing assay (IGRA)

8P67 Does gestational intake of adequate diets using the FAO women's dietary diversity indicator affect haemoglobin levels at delivery and newborn health outcomes? Preliminary findings from a prospective cohort study in Volta region, Ghana
Agbozo F., Abubakari A., Jahn A. (Germany & Ghana)
8P68 Low birth weight or prematurity in teenage mothers from rural areas of Burkina Faso

8P69 Impact of maternal STH infection on infant height and weight gains at 24 months of age
Gyorkos T.W., Sarker H., Mofid L.S., Montresor A., Razuri H., Casapia M. (Canada, Switzerland & Peru)

8P70 Prevalence, associated factors and evolution of gestational diabetes mellitus in Ouagadougou

8P71 Sociodemographic, clinical and service predictors of post-surgical reintegration score among Ugandan women treated for obstetric fistula

8P72 Safe Motherhood at Endulen Hospital – A good practice public health example to introduce cultural-sensitive hospital care to improve mother and child health within the Maasai community in Northern Tanzania
Schneider F., Dillmann M. (Germany & Tanzania)

8P73 Frequency of malaria in pregnant women and rate of use of prenatal consulting services in Lubumbashi medical district 2011-2015 (D.R. Congo)
Kakisisi C., Mutombo A., Mukomena E., Mukulu C., Makan G., Wembsonyama S., Situakibanza N.H., Mwamba C., Luboya O. (D.R. Congo)

8P74 Difficulties in implementing a HPV/cervical cancer screening programme in Kinshasa

8P75 Misuse of antenatal care and its association with adverse outcome of pregnancy in a southern rural area of Vietnam

8P76 Assessing sexual health of very young adolescents in SW Uganda
Kemigisha E., Nyakato V.N., Ruzaaza G.N., Mlahagwa G.N., Miahagwa W., Leye E., Coene G., Degomme P., Michielsen K. (Uganda & Belgium)

8P77 Prevalence and distribution of hpv genotypes found in Kinshasa versus Flanders

8P78 Mothers delivering under the stars: Observations of facility deliveries and family planning procedures in community health centres of Uttar Pradesh, India
Name Srivastava A., Saxena M., Bhattacharya S. (India)

8P79 Users’ and providers’ perspective on quality of maternal care: A qualitative study of public health facilities in Uttar Pradesh, India
Bhattacharya S., Srivastava A., Saxena M. (India)

8P81 The importance of a community based approach in reaching out to survivors of sexual violence - The experience of two coffee cooperatives in the DR Congo
Cikuru M.N., Bosmans M. (DR Congo & Belgium)

8P82 Maternal deaths surveillance system: A tool to guide action at regional level in Morocco
Abouchadi S., Zhang W.H., Englert Y., Nejari C., De Brouwere V. (Morocco & Belgium)

8P83 Prevalence and predictors of health facility delivery of infants among mothers in Calabar, Cross River State, Nigeria

8P84 Adolescent childbearing in Zambia: Multilevel analysis of individual and community level factors
Kampata L., Sandoy I. (Norway & Zambia)

8P85 Midwifery care, medical interventions during labour and childbearing and neonatal outcomes in the first-line public health facilities in Cambodia
Matsui M., Iwaroilo A., Po R., Tung R. (Japan & Cambodia)

8P86 A catch-up visit increased coverage through home-based HIV testing in rural Lesotho but fails to reach 90%

8P87 Predictors of mortality in HIV patients with severe PCP admitted to intensive care unit: A systematic review
Lomencho A., Fantaye H., Azizah A. (Ethiopia)

8P88 Vaginal carriage prevalence of group B streptococcus (GBS), GBS serodistribution, risk factors for carriage of GBS and Escherichia coli, and microbiological and immune correlates of vaginal GBS carriage in three African populations

8P89 Hospital admission among HIV-patients: Causes and factors associated with AIDS-defining events in a referral tertiary care hospital in Antananarivo, Madagascar

8P90 Priority fast tracking HIV response in West and Central Africa to halt human and medical consequences of low ARV coverage
Cartier N., Akerfeldt K., Banda A., Philips M. (Belgium & South Africa)

8P91 Epidemiology of human coccidial infections in HIV positive women and children in Lagos state
Dlibajuba V.C., Obasaju O.A., Idowu T.E. (Nigeria)

8P92 The use of medical aspiration in the treatment of incomplete abortions: An interventional study from Malawi
Odlund M.L., Kafalufula U., Gadama G., Odlund J.O., Dan E. (Norway & Malawi)
8P93  A game-changing drug: Access to misoprostol and medical abortion in Dar Es Salaam, Tanzania
Solheim I.H., Moland K.M., Kahabuka C., Pembe A.B., Blystad A. (Norway & Tanzania)

8P94  Quality assessment of partograph recording in Mnazi Mmoja hospital, Zanzibar: A nested cross-sectional study
Van Eden J.W., Punt M.C., Housseine N., Rijken M.J., Franx A., Meguid T., Kwast B.E., Browne J.L. (The Netherlands & Tanzania)

8P95  Understanding maternal and neonatal vaccination acceptance in the Gambia
John P., Jaieteh F., Clarke E., Peeters Grietens K. (Gambia, Belgium & The Netherlands)

8P96  Implementation of a community engagement program in the pathogenesis and treatment of nodding syndrome in Uganda
Akun P.R., Anguzu R., Ogwang R., Oryema J.J.I., Ngwia A., Idro R. (Uganda & UK)

8P97  Logistics for field studies in resource-limited settings: Challenges and outcomes in DRC

8P98  Implementation research on acceptability of physicians using a tele expertise network in Mongolia
Molho S., Mungunchimeg D. (Mongolia)

8P99  Cognitive determinants of multiple sexual partnerships and non-condom use using multi-stage stratified random cross-sectional survey in South Africa
Manjengwa-Hungwe P.G., Mangold K., Musekiwa A., Kuonza L.R. (South Africa)

8P100  Sociocultural dimensions of hypertension in Merida (Yucatan, Mexico): Preliminary findings of an anthropological research

8P101  How rumours of ‘placentas sellers’ led to the decline of a malaria in pregnancy trial in Benin: An ethnographic study

8P102  What is the major issue to tackle neonatal infections in low income countries - Evidence from a community-based cohort study in Madagascar

8P103  Reducing maternal and neonatal mortality and morbidity by strengthening midwives’ skills and improving their work setting in Arsi Zone, Oromia Region, Ethiopia - End of project evaluation report 2013-2016
Habtamu A., Fauveau V., Kedir I., Muluye S., Gebreyohannes Y., Muleta M., Getachew E. (Ethiopia & France)

8P104  Comparison of data collection methods: Role of electronic data collection in the DRC

LBP1  Poor dissolution of anthelmintic medicines: A risk for reduced efficacy
Silesi B., Sultan S., Wynendaale E., Anne K., Duchateau L., De Spiegeleer B., Levecke B. (Belgium)

LBP2  Inhibition of Toxoplasma gondii proliferation by mTor blockers
Diaz Beltran W., González-del Carmen M., Huerta Cortés M.J., Rodriguez-Baez I.O., Varela-Cordoso M. (Mexico)

LBP3  Establishment of a recombinase polynucleotide amplification assay for rapid detection of Rickettsia spp.

LBP4  Genetic polymorphisms associated with chloroquine resistance among Plasmodium falciparum isolates from South Darfur State, Sudan
Abdalmoneim M. Magboul, Hanan B. Eltahir, Sayed M. Elbushra, Bakri Y. M. Nour (Sudan)

LBP5  Mobile suitcase laboratory for rapid detection of Plasmodium DNA at low resource settings
Adamowo G. O., Oyinloye O. E., Hansen S., Rafa M. K., Böhlken-Fascher S., Bakarey A. S., Czerny CP, Abd El Wahed A. (Nigeria & Germany)

LBP6  A novel diagnostic device for rapid quantitation of infectious disease in whole blood
Murray J., Mills L., Bannister R., Andrew S.C., Sánchez-Román Terán, F., Baum J., Kowalski K., Eickmann M., Ross S.A., Richards J. (UK & Germany)

LBP7  Role of PRAS40 in the intracellular proliferation of Toxoplasma gondii
González-del Carmen M., Osto Ramirez F., Carño Calvo L. (Mexico)

LBP8  New algorithm for testing of malaria before microscopy in an endemic setting by using LAMP
Hartnemyer G.N., Knudsen E., Kemp M. (Denmark)

LBP9  Safety and immunogenicity of yellow fever vaccine in HIV-1-infected patients: ANRS EP46 NOVAA
Colin de Verdière N., Durier C., Samri A., Lapaq O., Matheron S., Mercier-Delarue S., Molina J.-M., Autran B., Simon F., the ANRS EP46 NOVAA Group (France)

LBP10  In situ hybridization for Madurella mycetomatis using Madurella specific probe
Lim W., Ahmed SA., van de Sande W. (The Netherlands)

LBP11  A low-cost, rapid diagnostic test for Trypanosoma cruzi I/II/VI can replace ELISA for lineage specific serology in Chagas disease
Bhattacharyya T., Messenger L.A., Bremer Hinckel B.C., Ternes P., Gilman R. H., Miles M. A., Chagas Working Group in Bolivia and Peru (UK & USA)

LBP12  Rabies antibody response after booster immunization: A systematic review and meta-analysis
Langedijk A.C., de Pijper C.A., Spijker R., Grobusch M.P., Stijnis C. (The Netherlands)

LBP13  Accuracy of giant African pouched rats for diagnosing tuberculosis: Comparison with culture and Xpert MTB/RIF
Molho S., Mungunchimeg D. (Mongolia)
LBP.15 Preliminary results of large scale field trials of tsetse repellent technology validation in Kibo division of Kwale County of coastal Kenya

LBP.16 Downstream effects of globalization and agricultural policy on human risks to scrub typhus and tick-borne diseases
Kuo C.C., Huang J.L., Shu P.Y., Lee P.L., Kelt D., Wang H.C. (Taiwan & USA)

LBP.17 Higher abundance of vectors of scrub typhus in sites with invasion of exotic plants
Wèi C.Y., Kuo C.C. (Taiwan)

LBP.18 Association between adiposity and dengue severity: A systematic review and meta-analysis
Zulkipili M.S., Dahlui M., Jamil N., Peramaladah D., Hoe V.C, Bulgiba A., Rampal S. (Malaysia)

LBP.19 Hospital epidemiology of methicillin-resistant staphylococcus aureus (MRSA) in a tertiary care hospital in Moshi Tanzania as determined by whole genome sequencing

LBP.20 Patterns of infections, aetiological agents, and antimicrobial resistance at a tertiary care hospital in northern Tanzania
Kumburu H.H., Sonda T., Mmbaga B.T., Alifrangis M., Lund O., Kibiki G., Aarestrup F.M. (Tanzania, Denmark & Burundi)

LBP.21 Comparison of two artemisinin-based combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria among children in Rwanda
Uwimana A., Nisingizwe M.P., Ulyizeye D., Mbtuyumuremyi A., Penkunas M.J. (Rwanda)

LBP.22 Probable case of spontaneous encephalopathy associated to loiasis and further evidence of the effect of prolonged regimen of albendazole on loa microfilaremia
Arrey-Agbor D.B., Nana-Djeunga H.C., Mogoung-Wafo A.E., Mafo M., Danwe C., Kamgno J. (Cameroon)

LBP.23 Risk of Zika virus infection in asymptomatic Dutch military personnel after deployment in high endemic areas

LBP.24 Causes of severe febrile illnesses in hospitalized children, Nouna Burkina Faso

LBP.25 Mass drug administration for neglected tropical diseases: Benefits versus risks for global health in the 21st century
Molver L.J., Javadi R., Scourge R., Elder G. (Switzerland & USA)

LBP.26 Dengue risk stratification of transmission in three municipalities in Colombia, using data collected routinely by the local ETV control programs
Mina N.J., Vanlerberghe V., Echavarria M.I., Alexander N., Ocampo C. (Colombia & Belgium)

LBP.27 Operational research on malaria burden and costs of intensified control measures in pre-elimination stage in Bhutan: 2006-2014

LBP.28 Transforming the malaria landscape: Results from a three-year implementation research project expanding access to seasonal malaria chemoprevention in seven Sahelian countries (ACCESS-SMC)
Moros O. on behalf of the ACCESS-SMC project partnership (Uganda)

LBP.29 Integration of an ancillary project to support national Kala-azar elimination program in Bangladesh
Shomik M.S., Akhtar Hossain A.F.M., Taahima S., Mamun Huda M., Sakawat Hossain Md., Ghosh D., Chowdhury R., Khair Mohammad Shamsuzzaman A., Aggarwal V., Misra K., Mondal D. (Bangladesh & India)

LBP.30 Detection and treatment delay among drug-resistant tuberculosis patients in provincial hospital in Bandung, Indonesia
Lestari B.W., Andriyoko B., Hill P., van Crevel R., Yuwono Soeroto A. (Indonesia, New Zealand & The Netherlands)

LBP.31 Maternal healthcare assessment: An insight on community health workers program's key indicators
Maulide Cane R., Chidissicua J.B., Chicumbe S., Goncalves M.P., Mbofana F. (Mozambique)

LBP.32 Evaluation of the expanded home-based management for malaria program in Rwanda: An interrupted time-series study
Uwimana A., Nisingizwe M.P., Ulyizeye D., Hakizimana D., Mbtuyumuremyi A., Musanabaganwa C., Penkunas M.J. (Rwanda)

LBP.33 Ensuring accountability in health sector through ‘health information dashboard’: An open data visualization tool for decision makers and citizens of Bangladesh

LBP.34 Feasibility of a pharmacy-based hypertension care program using e-monitoring of patients in Lagos, Nigeria

LBP.35 Stakeholders’ perceptions and practices regarding hypertension, pharmacy-based care, and e-monitoring in urban Nigeria: A mixed methods study

LBP.36 What future for universal health coverage in an illiberal age?
Forman L. (Canada)

LBP.37 Training doctors without borders: Medical internationalism and its impact in pacific island countries
Molver L.J., Jones S., Manahan D., Campbell D., Ward B. (Australia & Switzerland)
LBP38  The cost of integrating maternal postpartum care to infant immunization service in Kaya health district (Burkina Faso)
Yugbaré Belemsaga D., Goujon A., Degomme O., Nassa S., Duysburgh E., Kouanda S., Temmerman M. (Burkina Faso, Austria, Belgium, Burkina Faso & Kenya)

LBP39  Acceptability and performance of directly assisted HIV self-testing in adolescents in rural Mozambique

LBP40  Night club HIV counselling in northern rural Mozambique: A successful method to attract a high-risk key population
Jefferys L., Dekker H., Rafael I., Ehmer J., Hobbins M.A., Hector J. (Mozambique & Switzerland)

LBP41  Early results of operational research on the continuous improvement process in decentralised management of flexible funds for maternal and child health in the Amazonas and Cajamarca regions, Peru
Haghebaert G., Gushiken A., Pinto De La Sota M., Velkeneers E., Seinfeld J. (Peru)

LBP42  Clinical profile and outcomes of HIV-Infected severe malnourished children in Bukavu, Eastern of Democratic Republic of Congo
Bwija J., Lufungulo Y., Nkaba E., Mashukano B., Ntagerwa J., Kambale R., Masumbuko B. (Congo)
Swiss TPH - a Global Health Institution

Excellence in Health Research, Teaching and Services for more than 70 years

The Swiss Tropical and Public Health Institute (Swiss TPH) is a world-leading institution in health research, training and services. It improves, maintains and promotes the health of individuals and societies all around the globe, with a special emphasis on resource-constrained countries. The multidisciplinary activities range from laboratory studies to clinical work, and the practical transfer of conceptual and technical expertise into health system planning and programmes. Sharing and mutual learning for change are the building blocks of our success.

Generating, Sharing and Applying Knowledge

Swiss TPH works along a value chain from innovation to validation and application. The institute’s activities contribute to the improvement of human health and wellbeing through better understanding of diseases and health systems. This knowledge is the foundation for health actions.

Upcoming Symposia

Helminth Infection - from Transmission to Control
7-8 December, 2017
Basel, Switzerland

Clinical Research in Resource Limited Settings – Mission Impossible, or Role Model for Future Drug Development?
28 June, 2018
Basel, Switzerland

Key Areas of Activity

- Basic Research and Infection Biology
- Preclinical Research and Development
- Clinical Research and Development
- Molecular and Genetic Epidemiology
- Emerging Infectious Diseases
- Statistical and Mathematical Modelling
- Personalised Health
- Environmental Epidemiology
- Health in Socio-Ecological Systems
- Society, Culture and Health
- Sexual and Reproductive Health and Gender
- Health Systems and Policy
- Travel and Tropical Medicine
- Mobility, Migration and Health

Upcoming Symposia

Gorilla 3
Tuesday, 17 October - 12.30 - 13.30 hrs
The Contribution of Diagnostics to Control and Elimination of NTDs

12.30
Diagnostic needs for case management (IDM) NTDs
Daniel Dagge (WHO)

12.45
The Francophone network on neglected tropical diseases
Philippe Solano (IRD)

12.55
Evaluation of diagnostic tools for human African trypanosomiasis elimination and clinical trials
Veerle Lejon (IRD)

13.05
Diagnostics for Leishmaniasis in elimination settings: modelling and evaluation
Emily Adams (LSTM)

13.15
Round table
Chair: Joseph Ndung’u

Gorilla 3
Thursday, 19 October - 12.30-13.30 hrs
Evidence-Based Humanitarian Aid and Development: The Example of First Aid Training as Cost-Effective Measure in Low & Middle-Income Countries

Belgian Red Cross-Flanders’ Centre for Evidence-Based Practice: strategic choice towards cost-effective interventions
Emmy De Buck, Belgian Red Cross-Flanders

Evidence-based first aid materials: from scientific studies to practical training materials
Vere Borra, Belgian Red Cross-Flanders

Implementation of evidence-based African First Aid Materials in Sub-Saharan Africa: A view from the field
Adam Mbewe Makwemba, Zambia Red Cross Society

Gorilla 1
Thursday, 19 October - 12.30-13.30 hrs
EU Research Strategy on Neglected Infectious Diseases (NIDs)

Organiser:
European Commission – DG Research and Innovation – Unit E3, Fighting Infectious Diseases and Advancing Public Health

Chairs:
Line Matthiessen (European Commission) & Michael Makanga (EDCTP)

Introduction on EU research Strategy on NIDs
Matthiessen L.

Vaccine development for NIDs – Challenges and opportunities
Van Leeuwen R. (The Netherlands)

Drug development for NIDs – Challenges and opportunities
Pierce R. (France)

The role of the Biopharmaceutical industry: evolving perspective towards NIDs
Reinhard-Rupp J. (Switzerland)

Summary of discussion
Makanga M.

Future EU funding opportunities for NIDS
Matthiessen L. and Makanga M.
EDCTP’s mission is to contribute to the reduction of the individual, social and economic burden of poverty-related infectious diseases in sub-Saharan Africa.

We fund collaborative clinical research to accelerate the development of accessible, suitable and affordable medical interventions to identify, prevent or treat these diseases, including neglected infectious diseases. Our approach integrates development of African clinical research capacity.

EDCTP is a partnership between 14 European and 15 African countries. The EDCTP programme is supported under Horizon 2020, the European Union’s Framework Programme for Research and Innovation.

Join us at our session on:
Development, validation and implementation of diagnostic tools in resource-limited settings
19 October at 15:30 | Room 9 | 6OS7

EDCTP proudly sponsors
the 10th European Congress on Tropical Medicine and International Health.
The Institute for Tropical Medicine Antwerp (ITM)

We Learn, Know, Do For A Healthy World

Tropical diseases, HIV/AIDS, tuberculosis and poor health care affect the lives of billions of people around the world. The Institute of Tropical Medicine (ITM) in Antwerp advances the medical sciences which can improve their fate, through fundamental and applied research, advanced education and the provision of expert services.

Learn

At ITM, researchers, medical doctors, veterinarians and nurses from all over the world specialise in tropical medicine and public health. In a stimulating international environment, they take post-graduate master, PhD and specialist expert courses in English or French. The courses stimulate research-mindedness, independent learning and the exchange of experiences.

Know

Our innovative and interdisciplinary research focuses on Pathogens, Patients and Populations - the “3 P’s”. ITM researchers improve our understanding of tropical diseases, and develop better methods for their diagnosis, treatment and prevention. Others study the organisation and management of health care and disease control in regions where means are limited, but needs are huge. We also pay attention to the health of animals, with a focus on the diseases they spread to humans.

Do

Each year, we vaccinate tens of thousands of travellers, and provide care to those who return from abroad with an illness. As a reference centre for tropical diseases, public health and HIV/AIDS, we also deliver a range of other expert services in Belgium and collaborate with partner organisations across the globe. We develop and validate diagnostic tests for infectious diseases and perform clinical trials for new or improved treatments. Thirteen ITM laboratories are recognised as national or international reference centres.

Be-cause Health

Be-cause Health is a Belgian platform for International Health that unites academic institutes, services and schools for public health, development organisations and NGOs as well as government services around international healthcare. It aims at strengthening the role and the effectiveness of all actors in the Belgian development cooperation to make quality health care accessible worldwide, through mutual agreement, coordination, and activities that go beyond organisations.

Be-cause Health delegated the task of organizing the ECTMIH congress in 2017 to the Institute for Tropical Medicine Antwerp (ITM).

Federation of European Societies for Tropical Medicine and International Health (FESTMIH)

The Federation was founded in 1995 at Hamburg, during the first European Conference on Tropical Medicine. Fifteen European countries are currently represented on the Federation Council by their respective national societies. FESTMIH provides a strong platform for collaboration toward common goals with sister societies and colleagues in the south.

The objectives of FESTMIH are to build upon the interdisciplinary expertise of the national Societies in Europe, for developing European collaboration and North-South partnership towards health development in the tropics, in respect of regional specificities.

The Federation wants specifically to promote harmonisation of health strategies and recommendations related to developing countries, emergency situations and international travellers, to seek the advice from overseas partners for pertinent identification of their health and research priorities, to foster the formation in the tropics of new scientific societies dealing with health sciences, to encourage European harmonisation of training in tropical medicine, and to organise in Europe regular conferences on tropical medicine and international health, as a platform for debate on European research and cooperation in international health.

FESTMIH’s is co-publisher of the periodical Journal “Tropical Medicine and International Health” (TM&IH) and has become one of the leading journals in its field.

The Federation is a member of the World Federation of Academic Institutions for Global Health; it is also a member of the European Academic Global Health Alliance where FESTMIH’s president is also a member of the executive board. The Federation is in close collaboration with the periodical Tropical Medicine and International Health and has established links with the European Schools of Tropical Medicine (Trop Med Europ).

MEMBER SOCIETIES

(AU) Österreichische Gesellschaft für Tropenmedizin, Parasitologie und Migrationsmedizin
(BE) Be-Cause Health
(CZ) Society of Tropical and Travel Medicine (under the umbrella of the Czech Society of Infectious Diseases)
(FI) Finnish Society for International Health
(FR) Société de Pathologie Exotique
(DE) Deutsche Gesellschaft für Tropenmedizin und Internationale Gesundheit (DTG)
(IT) Società Italiana di Medicina Tropicale (SIMET)
(NL) Nederlandse Vereniging voor Tropische Geneeskunde
(NO) Norwegian Forum for Global Health Research
(PT) Associação para o Desenvolvimento da Medicina Tropical
(ES) Sociedad Española de Medicina Tropical y Salud Internacional (SEMTSI)
(SE) Svensk förening för tropikmedicin och internationell hälsa
(CH) Swiss Society of Tropical Medicine and Parasitology
(UK) Royal Society of Tropical Medicine and Hygiene
Centre for Tropical Medicine & Global Health

The Centre for Tropical Medicine and Global Health, University of Oxford, is a collection of research groups permanently based in Africa and Asia as well as Oxford. Aiming to tackle infectious diseases, our research ranges from clinical studies to behavioural sciences, with capacity building integral to all of our activities.

Doctors without Borders

Médecins Sans Frontières (MSF) is an international medical humanitarian association providing assistance to populations in distress, to victims of natural or man-made disasters or to people caught up in armed conflict. They do so irrespective of gender, race, religion, or political affiliation.

European & Developing Countries Clinical Trials Partnership (EDCTP)

The European & Developing Countries Clinical Trials Partnership is a partnership between 14 European and 15 African countries, supported by the European Union. Its mission is to reduce the individual, social and economic burden of poverty-related and neglected infectious diseases (PRDs) in sub-Saharan Africa. EDCTP funds collaborative clinical research to enhance research capacity and accelerate the development of accessible, suitable and affordable new or improved medical interventions to identify, prevent or treat PRDs, including (re-)emerging infectious diseases. All phases (I-IV) of clinical trials are supported, with particular focus on phase II and III studies, in addition to product-focused implementation research.

Emergency

EMERGENCY is an independent Italian organization that provides free, high quality medical and surgical treatment to the victims of war, landmines and poverty. It promotes a culture of peace, solidarity and respect for human rights. Since 1994 over 8 million people have received free, high quality health care by EMERGENCY.

Foundation for Innovative New Diagnostics (FIND)

FIND is an international non-profit organization based in Geneva, Switzerland. The organization is dedicated to activities that result in: 1) new diagnostic tools for poverty-related diseases in low- and middle-income countries; 2) expanded access to these tools; and 3) strengthened diagnostic testing capacity in low- and middle-income countries.

Gilead Sciences

Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercialises innovative medicines in areas of unmet medical need. Gilead's therapeutic areas of focus include HIV/AIDS, liver diseases, haematology and oncology, inflammatory and respiratory diseases, and cardiovascular conditions. Gilead has a rapidly expanding product portfolio, a growing pipeline of investigational drugs and over 9,000 employees in offices across six continents. Millions of people around the world are living healthier lives because of innovative therapies developed by Gilead.

International Society of Travel Medicine (ISTM)

The International Society of Travel Medicine promotes and fosters healthy and safe travel through the education of travellers and those who counsel travellers. The Society also works to identify and raise awareness of social, environmental, cultural and health issues caused by travel and tourism within destination communities.

London School of Hygiene & Tropical Medicine (LSHTM)

The London School of Hygiene & Tropical Medicine is a world leading centre for research and postgraduate education in public and global health. Located in London, UK but with global presence and collaboration at its heart, the School is uniquely qualified to make a difference in improving health worldwide. www.lshtm.ac.uk.

Medicus Mundi International (MMI)

Health cooperation beyond aid? We care! With its events and publications, the Medicus Mundi International Network (MMI) provides spaces for an in-depth reflection and dialogue on the relevance, legitimacy and effectiveness of health cooperation, promoting at the same time interaction and collaboration among the Network members. Join us! www.medicusmundi.org

Meridian Bioscience Europe

Meridian Bioscience manufactures diagnostic kits for the early diagnosis of gastrointestinal, respiratory, sexually transmitted, neonatal and newly added vector borne infections (Malaria). Our diagnostic tests aid clinicians in the appropriate management of patients with acute infections. Flagship parameters with the illumigene molecular range include our award-winning assay for Malaria.
Point-M

Point-M is a start-up organization that technically supports Healthcare Systems to standardize improved Care Logistics long-term and to socially franchise “Model” Dispensaries, Health Centers and Hospitals that are accessible to the poor and appealing to the middle class, thereby increasing the quality and accessibility of healthcare services.
More information: geert.vanneste@pointm.org

Sanofi Pasteur

Sanofi Pasteur is a world leader in human vaccines. Producing a portfolio of high quality vaccines that match our areas of expertise and ensure a sustainable future.
Providing more than 1 billion doses of vaccines each year making it possible to immunize more than 500 million people worldwide per year.

Swiss Tropical and Public Health Institute

Swiss Tropical and Public Health Institute (Swiss TPH) is a world-leading institution in health research, training and services. It improves, maintains and promotes the health of individuals and societies all around the globe, especially in resource-constrained countries. Its multidisciplinary activities range from laboratory studies to clinical work, and the practical transfer of conceptual and technical expertise into health system planning and programmes. Sharing and mutual learning for change are the building blocks of our success.

The Global Health Network (TGHN)

The Global Health Network accelerates research by supporting efficient research processes; impactful knowledge exchange and know-how transfer between organisations, disease areas, and regions; and by effective research capacity development. Examples of our indispensable tools and resources include free online learning, Process Map guiding initial research set-up, and Professional Development Scheme.

Wiley

Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical, and scholarly journals, combined with our digital learning, assessment and certification solutions help universities, societies, businesses, governments, and individuals increase the academic and professional impact of their work.
REGISTRATION

Registration Fees On-Site

Participant
Full Period € 750,00
One-Day Registration** € 375,00
One-Day Registration on Friday € 250,00

Student*
Full Period € 450,00
One-Day Registration** € 225,00
One-Day Registration on Friday € 150,00

Social Events
Welcome Reception, October 16 € 00,00
Welcome Reception Partner, October 16 € 25,00
Congress Dinner, October 18*** € 80,00

* Certificate or proof of status is required.
** If you wish to attend several days, you need to register for each day separately.
*** If seats are still available.

The registration fee includes:
• Access to all scientific sessions
• Access to the industrial exhibition
• Meeting bag with programme, tourist and other information
• Access to the zoo
• Welcome Reception on Monday, October 16
• Daily lunches and coffee breaks as announced in the programme

Registration Desk
The registration desk of ECTMIH2017 is located on the ground floor of the FMCCA.

On-site Registration Opening Times
Monday, October 16, 2017 15.00 – 20.00 hrs
Tuesday, October 17, 2017 07.30 – 18.30 hrs
Wednesday, October 18, 2017 08.00 – 18.30 hrs
Thursday, October 19, 2017 08.00 – 18.30 hrs
Friday, October 20, 2017 08.00 – 13.30 hrs

Badges
Participants are obliged to wear the official ECTMIH2017 badges on all occasions.

Lost Badges
Participants who lost their badge will have to register and pay anew.
SOCIAL ACTIVITIES

Opening Session and Reception, Monday, October 16
The Opening Session will start at 17.00 hrs in the Elisabeth Hall.

Congress Dinner, Wednesday, October 18
Participants having registered for the Congress Dinner are requested to join us at 19.30 hrs at Horta.

Address:
Hopland 2
2000 Antwerp

The Horta can be reached on foot from the Congress Venue in approximately 20 minutes.
Free parking is offered in Parking Horta, Hopland 24, 2000 Antwerp.
Validate your parking ticket at the cloak room of the Horta.

GENERAL INFORMATION

Venue
Flanders Meeting & Convention Center Antwerp (FMCCA)
Koningin Astridplein 20
2018 Antwerp
http://www.elisabethcenter.be/

Access to the Zoo
ECTMIH participants wearing the official congress badge can access the zoo free of charge for the duration of the Congress.

How to get there
By train
The FMCCA is adjacent to Antwerp Central Station. There is a direct train connection between Antwerp and Brussels International Airport. The train journey takes only 34 minutes.
Antwerp has high speed rail connections with Paris, Amsterdam, London and Cologne.

By car
The FMCCA is situated in a low emission zone (LEZ) which the city of Antwerp is reinforcing as of 1 February 2017 to enhance air quality. As a result, the most polluting vehicles are banned from the city centre.
Parking Station ZOO (formerly Nova): Visitors of the Elisabeth Center Antwerp pay €4 for a day ticket.
Address: Van Schoonhovestraat 25-27, 2060 Antwerp
Parking Breidel: Visitors of the Elisabeth Center Antwerp get a 50% discount on the normal hourly rate.
Address: Breydelstraat 15-17, 2018 Antwerpen

Don't forget to validate your parking ticket! A ticket machine is available at the cloakroom.

Language
The official language of ECTMIH2017 is English.

Abstracts of Invited Lectures and Oral Presentations
The abstracts of the oral and poster presentations can be consulted via the mobile App or on the ECTMIH website.

Conventional Poster and ePosters
Conventional Posters are on display in the Marble Hall. Poster tours are organised on Tuesday, Wednesday and Thursday at lunch time (12.30 – 13.30 hrs).
ePoster corners are installed in the Galapagos Room on Level 2. ePosters can be viewed throughout the Congress.

Speaker Room
Speakers with oral presentations are requested to upload their PowerPoints onto the central server system at least 2 hours prior to their scheduled presentations. The Speaker Room is located on the ground floor, next to the exhibition.
Professional technicians will assist you in uploading your presentations onto the system.

Coffee and Lunch
Coffee will be served in the exhibition area on the ground floor permanently. Lunch is included in the registration fee and is served in the exhibition area on the ground floor.
Accreditation
ECTMIH2017 has been granted 25 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME). Participants are requested to sign the attendance list 2 times a day: at 08.30 hrs and at 13.30 hrs. Participants will receive a certificate of attendance via email after the Congress.

Disabled Persons
The Flanders Meeting and Convention Center is entirely wheelchair accessible.

Cloakroom
A guarded cloakroom is available on the ground floor. Luggage can also be stored here.

Liability
In registering for ECTMIH2017, participants agree that neither ITG nor the Organising Secretariat assume any liability whatsoever. Participants should therefore organise their own health, travel and personal insurances.

Emergency Number
In case of emergencies (police, ambulance), dial 112.

Official Organiser
MediCongress Services NV
Noorwegenstraat 49
9940 Evergem, Belgium
www.medicongress.com
info@medicongress.com

Social Media
Follow us on Facebook and Twitter and share your information using the official hashtag #ECTMIH2017.

App
Download the ECTMIH2017 app in the App Store and Google Play by scanning the below QR-code.
Sleeping sickness threatens millions of people in sub-Saharan African countries. This disease is fatal if not treated.

Sanofi, through its partnership with the WHO, has contributed to having 34 million people screened and close to 200,000 patients treated for sleeping sickness since 2001. And, since 2009, we work with the DNDi (Drugs for Neglected Diseases initiative), to develop the first fully oral treatment for all stages of this disease.

Thanks to all partners, elimination of sleeping sickness as a public health problem is now in sight.

www.sanofi.com